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Cis-platinum is a widely used cytotoxic agent with known radiosensitising properties. 
It is used in the treatment of various types of lung cancer that may include radiation to 
the lung as part of the treatment protocol. There is little evidence and some conflict as 
to whether it sensitises pulmonary tissue to the effects of radiation treatment. This 
project investigates the effect of cis-platinum alone or in combination with radiation 
on mouse lung. 
Four end points were used to evaluate treatments. They were: the release of pulmo-
nary surfactant, changes in breathing rate, a histology based score of damage and 
changes in TGF-f3 - a cytokine important in the development of fibrosis . Single doses 
of either cis-platinum or radiation, cis-platinum given immediately before a single 
dose of radiation, cis-platinum given immediately before the first of two fractions of 
radiation and cis-platinum given at various times before and after a single dose of ra-
diation were investigated. 
Cis-platinum alone was observed to cause an increase in the phospholipid content of 
lavaged surfactant. Cis-platinum was observed to cause an early release in surfactant 
and a trend existed for it to induce an early increase in breathing rates as compared to 
that induced by radiation alone. Cis-platinum was observed to increase radiation dam-
age as assessed using a histology based scoring system. Higher TGF-f3 levels in la-
vaged surfactant were observed in C57 /Bl mice as compared to Balb/C. No difference 
in TGF-f3 levels was seen in homogenised lung between the strains. Cis-platinum may 
cause changes in TGF-f3 in C57/Bl mice but further work is necessary to confirm this. 
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Chapter 1. Overview 
This project was designed to test the hypothesis that cis-platinum causes an adverse 
increase in pulmonary radiation toxicity. 
Cis-platinum, while used primarily as a cytotoxic agent is a potential radiation sensi-
tiser. It is a desirable component in treatment of cancer in combination with radiation 
therapy of the thoracic region. There is, however, scant and conflicting evidence of its 
role in lung radiation damage. 
Three indicators of lung damage were chosen for testing the hypothesis that cis-
platinum causes an adverse increase in radiation pulmonary toxicity. They were 
measurement of pulmonary surfactant in broncho-alveolar lavage: a breathing rate 
assay and histological evaluation of lung sections. 
It is of interest to consider what is meant by 'radiation damage', as in different cir-
cumstances the term will have different significance. In a study with direct clinical 
implications, such as this one, it is important to relate the term back to end points of 
clinical interest. Treatment-induced life shortening is of obvious concern and relates 
directly to LD50 type studies in experimental models. Undesirable side effects caused 
by treatment may, however, become important at much lower doses or dose volumes 
than would be necessary to induce death in humans. Functional or mechanistic assays 
in experimental models may thus be used either relating in a direct way to a clinical 
endpoint- e.g. increased breathing rate in rodents as a model of shortness of breath in 
patients - or as predictors of later responses. Breathing rate has also been used in this 
way i.e. as a predictor of radiation-induced mortality. 
The possibility of schedule dependence was tested by administering cis-platinum at 
different times relative to a single dose of radiation. The endpoints used were the 
breathing rate assay and the surfactant assays. The role of cis-platinum in fractionated 
radiation protocols was investigated by determining its effect on a split dose of radia-
tion, again using the breathing rate and release of surfactant as endpoints. 
Tumour Growth Factor J.3 (TGF-J.3) is a cytokine that may be involved in the induction 
of pulmonary fibrosis after radiation (Rubin et al. 1990, Rodemann et al. 1995 and 
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Johnston et al. 1995). Further it has been proposed that TGF-13 is a mediator of drug-
induced pulmonary fibrosis (Hoyt and Lazo 1988, 1990). This common mechanism 
may be the way in which drugs such as bleomycin and cyclophosphamide interact 
with radiation to cause enhanced radiation toxicity. Experiments were performed to 
investigate whether cis-platinum causes an increase in TGF-13 either alone or by en-
hancing the release caused by radiation. 
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Chapter 2. Introduction to radiation effects on the 
lung 
The lung is the dose-limiting organ in radiation treatment involving the thorax (Rubin 
et al. 1968). Tolerance is dependent on total dose, fractionation and irradiated volume 
with the "critical lesion" leading to impaired ventilation and perfusion. This may ex-
hibit as shortness of breath in varying degrees and if severe, death. What is not clear is 
what specific events are critical in the pathway to pulmonary insufficiency. 
A simple explanation for the development of radio-pathology attributes development 
of a lesion to loss of an underlying cell population. It has been a tenet of radiobiology 
that cell death occurs when the cell attempts to divide. Tissues have been divided into 
acutely responding and late responding, according to the time and nature of response. 
Acutely responding tissues usually have an identifiable critical cell population with a 
short cell cycle and rapid turnover. For example in the gastro-intestinal system sur-
vival of the stem cell population of the jejunal crypts will determine the development 
of radiation induced pathology (Scherer et al. 1991). Late responding tissues may 
have identifiable critical cell populations with long cell cycle times and slow turnover. 
For example in the central nervous system development of radiation pathology has 
been attributed to glial cells (Scherer et al. 1991 ). 
The case is not so clear for the development of lung pathology. With over 40 cell 
types with widely varying population kinetics the lung is a complex organ functioning 
both as an interface for gas exchange and an important biochemical processing plant. 
While the critical lesion from a clinical point of view ( determined by dose) occurs 
late, the development of its radio-pathology is characterised by a number of preceding 
events that occur relatively early. As yet, no single cell population has been clearly 
identified as responsible for this pathology. 
A number of candidates have been proposed including vascular endothelial cells and 
type II pneumocytes. An emerging hypothesis is that the radiation response of the 
lung is likely to be due to a complex cascade of biochemical signals (such as those 
involving cytokines) triggered by radiation. In this model the development of radia-
tion pathology (fibrosis) is seen as a continuum with an inflammatory response lead-
Cis-platinum, radiation and mouse lung Chapter 2 - Radiation lung pathology page 17 
ing to the expression and maintenance of a cascade of inter-cellular and intra-cellular 
messages. Both the debate over vasculature vs. interstitium and the importance of 
molecular messengers is not unique to the lung. 
It is clearly vital that an understanding of these complex processes be gained if more 
effective treatments are to be devised and undesirable side effects of radiation treat-
ment of the lung avoided. A central theme of radiobiological research into the devel-
opment of lung pathology is thus the elucidation of the underlying radiation lesions. 
Some of the research investigating this and key aspects of radiation induced lung pa-
thology are outlined in the subsequent chapters. 
The experimental work described in this thesis started as an empirical investigation of 
the response of the lung to combined treatment with cis-platinum and radiation. Three 
endpoints were used in this investigation. These were measurement of the release of 
surfactant after treatment, measurement of breathing rates after treatment and a simple 
histological scoring technique. Cis-platinum, its interaction with radiation and previ-
ously published research where damage to the lung was assessed is reviewed together 
with literature relevant to the experimental methods used. 
The experimental work was performed using a mouse model. Strain dependent differ-
ences in the response of mouse lung have been recorded prompting the use of two 
strains. The background for this is discussed below. 
The empirical approach is, however, of limited benefit and contributes little to a gen-
eral understanding of the processes involved. Although far from complete, an attempt 
was made to investigate possible mechanisms of interaction between cis-platinum and 
radiation by examining the effect of radiation alone or in combination with cis-
platinum on TGF-J3 - a cytokine implicated in the fibrotic process. The role of TGF-J3 
in the development of radiation induced lung fibrosis is discussed below. 
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Chapter 3. Lung Pathology induced by Ionising 
Radiation 
The radiation response of the lung may be divided into three phases: an immediate 
reaction, an early response and a late reaction. These have been labelled as the latent 
phase (no gross histological changes); the pneumonitic phase and the fibrotic phase. 
The appearance and extent of each phase is dependent on the total dose administered 
and the fractionation of the dose. The overall clinical response will also depend on the 
volume of lung irradiated (Coggle 1986). 
The latent phase 
The latent phase, seen after moderate doses (greater than - 10-15 Gy) is characterised 
by features also seen in other tissues soon after treatment with radiation - fluid leak-
age in the interstitium, cell swelling, and membrane effects. This phase may be non-
existent at doses less than 1 OGy. In the case of the lung an important consequence of 
this type of reaction is the release of surface active material (surfactant) into the al-
veolar space within hours after 30Gy 137 Cs gamma rays administered to mouse lung 
(Rubin et al. 1980). Early changes in fine structure (using electron microscopy) of 
mouse lung have also been noted and include increased oedema, fibrin deposition, 
histiocytic invasion and fibrosis, which were observed to occur, usually in the noted 
order within 24 h of exposure to 10 to 30Gy of 280kVp x-rays (Penny et al. 1977). 
After single doses at both 1 h and 24 h post treatment pronounced depletion of lamel-
lar bodies in Type II pneumocytes was observed. This decrement was not specifically 
dose related and was usually followed by cellular hypertrophy and increased numbers 
of lamellated structures by 7 days after treatment. 
Some controversy exists about endothelial changes observed after radiation. In the 
period up to one month after treatment Penny et al. (1977) did not observe significant 
changes in endothelial cells (10 to 30Gy of 280KvP x-rays). They did observe micro-
villi projecting into the capillary lumen. 
This can be contrasted with the observations of Adamson et al. (1970) who noted the 
primary site of injury to the lung as being the capillary with the earliest evidence of 
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injury exhibited at 2 days after treatment with 11 Gy, with the appearance of intra-
cellular vacuolation leading to occlusion of capillary lumina. After a few days vacuo-
lated cells were seen to rupture and strip off the basement membrane. The observed 
lesions reached a maximum at day 10 after 1 lGy. No damage was observed in type II 
pneumocytes. Injury to endothelial cells and not to epithelium was also reported by 
Phillips (1966) and again by Phillips and Margolis in 1974. 
The pneumonitic phase 
Radiation pneumonitis follows the latent phase and may prove lethal if the dose is suf-
ficiently high. The most significant changes in mouse lung are observed in the period 
from 2 to 6 months (8 to 24 weeks) post irradiation (Molls and Van Beuningen 1991). 
The characteristic features of radiation pneumonitis are interstitial oedema, oedema 
into the alveoli, infiltration by inflammatory cells and desquamation of epithelial cells 
from the alveolar walls. Alveolar septa were noted to be thickened. During this phase 
changes have also been noted in capillaries. 
Physiological changes noted during the pneumonitic phase include a decreased arte-
rial P02 and pulmonary hypertension (Tillman et al. 1989), both of which were noted 
first during the 2 days immediately post treatment after which they returned to normal 
and then persisting when radiation pneumonitis started. 
The type II pneumocyte in the pneumonitic phase 
Interest has focused on the type II pneumocyte both because of its relatively active 
division, its role as a stem cell for the type I pneumocyte and because of its surfactant 
producing status. The labelling index of type II pneumocytes after radiation has been 
examined by various authors. Gross et al. (1988) showed that after single doses of 
19Gy to the thorax of CF female mice the labelling index increased 3 fold relative to 
controls at 18-22 weeks post treatment. The increase in type II replicative activity was 
seen as a protective response to radiation that was enhanced by the administration of 
corticosteroids. Corticosteroids increased type II replicative activity. The authors sug-
gest that their results are evidence that the type II pneumocyte is a target cell in the 
radiation response of the lung. 
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A 50-70% decrease in total numbers of type I, type II pneumocytes and capillary en-
dothelial cells of rats irradiated unilaterally to the thorax with 30Gy was observed at 
12 weeks after treatment (Vergara et al. 1987). The increased replication rate and de-
creased cell number would indicate an increased turnover and reduced mean survival 
time for the type II pneumocytes. In work by Coultas et al. (1981) proliferation of 
type II pneumocytes in mice was observed to initially decrease for the first six days 
after lOGy x-rays or 7. 7Gy neutrons. Three to five weeks after treatment a gradual 
increase relative to controls was observed. 
The radiation response after selective stimulation of type II pneumocytes in Balb/C 
mouse lungs by butylated hydroxytoluene (BHT) showed an increased radiosensitivity 
as assessed by LD501180 (Ullrich et al. 1982). Both 300 kVp x-rays and fission neutrons 
were used to treat the mice. The LDso11so ranged from 2.69Gy with BHT given two 
days before irradiation with x-rays to 14.45Gy for BHT given 6 days before irradia-
tion. The LDso,180 was 9.59Gy without BHT. Similar differences were seen after neu-
trons but with LDso11so values ranging from 0.98Gy to 5.75Gy. These results may in-
dicate that the type II pneumocytes represent the target cell responsible for the radia-
tion response of the lung. 
No differential radioprotection of either type II pneumocytes or endothelial cells 
(mouse lung) was noted when assessed relative to lethality after the radioprotective 
compound WR2721 , was administered before treatment with single doses of 250 kVp 
x-rays (Travis et al. 1987). Endothelial cell function as assessed by angiotensin con-
verting enzyme levels and type II pneumocyte response was determined by lavaged 
phospolipids and proteins. This work suggested that neither the type II nor the endo-
thelial cell could be accepted or rejected as the target cell responsible for radiation 
pneumonitis. 
It has been suggested by Gross et al. (1988) that the response of type II pneumocytes 
may be a protective response initiated against radiation damage occurring in other tar-
get cells. This could be due to changes in surfactant mechanics, for example as a re-
sult of protein leakage, signalling the type II pneumocyte to compensate (Gross 1980). 
The administration of corticosteroids 10-11 weeks after radiation ( 19Gy 6°Co) caused 
an increase in type II pneumocyte replicative activity, an increase in surfactant pro-
duction and release and a concomitant decrease in mortality. This indicated that the 
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replicative ability of the type II pneumocytes was intact after radiation. Corticoster-
oids did not appear to cause any decrease in the amount of serum protein leaked from 
the capillaries (Gross 1980, Gross and Narine 1988). 
The replicative activity of type II pneumocytes in the lungs of CF# 1 mice after treat-
ment with 18Gy (250kVp X-rays) was examined by Gross et al. in 1987. No signifi-
cant changes in type II replicative activity as assessed by tritiated thymidine labelling 
were observed until 11 weeks post treatment after which the labelling index rose to 
between four and six times that of controls. At this time the breathing frequency was 
also noted to be elevated to approximately 1.5 times that of controls and histological 
examination showed pneumonitis. 
Strain dependent differences in the pneumonitic phase 
Strain differences in the radiation response of mice during the pneumonitic phase 
have been noted (Sharplin and Franko 1989a). These include differences in the protein 
content of oedema, absence or presence of hyaline membranes and absence or pres-
ence of fibrosis. Nine strains were tested and could be grouped into three categories 
based on histological appearance. Group 1 included strains of C57 /Bl origin and were 
characterised by protein rich oedema containing fibrin, hyaline membranes and fibro-
sis. Group 2 contained Balb/C and SWR/J strains and was characterised by both pro-
tein rich and protein poor oedema, hyaline membrane and small foci of fibrosis. The 
third group comprised C3H and CBA strains and showed protein poor oedema, wispy 
deposits in alveoli and no signs of fibrosis. 
Obstruction of 70% of acini (the respiratory bronchiole, alveolar duct and alveolar 
sac) in the mouse lung was noted as being sufficient to cause respiratory distress in all 
strains observed (Sharplin and Franko 1989a). All acini appeared to be perfused in the 
one strain (Balb/C) examined after infusion with carbon particles. Patent capillaries 
were also seen in oedematous and fibrosing alveolar walls of rat lungs (Travis et al. 
1977). The perfusion of non-ventilated regions of lung is a key factor in the develop-
ment of radiation pathology of the lung as blood flow through such regions will not 
result in gas exchange and will therefore increase pulmonary insufficiency. 
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Strain differences in the expression of radiation damage to the lung were also noted 
when comparing CBA with C57Bl mice (Down and Steel 1983). C57Bl mice did not 
show a pneumonitic response at doses causing a significant reaction in CBA mice . 
The LD501180 for C57 /Bl mice was observed to be greater than 20Gy whereas for CBA 
mice it was between 12 and 15Gy. 
This differences in radiation response by different mouse strains was investigated 
further by Ward et al. (1989) who observed lung angiotensin converting enzyme 
(ACE) activity, plasminogen activator (PLA) activity and hydroxyproline content in 
four strains of mice - C57Bl/6J, C57Bl/10J, CBA/J and C3H/HeJ. The C57Bl strains, 
which exhibit late fibrosis , showed lower levels of ACE and PLA than the other 
strains and these did not reduce in response to irradiation (14Gy 300-kV X rays). The 
levels measured in CBA and C3H/HeJ mice - strains not prone to fibrosis - were by 
contrast higher and showed a radiation induced reduction. 
The role of macrophages in the pneumonitic phase 
Radiation has been observed to produce a reduction in the clearance of inhaled bacte-
ria which is thought to be due to the direct killing effect of radiation on the pulmonary 
macrophage population (Lungren and Hahn 1979). A dose dependent decrease in 
numbers of lavaged macrophages, with subsequent recovery to greater than control 
numbers has been observed after thoracic radiation of mice (Peel and Coggle 1980). 
There appears to be a proliferating, radiosensitive population of pulmonary macro-
phages present in mouse lung (Gross 1977, Coggle and Tarling 1982). Steinberg et al. 
(1992) observed an initial reduction in the total cell content in broncho-alveolar la-
vage (BAL) from mice two days after irradiation with 1 OGy. The number of cells sub-
sequently increased significantly above controls to a maximum at day 56. A strong 
significant increase in number of bi-nucleated macrophages and in micronuclei con-
tent was also seen. The phagocytic activity was increased shortly after irradiation and 
decreased later. A highly significant threefold increase in alveolar macrophage num-
ber lavaged from mice at 4 months after treatment with 24Gy in two fractions was 
noted by Gross (1978). 
Alveolar macrophages from both lungs of unilaterally irradiated sheep exhibited an 
impaired ability to generate superoxide on stimulation with phorbol myristate (Till-
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man et al. 1989). Increased numbers of neutrophils were also noted in the irradiated 
lung indicating an acute inflammatory response. 
The capillary endothelium in the pneumonitic phase 
The response of the endothelium to radiation has been examined both in-vivo and in-
vitro (Kwock et al. 1987). A single dose of 30Gy resulted in a 70% decrease in perfu-
sion at 2-3 weeks post treatment in the irradiated right lung of rats. Pulmonary radio-
graphs after barium sulphate perfusion showed widespread loss of capillary filling. 
Histological examination of the treated lung showed intact capillaries and thus perfu-
sion deficiencies were thought to be due to alterations at the precapillary level. Arteri-
oles were observed to contain areas denuded of endothelium and regions where en-
dothelial cells appeared to be bulging into the lumen. The in-vitro work using endo-
thelial cells growing as mono-layers showed morphological changes and loss of at-
tachment after treatment. Delay in the onset of changes after fractionated treatment 
was observed in both systems. 
The fibrotic phase 
The fibrotic phase in the lung describes the phase in which gross evidence of fibrosis 
is evident on examination by light microscopy of suitably stained sections. Although 
its onset occurs gradually it is typically evident during the latter period of the devel-
opment of radiopathology - from about 32 weeks after radiation. 
As discussed below there is considerable variation in the fibrotic response of different 
mouse strains and this must be considered when using the mouse as a model for ra-
diation induced pulmonary injury. The dose limiting reaction in therapeutic treatment 
regimes is usually that of pneumonitis. Although fibrosis is a common consequence of 
radiation treatment of the lung it may only result in mild deterioration in lung function 
(Gross 1977). 
Changes observed in the development of fibrosis include alveolar wall thickening, 
accumulation of hyaline, deposition of fibrin in the alveolar space and occlusion of 
capillaries by fibrin (Molls and Van Beuningen 1991). 
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Strain dependent differences in the fibrotic phase 
There appears to be considerable variation in the type and extent of fibrotic response 
seen in different mouse strains (Sharplin and Franko 1989b ). Different strains of mice 
can be divided into three groups according to their response - no fibrosis , foci of fi-
brosis and extensive contracted fibrosis. Mice strain dependent differences observed 
in the pneumonitic phase as described above (Sharplin and Franko 1989a) are ob-
served in the fibrotic phase in that those strains that do not show indications of fibro-
sis in the pneumonitic phase do not develop later chronic fibrosis. 
Changes in perfusion during the fibrotic phase appear to be an important factor in 
pulmonary insufficiency. Right ventricular hypertrophy was observed in all mouse 
strains (three C57 strains, SWR, A, Balb/C, CBA and two C3H strains) tested after 11 
and 13Gy (Sharplin and Franko 1989b). In addition non-perfused areas were observed 
in all strains. Thickening of vessel walls, perivascular fibrosis and narrowed lumina 
were all seen. 
Lung plasminogen activator and angiotensin converting enzyme (both markers for 
pulmonary endothelial function) activities were reduced to lower levels in mouse 
strains that showed fibrosis during the early radiation response than in non-fibrosing 
strains (Franko et al. 1991). The authors found the fibrosing phenotype to be autoso-
mal recessive by examining the response of hybrid strains. 
An increase in breathing rate was seen in CBA mice treated with 13Gy 230kV X rays 
at approximately 16 weeks after treatment. A second increase was seen at around 36 
weeks. The first increase coincided with histological changes typical of radiation 
pneumonitis. The second increase in CBA mice corresponded histologically with 
pleural effusions. Little evidence of fibrosis was present. C57 /Bl mice did not show 
the early functional or histological reaction however a similar response was seen at 
36 weeks after treatment. 
Vascular effects and the fibrotic phase 
The ratio of blood flow in irradiated left lung relative to unirradiated right lung of rats 
was determined using 99mTc techniques after single doses (Peterson et al. 1992a) and 
after fractionated doses (Peterson et al. 1992b). A significant dose dependent reduc-
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tion in blood flow in the irradiated lung was seen for both single doses (11-21Gy 
137 Cs) and fractionated doses ( daily fractions of either 3 or 4Gy for 4 weeks). The re-
duction was followed by recovery to near normal levels five weeks after lower doses 
(11-13 .5Gy). A lesser degree of recovery was seen after doses from 15 to 18Gy and 
almost no recovery was seen after 21 Gy for the duration of measurement - 50 weeks. 
The fibrotic response may be as a result of changes in endothelial structure and func-
tion. This has been investigated by several authors. Law (1985) looked at the connec-
tion between vascular permeability and late fibrosis by examining the accumulation of 
albumin and fibrinogen after unilateral lung irradiation of mice. Leakage and deposi-
tion of fibrinogen was hypothesised to result in its subsequent organisation increasing 
the amount of extravascular connective tissue in the irradiated lung. It was found that 
the extravascular content of both albumin and fibrinogen was increased from 1 - 12 
weeks after radiation. Subsequently protein levels returned to normal after lOGy, re-
mained elevated after 15Gy and increased after 20 and 25Gy. The collagen content of 
the lung was assessed by measuring the amount of hydroxyproline present. The hy-
droxyproline content per gram of dry weight lung tissue was increased at 18 weeks 
after doses of radiation (15-25Gy) sufficient to cause prolonged increase in extravas-
cular albumin and fibrinogen. Increases were however small and did not appear to 
progress into the late stage. No evidence for increases in fibrosis corresponding to the 
prolonged elevation in protein levels was seen. 
Adamson et al. (1988) investigated the relationship between alveolar epithelial injury 
and endothelial injury on the induction of pulmonary fibrosis using hyperoxia to in-
duce injury. They showed that the induction of fibrosis, as determined by hydroxy-
proline content per mg dry weight of cultured mouse lung explants, after exposure to 
95% oxygen, of the donor animals required significant denudation of the epithelial 
surface before hydroxyproline levels were increased. Explants cultured when the lung 
showed only endothelial injury were not different from air exposed controls. As al-
veolar damage increased, particularly to type I epithelial cells so did the amount of 
protein in lavage fluid increase and the overall rate of DNA synthesis in explants de-
crease. Injury to endothelium only was not associated with fibrosis. It should be noted 
that oxygen toxicity produces acute functional and structural changes unlike radiation 
damage, which is normally only expressed at the first mitotic division. 
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Law et al. (1989) investigated the causal relationship between exudation of vascular 
protein into the alveolar walls and into the air spaces during pneumonitis and the later 
development of fibrosis. Leakage into the alveolar wall was used as a measure of en-
dothelial damage and into the air space as a measure of epithelial damage. CFLP mice 
were irradiated with either 250kVp X rays or neutrons from 16MeV deuterons on Be. 
During the first 6 weeks lavaged surfactant and protein levels were elevated after both 
X rays and neutrons (RBE=l ). During pneumonitis at 12 to 14 weeks after irradiation, 
surfactant levels were normal, pulmonary blood volume was decreased and alveolar 
and interstitial albumin increased. At late times (42 to 64 weeks) alveolar albumin 
returned to normal while interstitial albumin remained elevated. RBE values of ap-
proximately 1.4 for changes in pulmonary blood volume and interstitial and alveolar 
albumin at 15 and at 46 weeks were comparable to the RBE of 1.5 for survival at 26 
weeks (180 days). The time course for release of albumin did not correlate with in-
creases in collagen biosynthesis. 
Hazard 
The hazard ( where hazard is the rate of death at a specified time and represents the 
risk of death from pneumonitis in mice still surviving at that time) function for radia-
tion pneumonitis in mice was investigated by Tucker and Travis (1992) and seemed to 
show multiple peaks corresponding to waves of death separated by about 33 days. The 
times of peak hazard were dose dependent with higher doses giving rise to earlier 
peak risks. As would be expected higher doses increased the risk of dying as indicated 
by a higher peak hazard value. A better understanding of the hazard function may 
shed light on underlying causes of death when correlated with biological events. 
Cis-platinum. radiation and mouse lung Chapter 3 - Radiation lung pathology page27 
Cis-platinum, radiation and mouse lung Chapter 3 - Radiation lung pathology poge28 
Chapter 4. Biochemical Changes in the lung after 
radiation 
The importance of biochemical changes in the lung has been emphasised by Rubin et 
al. (1992) who proposed that the release of trophic factors that act through autocrine 
or paracrine pathways resulted in the development of the radiation induced late effect. 
It was proposed that macrophages, type II pneumocytes and endothelial cells release 
factors such as tumour necrosis factor (TNF), Interleukin 1 (IL-1 ), platelet derived 
growth factor (PDGF) transforming growth factors a and 13 (TGF-a, TGF-13), prosta-
glandin E2 (PGE2) and mononucleocyte derived growth factor (MDGF). These factors 
act either directly or via other cells on the fibroblasts to stimulate the fibrotic process. 
Thus control of proliferation of pulmonary fibroblasts and of the synthesis and turn-
over of extracellular matrix components is effected by the production of locally pro-
duced factors which may be perturbed by radiation. 
Plasminogen activator and fibrinolysis 
Plasminogen activator (PLA, a key factor in the tissue fibrinolytic system) activity in 
lavage fluid and in alveolar macrophages from rats was examined by Ts'ao and Ward 
(1985) who found that PLA activity was decreased in the irradiated lung after unilat-
eral irradiation. The decrease, measured at 2 and 6 months after irradiation was dose 
dependent in the range 10 - 30Gy, however the levels measured at all doses at 6 
months were 10 - 15% higher than those measured at 2 months. The number of la-
vaged macrophages was increased in the irradiated lung. The PLA activity of macro-
phages was also reduced and their fibrinolytic inhibitor activity was increased but this 
appeared to be a result of the increase in the number of macrophages. The fibrinolytic 
activity as measured using a fibrin plate assay, of irradiated rat lung receiving 25Gy to 
the right hemithorax was also examined by Ts'ao et al. (1983). It was found that the 
fibrinolytic activity of the irradiated lung was about half that of the controls which 
was thought to be due to reduced plasminogen activator activity rather than increased 
fibrinolytic activity. 
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Angiotensin converting enzyme 
Changes in the level of angiotensin converting enzyme (ACE) after radiation were 
studied to investigate the role of the endothelium in the response of the lung to radia-
tion (Ward et al. 1983). ACE resides on the lumenal surface of the vascular endothe-
lium where it catalyses angiotensin II synthesis and bradykinin inactivation, and was 
used as an indicator of endothelial functional status. Angiotensin II is an important 
vasoconstrictor. Rats received a single dose of 35Gy to the right hemithorax. The right 
lung was noted to be significantly more perfused than controls at up to 14 days post 
treatment after which the perfusion decreased until 90 days after which a plateau was 
maintained. ACE activity showed no statistically significant changes for the first 
fourteen days after which a progressive decline was noted until reaching a plateau at 
90 days. No change was observed in ACE activity in the shielded left lung. The re-
duction in ACE activity may be as a result of endothelial cell loss. Ultrastructural 
changes noted were perivascular and endothelial oedema at up to 30 days. From 30 
days onward endothelial blebbing, degeneration and fragmentation, an increase in 
capillary basement membrane, increases in interstitial mast cells, fibroblasts, plasma 
cells and alveolar macrophages were observed. From 90 to 150 days interstitial colla-
gen deposition and gradual obliteration of capillaries by fibrotic reaction were noted 
(Ward et al. 1983). 
Prostacyclin 
In a set of experiments the production of prostacyclin (PGI2) was examined after uni-
lateral irradiation of rat lung by Ts'ao et al. (1983). The vascular endothelium in the 
lung is a major source of PGI2 which functions as an inhibitor of platelet aggregation 
and as a vaso-dilator. PGii showed a significant decrease during the first day post 
treatment after which it returned to control levels until day 14 after which it showed a 
steady increase until the experiment was terminated at 6 months. The shielded lung 
did not show any changes in PGii production. An inverse relationship between PGI2 
production and perfusion was noted when the quantities were expressed in terms of 
the ratio of irradiated lung values to unirradiated lung values. Increased production of 
the prostacyclin may be a compensatory response to the hypoperfusion observed. It 
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was thus not possible to discern from the results presented whether the increase in 
PGI2 is pathologic or compensatory (Ts 'ao et al. 1983). 
Serum proteins in lavage 
Gurley et al. (1993) examined the biochemical composition of broncho-alveolar la-
vage fluids from irradiated rat lung. Complex changes in the protein composition of 
the lavage fluid were observed after doses of 7.5 and 15Gy x-rays with dose depend-
ent differences in magnitude, kinetic course and qualitative nature being noted. It was 
found that the more traditional indexes of hyperpermeability in the lung, namely lung 
wet weight and total protein were not reliable indicators of the x-ray induced hyper-
permeability response as underlying changes in the protein compositions were noted 
before any changes in wet weight or total protein content could be measured. In addi-
tion to changes in the plasma proteins found in the lavage fluid, the authors also ob-
served changes in non-plasma constituents. Of the proteins identified albumin, trans-
ferrin and immunoglobulin were elevated by 15 fold, 10 fold and 5 fold respectively 
at 5 weeks after treatment. By week 9 all components were normal except for transfer-
rin and albumin which remained elevated and an uncharacterised component ( fraction 
6) which was decreased relative to controls. The authors suggested that the progres-
sive development of fibrosis may be caused by an increase in the lung permeability 
and associated protein leakage. 
Effects of B-interferon 
A study was undertaken by McDonald et al. (1993) to investigate the radiosensitising 
properties of 8-interferon in pulmonary damage in mice. The authors showed an in-
crease in early lung damage after 12.5Gy but a protection against radiation induced 
fibrosis that was hypothesised to be due to an alteration of immune mechanisms. 
Morphological changes observed after interferon alone showed Type I pneumocyte 
lysis, but no apparent changes in Type II pneumocytes or in endothelial cells. Septal 
wall thickening was reduced after interferon and 12.5Gy when compared to 12.5Gy 
alone. 
Independent mechanisms for the early pneumonitic response and the late fibrotic re-
sponse were proposed with the late response being seen as not simply replacement of 
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damaged cells but the result of a complex biomolecular process initiated at the time of 
radiation. The increased early toxicity was postulated as being due to additive toxicity 
of the interferon on the type I pneumocytes and radiation mediated toxicity in the type 
II pneumocytes. Lavaged procollagen at 7 days after irradiation with 12.5 or 15Gy 
was reduced in mice treated with interferon (McDonald et al. 1993). 
Biochemical effects on alveolar macrophages 
The role of the alveolar macrophage (AM) in this model was examined by measuring 
the effect of conditioned medium (from the culture flasks of alveolar macrophages 
extracted from irradiated rabbit lungs) on rabbit fibroblasts (Rubin et al. 1992). Ra-
diation (5, 10 or 17.5Gy) was shown to reduce the number of AM's in the lavage from 
the 1st week after treatment. Regeneration of AM' s occurred from week 2 and by 4 
weeks the number of AM's lavaged was twice that of controls. A stimulation of fibro-
blast proliferation was seen after all doses, but was most pronounced after 17.5Gy, 
with a maximum at 2 weeks after treatment. An increase in both TGF-B and TGF-a 
was measured, with a maximum level attained by 2 weeks and sustained for the 4 
weeks of measurement. 
Transforming Growth Factor - ~ 
TGF-a has been shown to be a strong stimulus for fibroblast proliferation (Coff et al. 
1987.) TGF-B is a strong signal for extracellular collagen matrix production 
(O'Conner-McCourt and Wakefield 1987.) 
Rubin et al. (1992) further investigated the cascade of biochemical changes in the 
lung with the measurement of transforming growth factor B 1,2 and 3 (TGFB1 ,2 & 3) 
mRNA expression, which was observed to be initially depleted at 1 day after treat-
ment and then raised at 14 days after treatment (Finkelstein et al. 1994). Collagen 
types I & III mRNA levels were found to be raised at 14 days after treatment. The 
collagen !:collagen III ratio was found to be increased at 14 days. Fibronectin and 
collagen IV mRNA levels were also increased at 14 days. The authors propose an af-
ferent/ efferent phase model of radiation induced injury and response. During the af-
ferent phase radiation induced damage in the cell triggers the release of cytokines 
Cis-platinum, radiation and mouse lung Chapter 4 - Biochemical changes poge32 
such as TGF-B. These factors act in an autocrine or paracrine fashion to initiate or 
control a cellular function such as fibroblast proliferation or collagen production. This 
response forms the efferent phase in the authors ' model and may lead to late compli-
cations such as pulmonary fibrosis . 
The multicellular interactions of epithelial cells, endothelial cells, macrophages, and 
fibroblasts, mediated by cytokines following radiation injury was reviewed by Rode-
mann and Bamberg (1995). The life cycle of the fibrocyte from stem cell, to fibro-
blast, to mature fibrocyte responsible for the synthesis of interstitial collagens, fibro-
nectin, proteoglycan and other extra cellular matrix components was presented in this 
review. The complex interaction of cell types via growth factors was stressed. It was 
proposed by the authors that after irradiation, specific cell types (e.g. alveolar macro-
phages and type II pneumocytes) may be stimulated to produce altered amounts of 
growth factors such as interferon-a, IL-I , PDGF, TGF-a and TGF-P. These factors 
could then alter the proliferation, differentiation and matrix gene expression of the 
lung parenchymal fibroblasts leading to pulmonary fibrosis . 
Three actions of TGF-P were proposed to be important in fibrosis . Firstly, TGF-P can 
directly affect the gene expression of extracellular matrix molecules in stromal cells to 
induce synthesis of collagen and inhibit the formation of collagenase. Secondly, TGF-
p can induce fibroblast proliferation by stimulating the production of PDGF that in 
turn acts on the fibroblasts to promote fibrogenesis. Thirdly, TGF-P can establish a 
state of autocrine stimulation in fibroblasts resulting in chronic activation and differ-
entiation to the fibrotic phenotype (Rodemann and Bamberg, 1995). 
The role of TGF-P 1 in radiation fibrosis has been further reported on by Burger et al. 
(personal communication, 1994a) and Burger et al. (1994b). Irradiation of primary 
cultures of type II pneumocytes from rats was shown to produce an immediate synthe-
sis of TGF-f31. This was then shown, using a co-culture system, to produce a signifi-
cant increase in the DNA synthesis, proliferation and clonogenic activity of fibro-
blasts. The irradiated type II pneumocytes were shown to cause an increase in the 
fraction of post mitotic cells in the fibroblast co-culture. This experiment is an ele-
gant demonstration of radiation effects in one lung cell type causing the release of 
factors that initiate a response in another cell type. In this case the type II pneumo-
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cytes are irradiated in isolation and then grown in co-culture with fibroblasts where 
they initiate changes indicative of a progression to a fibrotic state. 
TGF-B has also been proposed as being involved in the fibrotic response of the lung 
after treatment with drugs such as bleomycin and cyclophosphamide (Hoyt and Lazo 
1990). Levels for TGF-J3 mRNA were increased 1 week after treatment with bleomy-
cin in C57Bl/6 mice (a strain which shows pulmonary fibrosis after treatment with 
Bleomycin) whereas the TGF-J3 mRNA levels did not increase in Balb/C mice (a 
strain resistant to fibrosis) (Hoyt and Lazo 1988). Strikingly similar results were 
found in C57BL/6 (fibrosis sensitive) and C3H/HeJ (fibrosis resistant) mice after 
treatment with ionising radiation by Johnston et al. (1995). TGF-J31 mRNA and TGF-
J33 mRNA were increased twofold at 8 weeks in the C57/Bl mice while TGF-J31 re-
mained stable in the C3H/HeJ mice. TGF-J33 was increased slightly in the resistant 
strain at 8 weeks. 
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Chapter 5. Pulmonary surfactant after radiation 
What is surfactant? 
Surfactant is responsible for preventing the collapse of the small airways in the lung. 
It accomplishes this by reducing the surface tension in the alveoli. The surface tension 
in any particular alveolus is inversely proportional to the concentration of surfactant 
per unit area of alveolar surface. Should the alveolus tend to collapse the 
concentration of surfactant per unit area will increase and thus reduce the surface 
tension further, preventing collapse. The reduction in surface tension produced by the 
surface active properties of surfactant also facilitates breathing by reducing the 
amount of effort required to re-inflate the lungs at end expiration. 
Synthesis of surfactant is thought to take place in the endoplasmic reticulum before 
passing through the Golgi bodies to be stored in the lamellar body of the type II 
pneumocyte (Rooney et al. 1975.) The lamellar bodies migrate to the apical surface of 
the cell and are extruded into the alveolar space where they are thought to pass 
through a tubular myelin form before forming a mono-layer (Goerke, 1974.) 
The composition of surfactant is given in Table 1. The largest fraction comprises the 
phospholipids of which phosphatidylcholine-dipalmitate is the largest single 
component. 
Table 1. Percentage Compositions of Pulmonary Surfactant. Data from King et 
al. (1972). 
Chemical Components Lipid Fraction Phosphatidylcholine derivatives 
Lipid 85 Phosphatidylcholine 75 Palmitate 71 
Protein 13 Neutral Lipid 9.1 Myristate 6.1 
Hexose <1.7 Cholesterol Phosphatidyl- 6.3 Stearate 3.6 
ethanolamine 
Nucleic Acid <0.7 Sphingomyelin 2.1 Palmitoleate 11 
Hexosamine <0.5 Lysolecithin 0.9 Oleate 3.9 
Unident. 3.6 
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Radiation effects on pulmonary surfactant 
An increase in the amount of disaturated phosphatidyl choline (DPC) in both the lung 
and alveolar surface lining layer was reported by Gross in 1978 after irradiation of 
mouse lung with 250kVp x-rays. Mice were irradiated with 2 fractions of 6Gy sepa-
rated by 48h. This increase was observed to begin at 7 days post treatment and to have 
returned to control levels by 12 weeks. 
An increase in lavaged phospholipid from mouse lung was also observed by Rubin et 
al. in 1980 at 1 h, 24 hand 1 week following irradiation. LAF1/J mice were irradiated 
with 30Gy 137 Cs gamma rays. 
Sequential changes in the pulmonary surfactant system after irradiation with 13Gy 
and 19.5Gy 137Cs gamma rays included: increases in lavaged surfactant from as early 
as 24 h after treatment persisting to 4 weeks and returning to normal by 18 weeks; 
morphologic changes indicative of lamellar bodies in the type II cells discharging 
their content into the alveolar lumen during the first week post treatment; increases in 
lamellar body number by 18 weeks; elevated protein levels and some evidence of 
collagen formation by 18 weeks (Shapiro et al. 1982). No changes were seen after 
6.5Gy. This increase was linked in a later paper by the same group to the pneumonitic 
phase of pulmonary toxicity (Rubin et al. 1983). An increase was observed to occur in 
both the surfactant radiation dose response curve and in the dose response curve for 
lethality with a threshold dose of 12Gy in both cases. This was taken to indicate that 
the early release of alveolar surfactant may serve as a marker for later radiation dam-
age. 
The release of surfactant after irradiation by type II pneumocytes taken from rabbits 
and cultured in-vitro has also been shown, with a threshold dose of between 10 and 
15Gy (Shapiro et al. 1984). The response appeared to be via triggering of a membrane 
receptor. In addition radiation appeared to abolish the ability of the pneumocytes to 
respond to stimulation by terbutaline - a beta adrenergic agonist that normally initi-
ates a release of surfactant by type II pneumocytes. The in-vitro work suggest to the 
authors that the release of surfactant is a direct effect of radiation on the type II pneu-
mocyte. 
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Surfactant function was shown to be impaired during radiation pneumonitis after uni-
lateral irradiation of sheep lung (Tillman et al. 1989). The ability oflavaged surfactant 
to reduce surface tension was greatly reduced (producing a minimum surface tension 
twice that of controls) in lavage fluid from irradiated lungs. The protein content of 
lavage fluid from irradiated lungs was also increased compared to controls and it was 
suggested that this was responsible for reducing the surface activity of the surfactant. 
Increases in surfactant levels do not appear to be merely related to a radiation induced 
release of stored surfactant as changes in both turnover and synthesis of the compo-
nents of surfactant have been measured. A reduction in the rate of radioactivity loss 
from 3H-choline labelled disaturated phosphatidylcholine from the lung of mice was 
observed 2-6 weeks after irradiation with lOGy 250kVp x-rays (Coultas et al. 1987). 
This loss indicated a reduction in phosphatidylcholine turnover and occurred during 
the period when lavaged surfactant levels were elevated. At 3 weeks after irradiation 
an increase in 3H-choline incorporation into disaturated phosphatidylcholine was 
noted as indicative of increased synthesis. It was therefore proposed that there are at 
least two different responses leading to increased levels of surfactant - the initial one 
possibly due to release of stored surfactant and its reduced removal and a slightly later 
one due to an increased rate of synthesis. 
In addition to measuring surfactant release by determining the amount of lavaged 
phospholipid, the protein content of the lavage fluid may also be measured. Anderson 
et al. (1985) examined protein levels in lavage fluid from mouse lung after neutrons or 
x-rays and found a biphasic response. In the period up to 6 weeks protein levels in-
creased to 4 times control levels but did not appear to show a radiation dose response 
(in contrast to phospholipid release) nor an RBE relative to neutrons greater than 1. 
Protein level was therefore thought to be unrelated to cell death. The second phase of 
protein release with a maximum at about 15 weeks and with levels of 20-30 times 
control corresponded with times of animal death. This second phase was dose de-
pendent for both neutrons and x-rays. The authors could not determine the RBE for 
the endpoint of protein release during the second phase due to the range of doses used. 
In rats receiving either 7.5 or 15Gy to the thorax, changes in lung weight and volume, 
lavaged alveolar macrophage number, interstitial mast cell number, lavaged phospho-
lipid levels, lavaged protein levels and lavaged histamine levels were followed with 
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time for up to 13 weeks after treatment (Lehnert et al. 1991 ). In the 15Gy dose group, 
alveolar macrophages, mast cells, lavaged phospholipid, lavaged protein and lung 
weight were all increased by 5 weeks after treatment. These changes were not seen in 
the lower dose group at this time. By week 7 and 9 phospholipid levels had subsided 
in the 15Gy group as had hyperpermeability levels as indicated by lavaged protein or 
increases in lung wet or dry weight. The ratio of mast cells remained elevated and an 
increase in histamine levels was noted. In the 7.5Gy dose group lung weights and 
protein levels were significantly increased by week 13. An increase in phospholipid 
levels preceded that of protein levels and was thought to be independent of changes in 
the permeability of the lung. Changes in permeability were thought to be independent 
of mast cell status and histamine levels. The authors suggested that elevations in mast 
cell number may contribute to radiation induced fibrosis by mitogenic stimulation of 
fibroblasts (Lehnert et al. 1991). 
Surfactant composition after irradiation 
Gross (1979) reported that the phospholipid composition of the surfactant from irradi-
ated mouse lung appeared to be normal. In a later paper (Gross 1991) he reported dif-
ferent subtypes discernible when the surfactant was fractionated on continuous su-
crose density gradients. Analysis was performed when the breathing rate of mice ex-
ceeded 300 breaths per minute indicative of pneumonitis. The proportion of high 
buoyant density subtype was increased about twofold in surfactant from irradiated 
mice while the low buoyant density subtype was greatly reduced or absent. In irradi-
ated mice the high buoyant density subtype appeared to contain electron dense mate-
rial on examination by electron microscopy. This disappeared if the fraction was repu-
rified and the appearance of the subtype matched that of controls. The high buoyant 
density subtype of irradiated mice had abnormal surface activity which returned to 
normal on repurification. The phospholipid composition of all subtypes was the same 
in both irradiated and control mice. 
A possible explanation for the increase in high buoyant density subtype is offered by 
work showing inhibition of serine protease ( convertase) activity which is thought to 
be responsible for converting the high buoyant density subtype to the low buoyant 
density subtype (Gross 1991). It was found that the alveolar lavage fluid from mice 
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with radiation pneumonitis caused an inhibition of convertase with an 18-fold excess 
of antiprotease activity. 
Does surfactant predict later radiation effects? 
The response of the alveolar surfactant system in mouse lung after treatment with ei-
ther 7.5 MeV neutrons or 250 kVp x-rays was examined (Ahier et al. 1985). An in-
crease in lavaged surfactant, with a maximum at 3 weeks after irradiation was seen. 
No differences in response after neutrons or x-rays was observed with regard to the 
time course of surfactant release. The RBE for surfactant release was - 1 which did 
not correlate with the RBE for death. 
This work was used to support the contention that the release of surfactant is merely 
co-incidental to lethality and not part of the pathway leading to pneumonitic death. 
This point of view was placed before the editors of the International Journal of Radia-
tion, Oncology, Biology and Physics in a letter published by Down et al. in 1988. 
Three arguments supporting the contention that lavaged surfactant was not a marker 
for later radiation damage were presented. Firstly, the threshold doses for lethality and 
surfactant release differed in the rabbit (Rubin et al. 1986). Secondly, that there were 
mouse strain specific differences with regard to the time course of release of surfac-
tant. Thirdly, that the RBE for x-rays relative to neutrons, calculated using the end-
point of surfactant release was different to that calculated using death as the endpoint. 
In their response Rubin et al. (1988) agree that the mechanism for surfactant release 
and cell death (presuming that cell death were the true underlying radiation lesion in 
pulmonary injury) may be separate pathways but that this should not necessarily in-
validate the usefulness of surfactant release as a predictor for pneumonitic lethality. 
Rubin et al. ' s acknowledgement that surfactant release and later pulmonary damage 
may be on different pathways places the measurement of surfactant as an indicator of 
late radiation damage on the level of empirical coincidence. This would obviate its 
inclusion as a reliable marker for all but the protocols in which it had been measured 
as useful. 
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A different and possibly clinically more useful approach to early markers of pulmo-
nary damage has been reported by Rubin et al. (1989) who examined serum levels of 
surfactant apoprotein in rabbits. Serum apoprotein was found to be increased from day 
1 after treatment with lethal doses (14 - 16Gy 6°Co) of radiation, decreasing to near 
normal by day 21 after which it again increased. The dose response of the measured 
levels of protein in the serum paralleled that of lethality. Surfactant apoprotein was 
not measured in the serum after stimulation of surfactant release by terbutaline sup-
porting the hypothesis that damage to endothelium and basement membranes was es-
sential to release of apoprotein. 
A decrease in the compliance or elasticity of the lung during pneumonitis is thought to 
be due to a decrease in the compliance of the alveolar surface lining layer. This de-
crease may be associated with the leakage of proteins into the alveolar space causing a 
decrease in the surface tension reducing activity of surfactant (Gross 1978). The 
minimum surface tension of surfactant from irradiated mice was higher than that of 
controls. The same author (Gross 1981) found a decrease in lung compliance during 
the pneumonitic phase that may be attributable to changes in the surface layer me-
chanics. At nine months after treatment a low compliance was noted but this could not 
be attributed to changes in the surface layer and was ascribed to loss of compliance of 
the tissue element as manifested by the appearance of alveolar wall fibrosis (Gross 
1981). 
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Chapter 6. Breathing rates after radiation 
Travis et al. (1979) described a technique for measuring mouse breathing rates as a 
determinant of pulmonary function after irradiation. An apparatus was constructed 
consisting of a small airtight perspex chamber fitted at each end with a door. One of 
the doors contained a microphone. The signal from the microphone was fed through a 
series of amplifiers and filters culminating in a rate meter which produced a voltage 
proportional to the breathing rate of the mouse in the chamber. This signal was re-
corded on chart recorder as was a second signal proportional to the amplitude of the 
breathing the mouse' s breathing. 
The frequency of breathing was recorded as a function of radiation dose. Statistically 
significant changes in mean breathing rate at 16 weeks after irradiation were recorded 
at a dose of 15Gy with a threshold of about lOGy for the dose response. This increase 
preceded histological evidence of fibrosis and occurred before deaths from pulmonary 
insufficiency. It was concluded that the technique was a viable alternative for assess-
ing radiation lung damage in small animals and had the advantages of being non-
invasive, sensitive to lower doses than LDso, and allowed sequential changes to be 
assessed (Travis et al. 1979). Since then, numerous authors have used the technique to 
assess pulmonary damage after radiation. 
The amplitude signal was not calibrated in their experiments and was subject to more 
technical difficulties than the breathing rate measurements. Nonetheless, a dose de-
pendent reduction in amplitude was seen at 16 weeks post treatment. 
It was suggested (Travis et al. 1979) that factors affecting amplitude and breathing 
rate would include: airway resistance, ventilation, lung volume, shape of breathing 
cycle and changes in lung compliance. Pulmonary fibrosis would cause a change in 
lung compliance. However the changes in breathing rate noted by the authors were 
observed to occur before the onset of fibrosis noted in previous experiments (Travis et 
al. 1978.) The changes in breathing rate at 16 weeks were thus ascribed to a change in 
lung compliance due to oedema typical of radiation pneumonitis. 
It was concluded that the technical difficulties in consistently determining the ampli-
tude of breathing made breathing rate the measurement of choice. Breathing rate 
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measurements were seen to provide a quantitative, non-invasive method for assessing 
radiation lung damage. The method allowed changes to be recorded with time after 
treatment and was sensitive to lower doses than LD50. 
A number of factors were identified by Travis et al. ( 1981) as affecting the breathing 
rate of mice used for studies of radiation damage to the lung. These include age, ac-
climatisation to the measuring process, movement, mouse strain, and sex (in CBA 
mice). The importance of controlling measuring conditions and maintaining uniform-
ity within experiments was stressed. 
Since the publication of the work (Travis et al. 1979) the breathing rate technique has 
been widely adopted as a method of assessing the response of the lung to radiation. 
Breathing rates and radiation repair 
The repair capacity of mouse lung as assessed by a reduction in the breathing rate 
compared to that produced by a single dose of radiation has been investigated by a 
number of authors. These include Travis et al. 1983a; Travis et al. 1983b; Parkins et al 
1985; Down et al. 1986; von Rongen et al. 1995. In each case the technique has pro-
duced results comparable to that obtained using other methods, such as LDso studies, 
for assessing pulmonary damage. It has also proved sensitive to changes induced by 
small doses per fraction. Von Rongen et al. (1995) showed a repair half time (tv,) of 
between 0.25 and 0.75 h for mice irradiated with six equal dose of 2.09Gy given at 
intervals of O to 45 minutes and topped up 24 h later with a range of single doses. The 
tY, values obtained were similar for both the breathing rate endpoint and for death due 
to radiation pneumonitis. Parkins et al. (1985) used breathing rate measurements to 
determine repair parameters at up to 17 months after irradiation with either 1, 10, 20 
or 40 equal fractions of fast neutrons or x-rays. The data obtained could be well fitted 
using the linear-quadratic model ofradiation damage. 
Down et al. (1986) used the technique to determine dose recovery factors (DRF) after 
treatment with progressively lower dose rates. A continuous increase in tolerance for 
early radiation pneumonitis reaching a DRF of 2.6 at 2cGy/min was observed. 
Terry et al. (1988) assessed the amount of residual damage in lung after a range of 
radiation doses was administered. A second dose of radiation administered at between 
Cis-platinum, radiation and mouse lung Chapter 6 - Breathing rates poge42 
1 and 6 months after initial treatment was used to determine the amount of damage 
still "remaining" in the lung as a result of the first dose. Breathing rate data were used 
to show that the amount of residual damage was highest at 1 month after treatment 
and lowest at 3 months. This partial recovery was followed by an increase in the 
amount of damage remembered - i.e. a reduction in the amount of second dose that 
could be delivered for the same effect. It was hypothesised that the data showed an 
early target cell depletion with regeneration up to 3 months. 
Breathing rates, radiation and chemical modifiers 
Breathing rates have also been used as an end point for assessing radiation treatment 
regimes including sensitizers and protectors. 
Travis et al. (1987) and Parkins at al. (1984) investigated lung radioprotection by WR-
2721 after single dose and fractionated doses respectively. The single dose work by 
Travis et al. showed dose modifying factors of 1.2 to 1.4 for pneumonitis and 1.5 to 
1.6 for the later occurring fibrosis. These dose modifying factors for pneumonitis and 
fibrosis were significantly different. It is interesting to speculate that this difference 
may be attributable to different mechanisms of injury involved in the two endpoints. 
If pneumonitis were an interim step on the path to fibrosis then one might expect the 
DMF values for pneumonitis to be similar to those obtained for fibrosis . It may be that 
cell populations with different susceptibility to protection by thiols are involved in the 
aetiology of damage for the different endpoints. 
A low protection factor (DMF = 1.2 - 1.4) was observed for WR.2721 administered 
before a single dose in air, a single dose in 10% oxygen or before 10 fractions in air 
(Parkins et al. 1984.) Considerable more protection (DMF = 1.5 - 1.7) was observed 
for 10 fractions in 10% oxygen. It was postulated that in 10% oxygen a sufficient pro-
portion of the normally well-oxygenated cells in the lung became sufficiently hypoxic 
to benefit from WR-2721 protection. Oxygen dependent protection of radiation lung 
damage in mice was also demonstrated by Down et al. in 1984 again using breathing 
rate as an endpoint for determining radiation effect. 
Protection by Interleukin 1 against lung toxicity after treatment with cyclophospha-
mide and radiation was observed by Dorie et al. ( 1991.) Interleukin 1 significantly 
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reduced the breathing rates for mice treated with high cyclophosphamide doses and 
radiation. 
Breathing rates, radiation and cytotoxic agents 
In 1986 Hill et al. investigated the effect of Actinomycin D in combination with ra-
diation on mouse lung. No effect on breathing rate was observed after combinations 
where drug was administered 4 weeks before, immediately after or 16 weeks after 
single doses of240kV x-rays. 
Lung damage, that is pneumonitis as assessed by breathing rates, was seen to occur 
earlier and to be more severe after maximally tolerated doses of cyclophosphamide 
followed by single doses of gamma rays at either 1, 3 or 6 months (Travis et al. 1990). 
This may indicate that the lung would be sensitive to re-treatment with radiation after 
full tolerance doses of cyclophosphamide. 
A number of different drug treatments were used to modify the dose dependent rise in 
breathing rate observed at 16 weeks after irradiation of mice hemi-thoraxes (Lockart 
et al. 1992). Cyclophosphamide was seen to accentuate and accelerate the rise in 
breathing rate. BCNU delayed the onset of the increase in breathing rates. Doxorubi-
cin, Carboplatin, vindesine and vinblastine all had no substantial effect on breathing 
rate. Busulphan in DMSO was seen to be radio-protective, an effect later attributed to 
theDMSO. 
Kallman ( 1994) reviewed a number of experiments in which the breathing rate tech-
nique was used to assess the therapeutic effectiveness of treatments in which various 
chemotherapeutic agents and radiation were combined. For every schedule, therapeu-
tic gain factors were determined as the ratio of effectiveness for tumour growth inhi-
bition to each of three normal tissue endpoints. The normal tissue endpoints used 
were: pneumonitis (breathing rate at 5 months); pulmonary fibrosis (breathing rate at 
10 months) and duodenal crypt cell survival. For every combination tested there was 
at least one schedule seen to be therapeutically superior. Substances tested included 
cis-platinum, 5FU, cyclophosphamide and etoposide. The cis-platinum work is com-
mented upon in more detail below. 
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Breathing rates and irradiated volume 
Herrmann et al. (1997) showed that the induction of structural lung damage as as-
sessed by histological evaluation and hydroxyproline content was independent of irra-
diated volume. However functional damage as assessed by breathing rates depended 
on the volume irradiated. The lack of volume effect at the structural level would indi-
cate that damage is dependent only on dose deposited within the volume being as-
sessed and is not influenced by dose deposited outside the volume being assessed. A 
contrasting scenario might be that where factors released in adjacent irradiated tissue 
modified the response of the volume under consideration. 
A heterogeneous response to irradiation of partial lung volumes has been shown by 
Liao et al. (1995) and Travis et al. (1997.) Higher doses were needed to obtain 
equivalent response when smaller volumes of lung were irradiated. Increases in 
breathing rate correlated with lethality when irradiated volume was greater than 50% 
of a reference volume. For irradiated volumes less than 40% of the reference volume 
breathing rate increases were not accompanied by increases in lethality. It was also 
noted that for a given volume irradiated the iso-effective dose was always lower for 
treatment areas in the base of the lung than for areas treated in the apex of the lung. 
The authors suggested that the heterogeneity of response is a results from the anatomy 
of the tracheo-bronchial tree. The distribution of non-gas exchanging airways in the 
irradiated volume will influence the dose response. It was also noted that histological 
evidence of damage was always confined to the irradiated volume only. This is in 
contrast to results reported by Morgan et al. (1995) who showed bilateral lymphocytic 
alveolitis of activated T lymphocytes and a diffuse increase in gallium uptake after 
unilateral lung irradiation. 
Inter-strain differences in breathing rate 
Different strains of mice have been shown to respond differently to radiation treat-
ment of the lung. These strain dependent differences could be used to provide models 
for mechanistic studies of the radiation response of the lung. 
Down et al. (1983) using breathing rate and lethality as end points contrasted the re-
sponse of CBA mice with that of C57Bl mice. It was found that two distinct phases of 
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damage could be observed in CBA mice as an early pneumonitic phase and a later 
phase associated with pleural effusions. C57Bl mice failed to show the pneumonitic 
phase. The authors speculated that the difference suggested damage to separate tissue 
compartments as being responsible for the acute and chronic phases of radiation in-
Jury. 
Down et al. (1986) refined this work using CBA, C57Bl mice and their Fl hybrid 
cross (CBBFl). CBA mice showed a peak response at 16 weeks after which the 
breathing rates declined. The response of C57Bl mice was considerably delayed in 
comparison and that of the CBBF 1 mice was intermediate between the parent strains. 
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Chapter 7. Cis-platinum 
(cis-dichlorodiammineplatinum II) 
What is cis-platinum? 
The biological activity of platinum co-ordination complexes was first noted in ex-
periments in which bacteria were cultured in the presence of platinum electrodes and 
media containing ammonium chloride where an inhibition of bacterial growth sur-
rounding the platinum electrode was recorded (Rosenberg et al. 1965). Rosenberg 
(1969) soon noted the potential for the clinical use of platinum co-ordination com-
plexes in the treatment of malignancies. 
Cis-dichlorodiammineplatinum II ( cis-platinum) was the original complex generated 
in Rosenberg's experiments and has since proved to be one of the more effective 
clinical agents in the treatment of cancer (Muggia 1991, Comis 1994). It is the com-
pound of interest in this study. Its structure and chemistry have been extensively re-
viewed (Calvert et al. 1993). 
Cis-platinum is thought to exert its biological effect by bidentate binding of the cis-
platinum to DNA It binds to all bases except thymine with a marked preference for 
guanine (Munchausen and Rahn 1979). Denaturation of DNA is caused at very low 
doses of cis-platinum. Inactivation of translation (1 molecule of cis-platinum per 100 
bases) is observed before interstrand cross linkage occurs (20 molecules of cis-
platinum per 1000 bases) (Munchausen and Rahn 1979). 
Work published by Sorensen et al. (1988) has failed to show a correlation between 
inhibition of DNA synthesis and lethality. Repair deficient CHO cells were observed 
to die at doses of cis-platinum which failed to cause inhibition of synthesis while re-
pair proficient CHO cells survived doses which inhibited synthesis and arrested the 
cells in S-phase (Sorensen and Eastman 1988). It was suggested that toxicity may oc-
cur via induction of apoptosis. Both Sorensen et al. (1990) and Barry et al. (1990) 
have shown that cell death following administration of cis-platinum was accompanied 
by fragmentation of DNA into multimers of about 180 base pairs consistent with in-
temucleosomal cleavage by an endonuclease, followed by loss of membrane integrity 
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and cell shrinkage, all features which have been reported as characteristic of apoptosis 
(Wyllie et al. 1980). 
Cells are capable of repairing cis-platinum lesions. This was demonstrated when nor-
mal human fibroblasts were allowed to remain confluent after treatment with cis-
platinum and survival was seen to increase with time (Pera et al. 1981). The number 
of platinum-DNA residues decreased as a first order process with a half-life of 2.5 
days. This is in agreement with work by Van den Berg et al. (1975) that showed that 
damage to DNA arising from cis-platinum treatment could be repaired by a caffeine 
sensitive post replication repair process. 
A number of proteins have been observed to bind to cis-platinum adducts (Chu 1994). 
These include XPE-BF and ERCCl , which are involved in repair of cis-platinum le-
sions. HMGl, HMG2, SSRPl and human upstream binding factor have also been ob-
served to bind to cis-platinum adducts. Cellular resistance or sensitivity to cis-
platinum may be viewed as a dynamic competition among proteins which either repair 
or interfere with repair or which signal for cell death via apoptosis (Chu 1994). 
Pharmacokinetics 
In-vivo, cis-platinum is cleared from the plasma by tissue uptake, urinary excretion 
and by irreversible binding to plasma proteins and metabolites (Calvert et al. 1993). 
Therefore, total platinum is made up of protein bound and ultrafilterable (unbound) 
species. The unbound platinum is thought to be responsible for anti-tumour activity 
and toxicity. Renal toxicity, when comparing platinum analogues with different lig-
ands has been seen to correlate with the stability of the compound in aqueous solu-
tions, with the distribution half-life and with the cumulative 24 h urinary excretion 
(Calvert et al. 1993). In addition toxicity has been observed to correlate with platinum 
retention in the kidneys of nude mice. 
Cis-platinum plasma levels have been observed to decay following a biphasic pattern 
with a short initial distribution half-life of the order of minutes followed by a longer 
elimination phase with a half-life of the order of days (Litterst et al. 1979). Seventy 
nine percent of an i. p. dose of cis-platinum was excreted in mouse urine on the first 
day after administration (Lange et al. 1972). Hydration before and after cis-platinum 
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(i.v.) administration was observed not to affect the levels of cis-platinum measured in 
plasma in mice, rats, dogs or sharks (Litterst et al. 1979). The same authors observed 
an initial distribution to nearly all organs in the body followed by an accumulation in 
kidney, liver, muscle and skin. The general distribution was independent of species 
studied. Tissue:plasma ratios of greater than 1 were maintained for at least 1 week af-
ter treatment and in kidney, liver, skin and lung may have been elevated for 2-4 weeks 
after treatment Litterst et al. 1979). 
A t y20 of 0.61 h and ty,p of 1.28 h was measured in lung for cis-platinum given i.v. 
(maximally tolerated dose of 4mg/kg) to mice with the highest concentration of 
1.9µg/g wet weight measured at the earliest time interval of 10mins after injection 
(Siddik et al. 1988). The initial rapid clearance of drug from the plasma is represented 
by tv.a, and tv.p is the half life for the longer elimination phase. The plasma tv.a was 
determined to be 0.27 h with a ty,p of 36.5 h (Siddik et al. 1988). Tissue to plasma ra-
tios for lung were seen to increase from 0.41 at 10 min to 12.3 at 6 days, indicating 
retention of drug in tissue. 
Maximum plasma concentration after an i.p. injection of 6mg/kg was seen at 5 min-
utes in C3Hf/Sed mice (Fu et al. 1988). The a half-life, after i.p. injection, of ultrafil-
terable platinum in plasma was determined to be 0.31 h and the p half-life was found 
to be 27.7 h. 
It may thus be hypothesised that maximum lung concentrations of cis-platinum occur 
within minutes of i. p. injection. However, these concentrations were measured by 
atomic absorption spectroscopy and thus represent the total tissue or plasma platinum. 
This does not necessarily reflect the amount of active drug in the sample. Cis-
platinum may be irreversibly bound to material not important in causing cell death 
(Melvik et al. 1992). 
The i.v. and i.p routes of administration gave comparable levels of drug in the lung at 
both 4 and 8 days after injection in dogs (Pretorius et al. 1981). The mean serum con-
centration of cis-platinum reached a maximum 4 h after i. p. injection. 
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Circadian variation in toxicity 
Several authors have noted a pronounced circadian variation in toxicity of cis-
platinum. Shakil et al. ( 1994) recorded that 80% of mice treated with 16mg cis-
platinum/kg died when cis-platinum was given 3 h after lights on compared to a 10% 
death rate when cis-platinum was given 9 h after lights on. 
Similar findings were noted by Boughattas et al. (1990) who reported that cortical tu-
bular necrosis in mice was half as severe when cis-platinum was administered 16 h 
after lights on than when given at O or 8 h after lights on. 
The lowest renal toxicity in rats was measured when cis-platinum was administered 
near to the normal circadian maximum urinary volume (Levi et al. 1982). 
A 3- to 8-fold difference in the time to 50% mortality was noted in rats after admini-
stration of cis-platinum. The lowest toxicity was observed when cis-platinum was 
given close to the mid activity span (Hrushesky et al. 1982). 
Interaction with radiation 
It is evident that cis-platinum is capable of increasing the severity of radiation damage 
in a number of systems. 
Cis-platinum was noted to interact with radiation by Zak et al. (1971) who observed 
an increased lethality in mice given cis-platinum i. p. and treated with single doses of 
x-rays. Enhanced survival was seen in mice inoculated with P388 lymphocytic leu-
kaemia cells when they were treated with both cis-platinum and radiation as opposed 
to either agent alone indicating possible radiosensitisation by cis-platinum (Wodinsky 
et al. 1974). 
Increased radiosensitivity was measured in bacterial spores after cis-platinum was 
administered before radiation (Richmond et al. 1977) and in E.coli (Richmond et al. 
1977b). 
Cis-platinum may increase sensitivity to radiation by interfering with repair of radia-
tion damage. Cis-platinum was observed to remove the shoulder in the radiation sur-
vival curve of TC40 mammalian cells (Alvarez et al. 1978). Cis-platinum, at mini-
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mally toxic doses, was seen to inhibit repair of radiation damage in split dose experi-
ments using V-79 cells (Dritschilo et al. 1979). Minimal inhibition of repair was seen 
after single dose, delayed plating type repair experiments. Cis-platinum ( even with 
non-toxic doses of 1 µmol dm ·3) was observed to increase the number of hypoxic V-79 
cells killed, especially at low (0-4Gy) doses of radiation (Korbelik et al. 1989). 
A trend toward greater than additive delay in tumour growth was observed in RIF-1 
and K.HT tumours after combined cis-platinum and radiation although this was not 
seen in the EMT6 tumour (Twentyman et al. 1979). An enhanced response was seen 
after combined treatment with radiation and cis-platinum of mouse mammary tumours 
and an intracerebral rat brain tumour (Douple et al. 1977). Supra-additivity was seen 
in the regrowth response of the SCVII and RIF-1 murine tumours to combined cis-
platinum and radiation treatment (Kallman et al. 1991 ). 
Sensitisation after treatment with both radiation and cis-platinum has also been ob-
served in normal tissue systems. 
In mice an enhanced reaction was seen in bladder for both early and late reactions by 
Lundbeck et al. (1992). An early (30 days after treatment) change in bladder reservoir 
function was seen in animals treated with 20Gy plus 6mg/kg cis-platinum at 24 h be-
fore, 15 min before and 4 h, 72 hand 336 h after radiation. A late (110 days after 
treatment) reduction in bladder reservoir function was seen after treatment with cis-
platinum administered at a range of times between 168 h before radiation and 72 h 
after radiation. 
In mouse kidney significant renal toxicity was seen when cis-platinum was combined 
with radiation with the toxicity of combined treatments always more severe than the 
single agent treatments. The a/13 ratio (from the linear quadratic survival model) was 
not changed by the presence of cis-platinum indicating that increased renal damage 
was most likely additive (Stewart et al. 1989). In intestinal crypts from mouse duode-
num cis-platinum caused a significant increase in cell death when combined with ra-
diation (Dewitt et al. 1985). Enhanced gut damage assessed using the intestinal crypt 
assay was seen for cis-platinum given up to 6 h before radiation but not at longer time 
intervals before or when given after (2 to 24 h) irradiation (Von der Maase 1984). In-
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creased damage has been observed in rat skin for cis-platinum given 2 h or immedi-
ately before radiation (Douple et al. 1979). 
Mechanism of interaction 
Cis-platinum may interact with radiation in one of two ways. Studies in bacterial sys-
tems (Richmond 1984) have indicated that cis-platinum can act as a reactive free radi-
cal, via radiation induced reactive Pt(I) intermediates and / or in part by interaction of 
Pt(II) species with DNA. This direct pathway has been termed sensitisation and al-
though dependent on free radical chemistry, other mechanisms such as sulfbydryl de-
pletion, radiolytic toxic product formation and cell cycle perturbation may be impor-
tant (Douple 1988). 
The second pathway of interaction is mediated not by direct interaction of radicals but 
rather by biomolecular processes that occur after radiation and result in the inhibition 
of repair. This has been termed potentiation (Douple 1988). Coughlin and Richmond 
(1989) hypothesised that in mammalian systems the relatively low concentrations of 
cis-platinum obtainable in the cell favours the biomolecular pathway rather than the 
more directly mediated free radical or radiolytic pathway. The initial sensitisation 
may depend on the presence of free drug whereas that of potentiation depends on 
bound drug. 
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Chapter 8. Cis-platinum and radiation damage to 
the lung 
Experimental studies 
Cis-platinum was reported by Von der Maase et al. (1986) as having no effect on lung 
damage .of C3D2F 1/Bom mice (C3H/Tif a x DBN2) as assessed by breathing rate and 
lethality when drug was given 15 minutes before graded doses of radiation. The 
authors state, but do not show data, that cis-platinum did not modify the radiation re-
sponse when given at different intervals from 28 days before to 28 days after radia-
tion. Cis-platinum was administered at a maximally tolerated dose defined as that 
dose which would kill 1 % of the mice within 150 days. 
Dose enhancement factors (DEF) of greater than 1 were found for lung damage in 
C3H/Km mice after a variety of different cis-platinum / radiation dose combinations 
(Tanabe et al. 1987). Cis-platinum was given i.p. at 4, 8, or 12 mg/kg or as 5 fractions 
of 0.8, 1.6 or 2.4 mg/kg when 5 daily fractions were given. Only the thorax was irra-
diated. The end point assessed was the breathing rate at 5 and at 10 months after 
treatment. In general it was found that the highest DEFs were obtained for schedules 
in which 5 daily drug doses were followed by 5 daily irradiations (1.15 - 1.47). How-
ever, it was also found that DEFs of greater than 1 were obtained where a single dose 
of cis-platinum was administered before a set of 5 daily irradiations and where cis-
platinum was given before or after each fraction. The authors noted (but did not show 
data) that a significantly depressed breathing rate was measured in mice after cis-
platinum alone at times associated with the early phase of radiation damage ( 5 
months). This had returned to normal by the time that late phase radiation damage 
would have been expressed (10 months). Breathing rates of combined treatment 
groups were elevated during both the early and late phases indicating that the breath-
ing rate changes reflected real interactions between drug and radiation and not merely 
general physiological effects caused by the drug. 
The greatest effects were observed when cis-platinum was given as 5 fractions daily 
during the week preceding 5 daily fractions of 4Gy each. The lowest DEFs for lung 
damage appeared to be achieved after simultaneous administration of cis-platinum 
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and radiation - contributing to a high therapeutic gain factor (TGF) where the TGF 
was defined as the ratio of the DEF for tumour to the DEF for normal tissue. A TGF 
of greater than 1 would signify a that the tumour tissue was being sensitised more than 
normal tissue. 
There did however appear to be a large variation between some experiments (See 
Table 2. presenting data from Tanabe et al. 1987). For 1.6 mg/kg given daily immedi-
ately before irradiation a DEF of 1.22 ± 0.06 was obtained at five months after treat-
ment. For both the lower dose of 0.8 mg/kg and the higher dose of 2.4 mg/kg cis-
platinum daily significantly lower DEFS of 0.8 ± 0.06 and 1.02 ± 0.07 respectively at 
5 months after treatment. 
In addition the DEF does not always correlate consistently with dose as evidenced in 
the group receiving a single cis-platinum dose 24 h before daily irradiation. In this 
case the DEF dropped from 1.20 ± 0.05 to 0.94 ± 0.09 for the 5 month endpoint and 
from 1.13 ± 0.03 to 1.03 ± 0.03 for the 10 month endpoint when the cis-platinum dose 
was increased from 4 mg/kg to 12 mg/kg. This would indicate that in these cases more 
cis-platinum does not result in a higher DEF. In contrast, for cis-platinum given 24 h 
after a set of 5 daily irradiations the DEF for the five month endpoint drops from 1.22 
to 0.98 as the dose increase from 4 mg/kg to 12 mg/kg while showing no significant 
change for the 10 month endpoint. 
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Table 2. Dose Effect Factors for breathing rates after treatment with cis-
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Dose Effect Factor Dose Effect Factor 
(5 months) (10 months) 
0.80 ± 0.06 1.00 ± 0.03 
1.22 ± 0.06 l.14 ± 0.08 
1.02 ± 0.05 1.07 ± 0.04 
I.IO± 0.07 1.07 ± 0.04 
I.IO± 0.05 l.19 ± 0.04 
1.12 ± 0.09 1.23 ± 0.06 
1.20 ± 0.05 1.21 ± 0.05 
1.25 ± 0.06 1.16 ± 0.05 
1.27 ± 0.11 1.30 ± 0.08 
1.20±0.05 1.13±0.03 
I.I I ± 0.06 1.08 ± 0.02 
0.94 ± 0.09 1.03 ± 0.03 
1.22 ± 0.06 1.08 ± 0.03 
1.12 ± 0.06 1.08 ± 0.04 
0.98 ± 0.06 l.14 ± 0.07 
1.15 ± 0.06 1.14 ± 0.03 
1.23 ± 0.07 1.17 ± 0.03 
1.25 ± 0.07 1.23 ± 0.05 
1.15± 0.05 1.09 ± 0.03 
1.47 ± 0.09 1.23 ± 0.04 
1.28 ± 0.08 1.31 ± 0.05 
There are thus two sets of interesting results on cis-platinum enhancement of radiation 
damage to the lung: Von der Maase et al. (1986) present data showing no effect of the 
drug on radiation whereas Tanabe et al. (1987) show schedule dependent increases in 
breathing rates after treatment with both agents. The primary difference between these 
studies is that Tanabe et al. (1987) used fractionated doses of radiation in combination 
with either single or fractionated doses of drug, whereas Von der Maase et al. (1986) 
describe results obtained using single doses of both agents. Since Tanabe et al. (1987) 
obtained some enhancement when cis-platinum was given as a single dose before or 
after 5 fractions of radiation it may be hypothesised that it is the division of the radia-
tion dose into fractions which may be important, possibly through cis-platinum influ-
encing repair between fractions. Work by Peckham and Collis (1981) supports this 
hypothesis as no effect of cis-platinum on radiation induced toxicity was observed. 
Clinical observations 
An anecdotal case of possible cis-platinum radiosensitisation of lung in a patient was 
reported by Golding and van Zanten (1983). A 41-year-old man was treated for a 
poorly differentiated squamous cell tumour in the upper left lobe. He was treated with 
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55Gy in 44 1.25Gy fractions. Two fractions were given per day with a three hour inter 
fraction time. Four mg of cis-platinum per m2 body surface area was given 15 minutes 
after each irradiation. Two months after the end of treatment he was diagnosed as 
having necrosis of the lung within the irradiated field. No micro-organism could be 
cultured in samples from the lung. A second infiltrative lesion in the peripherary of 
the radiation field was noted at four months after treatment. At both times there was 
no evidence of tumour. The authors suggest that the toxicity is a result of the combi-
nation of super-fractionated radiation and cis-platinum. 
In a study reporting on combined cis-platinum and radiation treatment of non-small 
cell lung cancer 331 patients were randomised into one of 3 arms (Schaake-Koning et 
al. 1994.) Radiation was administered as 10 by 3Gy fractions followed by a 3 week 
rest period then 10 by 2.5Gy fractions. Cis-platinum was given either as 30mg/m2 on 
the first day of each treatment week or as 6mg/m2 given daily before radiotherapy. 
Survival was significantly improved (p=0.009) in the radiotherapy plus daily cis-
platinum group compared to the radiotherapy only group. The radiotherapy plus 
weekly cis-platinum group showed an intermediate survival that was not different to 
either the radiation alone group or the radiation plus daily cis-platinum. While cis-
platinum did induce significant nausea and vomiting an increase of late radiation lung 
damage was not observed. 
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Chapter 9. Methods 
Mice 
Specific pathogen free female Balb/C and female C57 /Bl mice of age 4 - 6 months and 
weighing 20±2g were used in the experimental work. They were housed in standard 
mouse cages with bedding of wood shavings. They were fed mouse cubes (Specialist 
Animal Feeds, Cape Town) and water ad lib. A 12-h light/dark cycle was in effect, with 
lights on at 6:00 am. 
Irradiations 
A Perspex jig was constructed for irradiating mice. It comprised two rows of six. chambers 
each just big enough to hold one mouse. Lead blocks (8cm thick) were constructed to 
shield the head and abdomen of the mice. Beam divergence was accounted for in the con-
struction of the jig and shielding. Mice were introduced into the jig without anaesthesia 
for early experiments. D. Hirst (personal communication 1994) advised that anaesthetis-
ing the mice prior to placing in the chambers and for the duration of the irradiation would 
Figure 1. Radiation jig and shielding. The jig comprises two rows of six perspex chambers 
sized hold one mouse each. The shielding was milled to account for beam divergence at an 
SSDof80cm. 
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result in better dosimetry and would be of equivalent stress to jigging without anaesthe-
sia). Thus, mice were anaesthetised for the latter experiments. The jig and shielding are 
illustrated in Figure 1. 
The early experiments were performed using an Eldorado 6 6°Co unit. Dosimetry meas-
urements described below revealed an unacceptable variation in dose at different positions 
in the jig. For this reason the remaining experiments were done using a Theratron 2 6°Co 
treatment unit. 
The Eldorado 6 unit is dedicated for use in radiobiology and has a fixed head with the 
beam directed downwards. The Theratron 2 is a standard treatment unit in daily use in the 
Dept. of Radiation Oncology. 
Dosimetry was performed by placing an ionisation chamber in the position of one of the 
mice. A build up cap was used to ensure full dose build up and wax phantom mice were 
present in each of the jig positions to ensure that full scatter was present. The dose rate in 
the jig was found to be 0.8 times that of the open field dose rate. 
Figure 2. Close up of jig with one mouse in position. Shielding has been removed for the 
photo. 
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Figure 3. Trace of an X-ray of mice showing position in jig .. 
1 2 3 4 
Shadow cast by lead shielding. 
The actual x-ray could not be reproduced so a trace of the sali-
ent features is shown here. The lungs were identifiable on the x-
ray by the position of the spine, rib cage and the higher absorp-
tion of the soft tissue at the base of the lung. These mice were 
not anaesthetised and significant movement can be observed. 
Mice 2,4,5 and six have twisted onto their sides. Mouse 1 and 3 





An X-ray was made by duplicating the treatment set-up, including mice, on a diagnostic 
x-ray machine and exposing an x-ray film placed under the treatment jig. The film 
showed that on average only 85% of the lung was included in the field. It also revealed 
that the mice had too large a degree of movement available to them. The spinal columns 
of the mice are clearly visible and show a great variation in conformation. The film is 
shown in Figure 3, 
Further check films with wax phantom mice in the jig were exposed to 6°Co y-rays from 
the Eldorado 6 unit and scanned on a densitometer to investigate the uniformity of the 
dose distribution (Figure 4). An arbitrary spot on the film, selected by eye as being in the 
darkest region, was chosen to set the 100% reading. The results are presented in Chapter 
10. 
The incident dose was determined using a film placed on top of the jig without build-up. 
The exit dose was determined using a film placed under the jig. The figures obtained us-
ing the densitometer and the check films should be regarded as relative and not absolute 
and were used to determine the dose distribution in the radiation set-up. The 16% differ-
ence in incident dose rates between rows within the jig was deemed unacceptable and re-
sulted in a revision of the radiation set up. 
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Figure 4. Sample densitometer scans from check films of the treatment jig irradiated using 
the Eldorado 6 unit. 
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Densitometer scan of the 
entrance dose across the 
midline of the radiation por-
tal. A film was placed under 
a 5mm perspex plate on top 
of the jig but under the lead 
shielding. Slight bumps can 
seen from backscatter at each 
of the jig divisions. 
Densitometer scan of the 
entrance dose across the 
midline of the radiation 
portal. A film was placed 
underneath a 5mm perspex 
sheet on top of the jig but 
below the lead shielding. 
Wax phantom mice were in 
position. Small peaks from 
tangential scatter can be 
seen at each of the jig divi-
sions. Valleys caused by 
absorption can be seen in 
each division. 
Densitometer scan of the 
exit dose made perpendicu-
lar to the above two scans 
through position 3. The un-
even dose distribution is 
clearly evident. 
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1. The jig was modified by moving the head shielding to increase the amount of irradi-
ated lung. A Computer Assisted Tomographic scan of mice in the jig with markers in-
dicating the boundaries of the irradiation field showed that 100% of the lung was now 
included in the field. (Due to technical reasons at the time of the scan, it was not pos-
sible to obtain a hard copy and evaluation was performed on screen using the CAT 
software.) 
2. A Theratron 2 6°Co therapy unit was used for most of the experiments. This unit had 
the benefit of proper collimation, a higher dose rate and larger field size. A field size 
of 30cm by 30cm could be selected to improve the flatness of the field over the jig. 
3. Dosimetry was performed in each irradiation position within the jig using a PTW-
UNIDOS dosimeter and a Baldwin-Farmer ionisation chamber with full build up. 
4. Mice were anaesthetised prior to being placed in the jig. A 1 :4 mixture of 20mg/ml 
Xylazine: lOOmg/ml Ketamine was prepared on the morning of irradiation. Each 
mouse was injected with 1.5µ1/g (Balb/C) or 1.2µ1/g (C57/Bl) of the mixture, which 
provided approximately 50 minutes of anaesthesia. This resulted in a more consistent 
positioning of the mice and a more uniform dose distribution. Under anaesthesia, no 
movement apart from breathing occurred during irradiation. 
Cis-platinum 
Cis-platinum was obtained in 10mg vials of lyophilised powder from Lennon Ltd. A fresh 
vial was prepared on the day of use by dissolving the lyophilised powder in 20ml of ster-
ile saline (0.9%) to give a final drug concentration of 0.5mg/ml cis-platinum. Cis-
platinum was given by intra-peritoneal (i.p.) injection. Control mice not due to receive 
drug were given an i.p. injection of an equivalent volume of saline as a placebo. 
Mice were hydrated 2 h before and 1 h after administering cis-platinum by i.p. injection of 
1ml 0.5% Glucose in 0.45% saline. The hydration mixture was sterilised by filtration 
through a 0.22µm filter. 
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Control treatments 
All experiments included sham treated control groups. For those groups acting as controls 
for drug treated groups the sham treatment consisted of the hydration procedure and an 
equivalent amount of saline injected in place of cis-platinum. For those groups acting as 
controls for radiation treated groups mice were placed in treatment jigs and placed under 
the treatment unit for an equivalent time to that of the irradiated mice. 
Controls for combined treatment groups received both sham treatments. 
Plethysmography 
Description of unit 
A mouse sized whole body plethysmograph was constructed for use in investigating the 
breathing rates of mice after combined cis-platinum and radiation. 
A plastic tube of internal diameter 57 mm and length 165 mm was mounted on a base and 
fitted at both ends with removable doors sealed with rubber 0-rings. The volume of air in 
the chamber was determined to be 200 cm3 by filling the chamber with water and then 











Not to ecale. 
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mounted in the centre of one of the doors. Approximately one third of the chamber was 
filled with lead to reduce extraneous vibrations. The lead was separated from the chamber 
by a Perspex floor. The chamber is depicted in Figure 5. 
The signal from the microphone was fed to a purpose built amplifier and low pass filter 
from whence it was passed to an analogue to digital converter (PC-30B, Eagle Electric, 
Cape Town) for recording and analysis on an IBM-compatible PC. Data was collected 
using the software package supplied with the analogue to digital converter (STATUS 30 
V2.00 Data Acquisition Software, Eagle Electric, Cape Town.) This package allows data 
to be stored on disk and to be analysed by Fast Fourier Transformation. The circuit dia-
gram for the amplifier and filter is given in Figure 6. 
The amplifier design was based on four LF351 wide bandwidth JFET input operational 
amplifiers. This chip offers high input impedance, high slew rate, low input bias current 
as well as wide bandwidth. It also has very low noise. The initial stage comprises an 
emitter-follower that provides a high impedance load for the electret microphone. The 
signal from this stage is passed to an inverting amplifier with variable gain. The following 
stage is a low pass filter with a desired -3dB point at 15 Hz and roll-off of - 18db per oc-
tave. 
The frequency response of the electronic side of the system was determined by feeding 
v·- ----.---------,..---------.-----.--...----
Resistors (Ohms) 
R1, R2, 10k 
R3 22k 
R4 10M 




OUT R11 91k 
VR1 47 
Capacitors 
R11 C1 220 microF 
C2 1 microF 
C3,C4 1nF 
y _ __ _.__ _____ __._ ____ _._ ____ ___. __ 
Emitter-Follower Op-Amp Low Pass Filter x10 Op-Amp 
Figure 6. Circuit diagram of amplifier and filter for plethysmograph. 
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the signal from a signal generator into the input of the amplifier and determining the fre-
quency at both input and output using an oscilloscope. This was then compared to the fre-
quency obtained by collecting the same data on the PC and processing by Fourier Trans-
formation. 
Only data from the third week of measurement was included for analysis. When a clear 
peak could not be discerned in the Fourier Transform the mouse was returned to the 
chamber and the measuring cycle repeated. 
It was not possible to calibrate the plethysmographic chamber itself as apparatus capable 
of generating pressure changes of known frequency within the range 2 - 20 Hz was not 
available. 
Principles of Fourier analysis 
In 1807 J.B. Fourier showed that any function could be described as the sum of a series, 
which for a two dimensional wave (x,y) can be given as:-
00 
( n1lX) y(x)= LBnsin -
n=I L 
with Bn = A,. cos(co/0 - <'n) (French, 1982.) Thus a two dimensional wave can be de-
scribed as an infinite series of sine waves where con is the frequency of the nth wave, 8n 
its phase and A,. its amplitude. The frequency spectrum of the wave is then a collection of 
the frequencies of the underlying sine waves (harmonics) and their associated amplitudes. 
The Fast Fourier Transformation is a numerical technique that can be used to derive the 
frequency spectrum of a given wave. The spectrum may be plotted as a histogram of am-
plitude vs. frequency. The more closely a wave approximates a pure sinusoidal distur-
bance of infinite duration the narrower its spectrum will be - i.e. converge to a single line. 
The characteristic frequency of a complicated wave can be considered to be the harmonic 
with the largest amplitude. Thus the breathing rate of mice was recorded as the harmonic 
frequency at the centre of the highest peak in the frequency spectrum obtained by Fast 
Fourier Transformation of the recorded breathing wave. 
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Recording technique 
The breathing rates were sampled at a frequency of 50Hz. 4096 samples were taken each 
time thus the duration of measurement was 81 . 92 seconds. 
Mice were placed in the chamber for 1 minute to acclimatise before recording started. 
After the initial measurement, they showed no signs of agitation at being in the chamber 
and willingly entered it. Measurements were performed weekly at approximately the same 
time each day. Measurements were performed sequentially across groups within an ex-
periment rather than sequentially within a particular group. This minimised the difference 
in time of measurement between different groups within an experiment. 
Surfactant analysis 
Introduction 
Two techniques were used to determine the phospholipid content of surfactant extracted 
by broncho-alveolar lavage (BAL). High Pressure Liquid Chromatography was used to 
determine the amount of phosphatidylcholine as an indicator of the total amount of 
surfactant. A colorimetric assay based on an enzymatic cleavage of phosphate was used as 
an indicator of total surfactant phospholipid content. 
Dissection and lavage procedure 
Mice were killed before broncho-alveolar lavage by cervical dislocation. They were then 
taped, dorsal side down, to a perspex jig and exsanguinated. The peritoneal cavity was 
opened and a small incision made in the peritoneum. The tissue surrounding the trachea 
was carefully excised and the trachea was cut above the level of the larynx. An 18G 
catheter was inserted in the trachea. A thread of cotton was tied around the trachea to 
prevent the catheter slipping out. 0.8 ml of ice cold saline was slowly injected into the 
lungs and withdrawn to lavage the surfactant from the lung. Three aliquots were collected 
from each mouse. The catheter was left in place until the last aliquot after which it was 
removed and any fluid retained in it added to the lavage. 
Samples were stored in liquid nitrogen until analysis. 
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HPLC 
The lipid content of a sample was extracted for analysis by HPLC using a modification of 
the method of Bligh and Dyer (1959). 3ml of methanol:chloroform (2:1) followed by 1ml 
chloroform and 1ml Millipore filtered water was added to 0.8ml of lavage fluid. This was 
vortexed vigorously for 2 minutes and then spun at 1 OOOg for 10 minutes. The lower 
chloroform layer was drawn off using a Pasteur pipette. 2ml chloroform was added to the 
supernatant and the sample was vortexed and centrifuged. The lower layer was drawn off 
and added to the previous chloroform extract. 
The chloroform was evaporated off at 3 7°C under nitrogen. The lipid fraction was then 
left as a thin layer on the bottom of the tube. This was re-dissolved in 100µ1 
spectrographic grade ethanol (Merck). 
The lipids were analysed by HPLC using a method published by Jungawala et al. (1975). 
An LKB variable wavelength monitor set at 203nm was used to detect peaks. A 25cm * 
4.6mm Spherisorb silica column with average particle size 5µm was used. A flow rate of 
lml/minute acetonitrile:methanol:water in the ratio 65:21:14 was used as the mobile 
phase. 10µ1 of sample was injected for each run. 
Integration was carried out using a dedicated Apple Ile computer running Chromatochart 
from Interactive Microware Inc. A sample trace is show in Figure 7. The area under the 
peak, in arbitrary units, eluting at approximately 13 minutes was used as a relative 
measure of lavaged surfactant. 
The column was regenerated by running 20-30 column volumes of each of the following: 
methanol; dichloromethane; iso-propyl alcohol; hexane and then in the reverse order 
through the column. In addition, a 40µm guard column was fitted to increase column life. 
This did not significantly affect retention time or peak width of the chromatogram. After 
about 150 injections the back pressure and retention time of the column had increased and 
a new column was fitted. 
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Enzymatic assay 
A total phospholipid assay kit (Boehringer Mannheim No 691844, Mannheim, Germany) 
was adapted to enable numerous small samples to be processed. The kit as supplied 
consists of a buffer, enzymes and a standard. The composition of these is shown in Table 
3. An additional buffer was prepared comprising lmg/ml Triton X in 6mM CaCh 
(Takayama et.al. 1977.) The enzyme solution was prepared for storage by adding 2 ml of 
the manufacturer's buff er to the enzyme mixture and gently agitating until the enzymes 
were dissolved. The resulting solution was divided into 10 by 200µ1 aliquots and stored in 
liquid nitrogen. 
When required an aliquot was thawed and dissolved in a 50/50 mix of the manufacturer's 
buffer and the Triton X buffer. Total volume of the resulting solution was 48ml. 
The solution was then divided into 1ml aliquots for use in the assay. To each aliquot 
Figure 7. Sample trace of the phospholipid component from broncho-alveolar lavage fluid 
extracted from Balb/C female mice and analysed using HPLC. The area of the peak 
labelled with an arrow was used as arelative measure of surfactant. 
13 minutes 
Solvent Front 
Elution Time (min) 
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100µ1 of extracted surfactant was added. The samples were incubated at 37°C for 25 min 
before being read in a Phillips SP8-400 spectrophotometer at 500nm. 
Each group of samples read included a control at the start and finish of the run, as well as 
standards for construction of a standard curve. The amount of phospholipid per 100µ1 
extracted lavage was interpolated from the standard curve and the amount of lavaged 
phospholipid per mouse lung was then calculated. 
Table 3. Composition of enzyme assay kit, as supplied by the manufacturer. 
Buffer 
Tris hydroxymethyl aminomethane 
Phenol 












~ 800 U/1 
8mmol/l 
54.1mg/100ml 
Mice were killed by cervical dislocation at 120 days after treatment. Four groups of mice 
were treated. A control group received placebo. Groups were treated with 6mg cis-
platinum/kg, 12Gy 6°Co y-rays and with 6mg cis-platinum/kg immediately before 12Gy 
6°Co y-rays. 
The ventral chest wall was opened and the trachea freed from surrounding tissue. A 
catheter was inserted into the trachea and tied in place with a length of thread. The lungs 
and heart were then removed en-bloc and suspended in 10% phosphate buffered formalin. 
0.8ml of 10% phosphate buffered formalin was used to gently inflate the lung. The 
catheter was removed and the trachea tied closed with the thread. The tissue was then left 
in formalin for at least 4 weeks to fix before being processed for sectioning. Dehydration 
was carried out by successive immersion in increasing concentrations of alcohol before a 
final xylene bath and then immersion in wax. Sections of approximately 5µm thick were 
cut parallel to the thoracic midline and from about midway through the right lung. 
Sections were stained with haematoxylin and eosin (H&E) and with Von Giesons stain for 
collagen. 
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The reaction was qualitatively evaluated as well as scored using a modification of the 
reaction scoring system described by Travis (1980). A grid of 100 blocks in a 20x objective 
and a 1 Ox eyepiece was used to evaluate sections stained with H&E. A block was scored as 
positive if it contained one or more of the following :-
• macrophage infiltration in air spaces 
• mononuclear inflammatory cells in alveolar walls 
• oedema in alveolar wall or air spaces 
• fibrin in air spaces. 
Three, randomly selected grids not including airways or blood vessels were counted for each 
lung section. The percentage of lesion occupying the section was then calculated as the mean 
percentage of positive blocks. 
TGF-J3 Analysis 
Principle of assay 
The Quantikine™ human TGF-f31 immunoassay kit from R&D Systems (R&D Systems, 
Increase, Minneapolis, USA) was used to measure TGF-f3 l in broncho-alveolar lavage 
fluid and homogenised lung tissue from mouse lungs. This kit is suitable for the quantita-
tive determination of active transforming growth factor beta 1 concentrations in cell cul-
ture supemate, serum, plasma and other biological fluids. It is a sandwich enzyme immu-
noassay technique. 
The microtiter plate provided in the kit is coated with TGF-f3 soluble receptor type II that 
binds TGF-f31. Standards and samples are pipetted into the wells of the plate. The immo-
bilised receptor then captures any active TGF-f3 present in the solutions. After washing, a 
polyclonal antibody specific for TGF-f31 is added. This binds to the immobilised TGF-f3 
forming a sandwich comprising the receptor, the growth factor and the antibody. After 
washing, a substrate solution is added which, develops colour in proportion to the amount 
of sandwiched TGF-f31. This can be quantitated using a multi-well plate reader. 
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Method 
Mice were killed by cervical dislocation and the lungs dissected and lavaged with ice-cold 
saline as described earlier in the methods section. The lavage fluid was centrifuged at 
1000 x g for 10 minutes to remove any cells from suspension. The supernatant was drawn 
off and stored in liquid nitrogen for analysis once all samples had been collected. 
The samples were thawed before analysis. An activation procedure was followed to en-
sure that any TGF-J3 existing in the samples in latent form was converted to the active 
form required for recognition in the assay. The activation procedure followed was slightly 
different from that in the kit and is described below. 
A solution of 2.5 N acetic acid/10 M urea was made by slowly adding 35.9ml of glacial 
acetic acid to 100ml of de-ionised water. 150.2g of urea was added to the well-mixed so-
lution. This was mixed until the urea had dissolved and then made up to 250ml using de-
ionised water. A solution of 2.7 N NaOH/1.0 M HEPES was made by slowly dissolving 
27g NaOH in 150ml de-ionised water. This was mixed and then 59.5g HEPES was added. 
The solution was mixed and the volume brought to 250ml with de-ionised water. 
0.5ml of 2.5 N acetic acid/10 M urea was added to 0.5ml oflavage fluid. This was mixed 
and then incubated for 10 minutes at room temperature. 0.5ml of 2.7 N NaOH/1.0 M 
HEPES was added to each to neutralise the acidified sample. The pH was checked to con-
firm a reading of between 7.2 and 7.6. The activation procedure resulted in a 1:3 dilution 
of the original sample. 
A dilution of 1 :4 - sample:RD6M diluent as recommended by the manufacturer for plate-
let poor plasma was made by adding 4.5ml RD6M to each activated sample. 
The wash buffer was prepared from the concentrate supplied in the kit by diluting 20ml of 
supplied concentrate to a final volume 500ml with de-ionised water. 
The TGF-J3 standard was reconstituted with 2ml of RD6M to give a resultant solution of 
concentration 2000 pg/ml TGF-J31. This was left to stand for 15 minutes with gentle agi-
tation before making a dilution series with concentrations of 2000pg/mL, 1 OOOpg/mL, 
500pg/mL, 250pg/mL, 125pg/mL, 62.5pg/mL, 31.25pg/mL and Opg/mL. 
Cis-platinum, radiation and mouse lung Chapter 9 - Methods page70 
200µL of sample or of standard was added to each well in the multi-well plate. Each sam-
ple and each standard was analysed in duplicate. The wells were covered with the adhe-
sive strips provided in the kit and left to incubate for 3 h at room temperature. Each well 
was then aspirated and washed by the addition of 400µL wash buffer for a total of four 
washes. At each wash step, care was taken to remove all of the wash buffer. The plate was 
inverted and blotted dry after the last wash. 
200µL of TGF-f31 conjugate was added to each well and the wells covered with a fresh 
adhesive strip. The plate was then incubated at room temperature for 1.5 h after which the 
wash process as described above was repeated. 
200µL of Substrate Solution was then added to each well, followed by an incubation of 20 
minutes at room temperature. After this period, 50µL of Stop Solution was added to each 
well. The plate was gently tapped to ensure thorough mixing of the solution. 
The optical density at 450nm was read on an Anthos Labtec H2 multi-well plate reader 
with wavelength correction at 540nm. 
A standard curve was constructed by plotting the mean absorbance vs. concentration of 
TGF-f3 standard. A linear regression was performed on the data using the regression mod-
ule in STATISTICA (Statsoft, Inc.) The resulting equation representing the best fit to the 
standard curve data was then used to calculate the concentration of TGF-f3 in the sample. 
The measured concentration was then multiplied by a factor of 12 to account for the dilu-
tion occurring during the extraction and activation procedure. 
Analysis of TGF-p in lung tissue 
A modification of the above technique for analysing surfactant was used to analyse the 
amount ofTGF-f3 in lung tissue. 
Mice in which TGF-f3 was to be measured in lung tissue were treated with radiation and / 
or cis-platinum as described in Chapter 10, page 117. At 1 week and one month after 
treatment, mice were killed by cervical dislocation and their lungs excised and stored in 
liquid nitrogen until the time of assay. 
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Lungs were removed from liquid nitrogen, allowed to thaw before being blotted on tissue 
paper, and weighed. The samples were homogenised with 4ml of 2.5 N acetic acid/10 M 
urea per gram of tissue. The resulting homogenate was transferred to polypropylene tubes 
and allowed to incubate for 10 minutes at room temperature. The samples were then spun 
at 10000 x g for 10 minutes. The centrifuge temperature was maintained at 4 °C. The su-
pernatant was transferred to clean tubes and 4ml 2.7 N NaOH/1.0 M HEPES per gram of 
original tissue was added. The samples were vortexed and then spun for a further 10 min-
utes at 10000g. 
200µ1 of the homogenised lung sample or standard was added to the wells in a multi-well 
plate and the analysis completed as described above. 
The measured concentration was multiplied by a dilution factor of 9 to account for the 
dilution occurring during the homogenisation and activation procedure. 
Protein determination 
The Bio-Rad Protein Assay (Bio-Rad Cat No. 500-0002) based on the Bradford dye-
binding procedure (Bradford 1976) is a simple colorimetric assay for measuring total 
protein concentration. The standard assay is used with samples having protein concentra-
tions between 200 µg/ml and 1400 µg/ml (20-140µg total). The assay is based on the col-
our change of Coomasie brilliant blue G-250 dye in response to various concentrations of 
protein. The dye binds to primarily basic ( especially arginine) and aromatic amino acid 
residues. The assay is useful for measuring proteins and polypeptides with MW greater 
than 3000-5000, depending on the charged groups. 
The lung homogenate used in the TGF-f3 analysis was also analysed using the Bio-Rad 
protein Assay for total protein. 
The samples as prepared for the TGF-f3 assay were used for total protein analysis. As de-
scribed previously the samples were homogenised with 4ml 2.5 N acetic acid/10 M urea 
per gram of tissue. The resulting homogenate was transferred to polypropylene tubes and 
allowed to incubate for 10 minutes at room temperature. The samples were then spun at 
10000 x g for 10 minutes. The supernatant was transferred to clean tubes and 4ml 2.7 N 
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NaOH/1.0 M HEPES per gram of original tissue was added. The samples were vortexed 
and then spun for a further 10 minutes at 10000 x g. 
A standard curve was constructed using 0,2,4,6,8 and lOµg albumin / 1.6 ml water, to 
which 0.4ml Bio-Rad protein dye reagent was added. All samples were read at 595nm in 
the spectrophotometer. The absorbance of the homogenate samples, diluted 1 :50 was 
measured and the amount of protein determined. 
Statistics 
Statistica from Statsoft Inc. was used for all statistical tests. All error bars shown in the 
figures are standard deviations unless otherwise stated. In some instances not all error 
bars are shown in a figure to enhance clarity. 
Student' s t-test was used to assess significance of difference between groups. 
Kaplan-Meier product limit survival analysis techniques (Kaplan et al. 1958) were used to 
analyse survival of mice. The technique was also explored as a means of comparing 
breathing rate data from different treatment groups by defining a "response breathing 
rate". Mice that exhibited breathing rates above this response breathing rate were assessed 
as complete or "dead". Those not responding were included in the analysis as censored. 
Non-parametric techniques could then be used to compare groups and test for statistical 
significance. 
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Chapter 10. Experimental work - Results 
The experimental work is described in five sections: 
• Calibration and dosimetry 
• Surfactant analysis 
• Breathing rate analysis 
• Histological analysis 
• TGF-P analysis. 
Calibration and dosimetery 
Densitometry 
The results of the densitometer scan of the check films made of the jig with wax phantom 
mice in position is given in Table 4. The densitometer readings showed a variation from 
an average reading of 110% for positions in row B to 94 % in row A in the incident dose 
rate. The exit dose rate averaged 95% in both row A and row B. 
Within row A, a maximum density produced by the incident beam of 97% was recorded 
for the central positions while a minimum of 90% was seen for the outside positions. 
Likewise, for row B a value of 113% was recorded for the central positions and 105% for 
the outside positions. 
Table 4. Densitometer readings expressed as a percentage relative to a control 
reading on the exposed film. 
Row A RowB 
Incident Exit Incident Exit 
1 91 95 106 94 
2 96 95 112 95 
3 97 95 113 95 
4 97 96 113 96 
5 94 96 110 95 
6 90 93 105 93 
Average 94 95 110 95 
The results of dosimetry performed using the Baldwin-Farmer ionisation chamber at the 
various positions in the mouse restraining jig is given in Table 5. The lowest dose rate 
was found to be 10% lower than the highest. In order to correct this imbalance, positions 
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that were contained within a spread of 5% were grouped. Thus, A 2-5 (Table 5) and B 1 -
5 were grouped to give a mean dose rate of 2.13Gy/min on 6th of December 1995. Mice 
treated in the remaining positions (mean dose rate of 2.0lGy/min on the 6th of December 
1995) were given an additional exposure to bring them up to the required total dose. 
Table 5. Exposure values for irradiation set-up on the Theratron 2 as measured 
on 6 December 1995. 
Position 
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Calibration of plethysmograph 
The results of the calibration procedure as described in Chapter 9 using a signal generator 
are presented in Figure 8 and Figure 9. A linear regression of data collected at a sampling 
rate of 50 Hz vs. the input frequency gave a correlation coefficient of R2 = 0.999, an in-
tercept of -0.132 ± 0.066 and a slope of 1.022 ± 0.0074 (Figure 8). 
A graph of log relative amplitude vs. log frequency is shown in Figure 9. It can be seen 
that the curve is not very flat over the region of interest (4-10 Hz). While this did not af-
fect the frequency response of the system as seen in Figure 8, it did make it impossible to 
compare the amplitude of breathing rate data obtained from mice. 
An example of recorded waves and their associated Fast Fourier Transforms is shown in 
Figure 10. As can be seen the pure sine wave produced by a signal-generator results in 
extremely sharp FFT' s. 
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The heterogeneous samples obtained from mice did not produce such sharp peaks in the 
Fourier transformation of the data. In general, the data from untreated control mice 
showed the most variability. In particular the data from mice measured for the first time 
gave very broad Fast Fourier Transformations. This was most likely due to the stress that 
the mouse experienced on being placed in the measuring chamber. 
FFT' s from mice are shown in Figure 11. 
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Figure 10. Plethysmograph calibration. The left hand, top figure shows the recorded trace 
from a 6Hz sine wave produced by a signal generator. The left hand bottom figure shows 
the recorded trace from an 8Hz sine wave. The right hand figures show the associated Fast 
Fourier Transform. 
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Figure 11. Breathing rate waves and associated FFT in a Balb/C mouse. Chart A shows a 
portion of the data collected for a Balb/C mouse. The screen was zoomed in to allow some 
detail to be discerned showing only 5 s of a total of 80 s collected. Chart B shows the Fast 
Fourier Transformation of the data. The breathing rate is read off the screen using a 
movable cross hair (not visible in the picture). The reading for this mouse was 5.47Hz. 
A 
B 
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Surfactant analysis 
In the initial work surfactant was measured at 28 days after treatment with either cis-
platinum, radiation or a combination of cis-platinum and radiation using the HPLC tech-
niques described in Chapter 9. These first experiments were performed to verify that the 
techniques used to measure surfactant produced similar results to those of Rubin et al. 
(1984). Once this had been established the effect of timing, of cis-platinum administration 
relative to radiation, on surfactant levels at 28 days after treatment was investigated using 
the HPLC technique and then the level of surfactant with time after treatment was investi-
gated using an enzymatic assay for phospholipids as described in Chapter 9. 
Surfactant after single doses of radiation 
The effect of single doses of 6°Co radiation on surfactant levels was measured at 28 days 
after 0, 9, 11, 12, 13, 14, 15, 16, 17Gy. Four mice were irradiated at each dose, using the 
Eldorado 6 unit. The data are displayed in Figure 12. 
Figure 12. Relative level of surfactant at 28 days after treatment with single doses of 60Co 
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The relative level of surfactant present in broncho-alveolar lavage fluid increased with 
dose after about 13Gy. Points at 9, 14, 15 and 16Gy were all significantly greater than the 
control (p<0.05). Only the 15Gy point was significantly greater than the 9, 11 and 13Gy 
points (p<0.05). 
Surfactant after single doses of cis-platinum 
The relative level of surfactant after cis-platinum alone was detennined at 28 days after 0, 
2, 4, 6, 8 and lOmg/kg cis-platinum. Four female Balb/C mice weighing 20g were treated 
by i.p. injection of cis-platinum at each dose as described in the methods section. No in-
crease in lavaged phospholipid content as determined relative to controls using the HPLC 
technique was seen with increasing doses of cis-platinum (Figure 13). lOmg/kg was esti-
mated as being the maximally tolerated dose (MTD) for Balb/C mice. 
Surfactant after cis-platinum at different times relative to radia-
tion 
Figure 13. Relative level of surfactant vs. dose of cis-platinum. Surfactant was measured 
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The effect of cis-platinum on the surfactant system at different times relative to a single 
dose of radiation was examined by administering 8mg/kg cis-platinum at 1 h, half an hour 
and immediately before and after 11 Gy 60Co. The Eldorado 6 unit was used for irradia-
tion. The cis-platinum dose of 8mg/kg was chosen as being 80% of the MTD in order to 
maximise potential drug effect without any drug induced lethality. Four mice were treated 
in each group and killed by cervical dislocation at 28days after treatment. The toxicity 
experienced during this experiment was higher than expected with the number of mice 
surviving in each point being very low. Only 1 out of 4 mice treated survived when cis-
platinum was administered 0.5 h after llGy. The data is displayed in Figure 14. An in-
crease in the level of surfactant relative to untreated control mice was seen for all times of 
cis-platinum treatment. This increase was generally lower, but not statistically significant 
at the 5% level, than that seen for 11 Gy irradiation only as determined in the radiation 
only group. 
Figure 14. Relative level of surfactant lavaged from Balb/C female mice at 28 days after 
treatment with 8mg/kg cis-platinum administered at different times relative to a single 
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Time course of surfactant release 
The time course of the release of surfactant was measured using the enzymatic assay of 
total phospholipid described in the methods section. 24 mice per group were treated as 
described in the methods with either 13Gy 6°Co alone, 8mg/kg cis-platinum alone or 
8mg/kg cis-platinum given immediately before 13Gy 6°Co. All irradiations were per-
formed using the Eldorado 6 unit. A control group was treated with placebo. The dose of 
cis-platinum was chosen as being 80% of the MTD. The dose of radiation was increased 
from 11 to 13Gy to bring it closer to the threshold dose required to produce an increase in 
surfactant ( as was seen in the experiment to determine surfactant levels after single doses 
of irradiation described above). 
Mice were killed, at were 1, 2, 7, 14, 28 and 56 days after treatment, in groups of four se-
lected randomly from the pool of 24 mice in each treatment arm. 
The data show a slight increase at 1 day after treatment with cis-platinum alone, a large 
increase at 28 days after treatment with radiation alone and a large early increase peaking 
Figure 15. Changes in lavaged phospholipid with time after treatment. Balb/C female mice 
were treated with either 8mg/kg cis-platinum, 13Gy 60Co or 8mg/kg cis-platinum immedi-
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at 7 days after treatment with cis-platinum and radiation. This is illustrated in Figure 15. 
The level of surfactant after cis-platinum alone is significantly higher than controls at 1, 2, 
7, 14 and 28 days with p < 0.0001 in each case. 
The different time course of release of surfactant after combined treatment is strikingly 
evident with significant differences between the radiation only and combined treatment 
groups being noted at 2, 7 and 14 days after treatment (p = 0.014, 0.0025, and 0.0015 re-
spectively). 
A second, large group (300) of mice were prepared and treated to investigate the release 
of surfactant after 6mg cis-platinum/kg given at different times relative to 12Gy 6°Co irra-
diation. This was intended to be a repeat of the earlier experiment examining the effect of 
the timing of cis-platinum relative to radiation. The experiment was abandoned when 
nearly half of the mice had died within the first two weeks after treatment. This early 
toxicity was presumed due to circadian variations in susceptibility to cis-platinum. Treat-
ment of this group took place in the early morning at approximately 7a.m., which is about 
one hour after lights on for the mouse house. It is possible that because of circadian varia-
tion in toxicity as discussed in Chapter 7, page 50, administration of the drug at 7a.m. re-
sulted in greater nephrotoxicity. 
Assessment of breathing rates 
The experiments described in this section made use of a mouse plethysmograph and Fast 
Fourier analysis to assess the effect of cis-platinum, radiation and cis-platinum in combi-
nation with radiation on mouse breathing rate. Initial experiments in this section investi-
gated the effect of single dose of cis-platinum and radiation alone or in combination. The 
breathing rate of two strains of mice, Balb/C and C57 /Bl, were compared. The effect of 
timing of cis-platinum administration relative to radiation was investigated to determine if 
a particular time of administration produced a more severe normal tissue reaction. Possi-
ble effects of cis-platinum on repair were investigated by means of split dose experiments. 
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Single radiation doses 
Breathing rates after 8mg cis-platinum/kg and 13Gy 
The breathing rate of mice was determined in controls and after treatment with either, 
13Gy alone, 8mg/kg cis-platinum alone, 8mg/kg cis-platinum immediately before 13Gy. 
The Eldorado 6 was used for irradiation. Mice were selected on the basis of weight (20 ± 
2g) from stock that were 6 to 8 weeks old. 
Data was recorded weekly from 4 to 16 weeks after treatment. Each mouse was sampled 
in triplicate at 500Hz for 4096 samples. The sampling technique was changed at 12 weeks 
to sampling once at 50Hz for 4096 samples because no significant difference could be 
detected between the 500Hz sampling technique and the 50Hz sampling technique. The 
50Hz sampling technique allowed one measurement of longer duration to be made with 
less disturbance to the mouse. This resulted in far fewer readings having to be discarded 
because no clear peak could be discerned in the FFT. 
An age dependent decrease in the breathing rate was observed in all groups until about 12 
Figure 16. Changes in breathing rates with time after treatment. Balb/C female mice were 
treated with either 8mg/kg cis-platinum, a single dose of 13Gy 60Co or with 8mg/kg cis-
platinum immediately before 13Gy. Control mice received placebo treatments. Error bars 
show SD. 
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weeks after measurement started (Figure 16). Thereafter the breathing rate in the group 
treated with radiation rose from about 6.2Hz to about 7Hz. The control group showed a 
mean breathing rate of 6.03±0.08Hz during the period 12 to 16 weeks. The breathing rate 
of the cis-platinum treated group was not significantly different from the controls except 
at 4 and 13 weeks after measurement started. These differences were most likely due to 
random experimental error. A trend toward higher breathing rates in the cis-platinum 
treated group may be evident from 12 weeks onward. 
The combined treatment group showed a significantly higher breathing rate from 10 
weeks after treatment, after which it dropped to the level of controls at 16 weeks. It 
should also be noted that the group treated with cis-platinum and radiation started out 
with an initially lower breathing rate when measurements commenced at 4 weeks after 
treatment. The breathing rate in this group did not show the same age dependent decrease, 
but remained constant until 10 weeks after treatment. The breathing rate then dropped as 
described above. It is possible that cis-platinum changes the time course of radiation dam-
age to the lung causing the breathing rates to be increased earlier than for radiation alone. 
Figure 17. Changes in breathing rates with time after treatment Balb/C female mice were 
treated with either 7mg/kg cis-platinum, a single dose of 12Gy 60Co or with 7mg/kg cis-
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The radiation alone group showed an increase in breathing rates, compared to controls, 
from week 12 onwards which correlates with literature values and confirms that our tech-
nique was sensitive to radiation induced changes in breathing rates. 
Breathing rates after 7mg cis-platinum/kg and 12Gy 
The breathing rate of mice was determined for up to 180 days after treatment with 7mg/kg 
cis-platinum, 12Gy 6°Co radiation from the Eldorado 6 unit or 7mg/kg cis-platinum ad-
ministered immediately before 12Gy 60Co. Twelve mice were treated in each group. Five-
month-old mice weighing 20±2g were used. 
An elevation in breathing rates was evident at the time of the first measurement (Figure 
17). This was followed by a decrease, at 7 days after treatment, for mice receiving cis-
platinum and is most likely due to systemic effects caused by acute drug toxicity. Mice 
were observed to be hunched and fluffed up at this stage, generally sitting quietly. The 
cis-platinum plus radiation group showed an increase, starting at 14 days after treatment 
and persisting to approximately 60 days after treatment, in breathing rate above the level 
of either the radiation alone or cis-platinum alone groups. From 70 days onward the error 
bars overlapped except for one point at 77 days with a trend for the combined treatment 
group to have a higher breathing rate than the radiation alone group. An increase in the 
breathing rate of radiation treated groups was noted between about 120 and 140 days after 
treatment. This increase was seen to occur at about the same time as that seen in the next 
experiment, Figure 18. 
The group treated with cis-platinum and radiation in this experiment showed severe early 
toxicity with 8 out of 12 mice dead by the third week after treatment. Five out of 12 mice 
had died by the third week after treatment with cis-platinum alone. No mice had died at 
this stage in the group treated with radiation alone. Facilities to determine exact cause of 
death were not available. Symptoms displayed before death were loss of weight and ap-
petite, pinched in abdomens, fluffed appearance and quiet, isolated behaviour. On dissec-
tion the kidneys appeared pale and soft compared to normal mice of similar age. Acute 
nephro-toxicity caused by the cis-platinum was assumed to be the cause of death. 
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Breathing rates after 6mg cis-platinum/kg and 12Gy 
Mice were treated with 6mg cis-platinum/kg in an attempt to reduce the acute early toxic-
ity seen in the previous experiment. In addition to the cis-platinum alone group, groups 
were treated with 12Gy 6°Co y-rays (Eldorado 6) and 6mg cis-platinum/kg immediately 
before 12Gy 60Co y-rays. Six mice were treated in each group. No early deaths were ob-
served in the control group or in the radiation alone group. One mouse in the cis-platinum 
alone group died during the second week after treatment. All mice in the combined treat-
ment group died during the first week after treatment. 
The breathing rates as recorded for the control group, the cis-platinum alone group and 
the radiation alone group are shown in Figure 18. The control group did not show any 
significant change in breathing rate during the period observed, although a slight trend to 
lower breathing rate may be evident. The cis-platinum treated group showed an increased 
variability when compared to the controls but was not significantly different from the 
controls at any stage. The radiation alone group was not significantly different from con-
trols until 112 days after treatment at which stage a sharp increase in breathing rates oc-
Figure 18. Changes in breathing rates in Balb/C female mice with time after treatment 
with 6mg cis-platinum/kg or a single dose of 12Gy 60Co. (All mice receiving combined 
treatment in this experiment died within 1 week of treatment). Error bars show SD. 
Control mice received placebo treatments. 
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curred until 134 days after treatment. At this stage the mean breathing rate dropped rap-
idly. It is important to note however that two of the mice died at this stage leaving only 
three mice of six mice alive, which may have affected the mean breathing rate. 
Comparison between Balb/C mice and C571BI mice after treat-
ment with 6mg cis-platinumlkg and 12Gy 
Groups of 12 mice, either C57/Bl or Balb/C females were treated with 6mg c1s-
platinum/kg alone, 12Gy 6°Co y-rays alone (Theratron 2) or 6mg/kg given immediately 
before 12Gy. 12 Mice in each strain received placebo injections of saline and mock radia-
tion treatments. The treatments all took place at the same time of day ( approximately 
6pm) to minimise circadian variation in toxicity of cis-platinum. The breathing rate of 
each mouse was recorded once a week at the same time of day each week. Measurements 
were recorded across the groups as described in the methods section to minimise variation 
Figure 19. Cumulative proportion of Balb/c female mice surviving after treatment with 
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between groups. 
No early toxicity was observed. All mice survived more than 10 weeks post treatment 
with treatment related deaths starting at 110 days post treatment in the Balb/C groups and 
at 242 days post treatment in the C57/Bl mice. In the C57/Bl cis-platinum only treatment 
group 4 of 12 mice were dead by 350 days after treatment. No mice died in either the 
Balb/C or the C57 /Bl control group. 
Survival time - Balb/C and C57/BI mice 
Figure 19 shows the results of a Kaplan-Meier survival analysis on the Balb/C group. No 
mice died in the control or cis-platinum only groups. No tests of statistical significance 
were applied as 12 mice per group was considered to small for this type of analysis. A 
sample size of 30 or more is considered the minimum required for an accurate estimate of 
median survival, hazard rate or probability density in the Kaplan-Meier analysis. (Statsoft 
Figure 20. Cumulative proportion of C57 /Bl female mice surviving after treatment with 
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Inc. 1997.) The Cox F-test may be used as a two-sample test for comparing groups with n 
of less than 50 per group. However no trend to difference could be observed as illustrated 
in the figure and in view of the lack of reliability in the estimate of median survival at an 
n of 12 per group a test of significance was not applied. 
The same observations may be made with regard to C57 /Bl mice although the time of 
death is markedly different with the first mice dying at 245 days after treatment (Figure 
20). As for the Balb/C no difference in survival was seen for the combined treatment 
group as compared with the radiation only group. 
Breathing rates - Balb/C and C57/B1 mice 
The breathing rate of Balb/C mice after treatment with 6mg/kg alone, 12Gy 6°Co or 6mg 
cis-platinum/kg immediately before 12Gy 6°Co irradiation is shown in Figure 21. All 
groups showed an initially high breathing rate ascribed to the stress of the first measure-
Figure 21. Changes in breathing rate in Balb/C female mice with time after treatment. 
Mice were treated with 6mg cis-platinum/kg, a single dose of 12Gy 60Co y-rays or with 
6mg/kg immediately before 12Gy. Error bars show SD and have been omitted from some 
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ment. The breathing rate dropped until the third measurement and then "stabilised" for all 
groups until approximately 100 days after treatment when the radiation treated groups 
showed an increase in mean breathing rate as compared to both the control and cis-
platinum only groups. No significant difference could be discerned in the breathing rates 
of the cis-platinum treated group when compared to the control group although a trend 
toward higher breathing rate may be apparent. 
Similarly no differences could be detected in the radiation only vs. combined treatment 
groups. In this experiment the combined treatment group showed a trend to start increas-
ing earlier at about 100 days after treatment but this did not continue and after about 120 
days the radiation only group showed a higher mean breathing rate. 
The same observations can be made of the data collected during a repeat of the Balb/C 
experiment as illustrated in Figure 22. Once again groups of six mice were treated as 
Figure 22. Changes in breathing rate in Balb/C female mice with time after treatment. 
Mice were treated with 6mg cis-platinum/kg, a single dose of 12Gy 60Co y-rays or with 
6mg/kg immediately before 12Gy. Error bars show SD and have been omitted from some 
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controls, with 6mg cis-platinum/kg alone, 12Gy 6°Co y-rays alone (Theratron 2) and 6mg 
cis-platinum/kg immediately before 6°Co y-rays. In this case, however, there is a trend for 
the combined treatment group to exhibit a higher breathing rate than the radiation only 
group from 100 to 120 days after treatment. 
It should be noted that mice in both these groups started dying at about this time and by 
140 days at least 5 mice had died in each group that had received radiation as part of the 
treatment protocol. 
The data from treatment of C57/Bl female mice are shown in Figure 23. The C57/Bl mice 
show a much higher initial breathing rate that is consistent with their more excitable tem-
perament as compared to the Balb/C mice. This increase rapidly declines and by the third 
measurement appeared to be levelling off There may be an age-related decrease in 
breathing rate apparent from about 42 to about 110 days after treatment. After this the 
Figure 23. Changes in breathing rate in C57/BI female mice with time after treatment. 
Mice were treated with 6mg cis-platinum/kg, a single dose of 12Gy 60Co y-rays or with 
6mg/kg immediately before 12Gy. Error bars show SD and have been omitted from some 
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breathing rate of the control and cis-platinum only groups levelled off at just above 6Hz. 
Groups receiving irradiation showed a gradual increase in breathing rates from approxi-
mately 100 days after treatment until the experiment was terminated at 350 days by which 
time the breathing rate was about 7Hz. The combined treatment group showed a trend to 
higher breathing rates than the radiation alone group but the difference was never signifi-
cant. The maximum average breathing rate for Balb/C mice receiving irradiation reached 
approximately 8. lHz whereas for the C57/Bl mice it reached 7.25~. The maximum 
breathing rate for Balb/C mice receiving both cis-platinum and irradiation reached about 
8Hz. For C57 /Bl mice the breathing rate after combined treatment also reached 8Hz but 
was not significantly different from the radiation only group (approx. 7.1 lHz) at that time 
- 259 days. 
The most striking difference between the strains of mice was the time scale of changes. 
The Balb/C strain showed a marked response to radiation at 100 days after treatment with 
a steep increase in breathing rates that peaked at about 130 to 140 days by which time 
significant numbers of mice were dead (about 50% in each group that received 12Gy 6°Co 
irradiation.) At 100 days after treatment the C57 /Bi's showed a gradual increase in 
breathing rate of mice receiving irradiation. While the age effects complicated interpreta-
tion of the results it appeared as is if the increase levelled out after about 140 days. How-
ever, there was an indication of a second increase occurring in the combined treatment 
group, starting at about 245 days after treatment. 
For C57's 4 out of 12 mice died in the radiation only group between 266 and 315 days af-
ter treatment after which no further deaths occurred until the experiment was terminated 
at 350 days. 6 out of 12 mice died in the combined treatment group between 245 and 322 
days after treatment. 
Breathing rates after cis-platinum administered at different times 
relative to radiation 
Cis-platinum has been shown to produce a varied change in the radiation response of dif-
ferent systems when administered at different times relative to the time of radiation treat-
ment (Muggia at al. 1979, Douple 1988.). A possible variation in the levels of surfactant 
present in lavage fluid with the time of cis-platinum treatment relative to radiation was 
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seen in the present work and is illustrated in Figure 14. The experiment described in this 
section investigated the effect of administering cis-platinum at different times relative to 
radiation on breathing rate. 
Groups of six mice were treated with 6mg cis-platinum/kg administered either 1 h, 0.5 h, 
immediately before irradiation with 12Gy 6°Co y-rays from the Eldorado 6 and immedi-
ately, 0.5 h and 1 h after irradiation. Treatments were administered as described previ-
ously in Chapter 9. 
The response is shown in Figure 24. Both the group in which cis-platinum was given im-
mediately after treatment and group in which cis-platinum was given 1 h after treatment 
showed an earlier increase in breathing rates than the radiation alone group. However, the 
group that received radiation 0.5 h after cis-platinum did not follow this pattern and in-
stead the breathing rate of mice treated in this group increased at approximately the same 
time as that of the radiation only group. In each of these groups mice started dying at 
about 120 days and by 141 days there were only two mice left in the 1 h after and imme-
diately after groups. The 0.5 h after radiation group had 4 mice still alive at 162 days after 
treatment. 
When cis-platinum was given 1 h before radiation the breathing rates were greater than 
for control mice from about 90 days but the error bars (standard deviations) overlapped. 
At 169 days after treatment the breathing rate in this group dropped to below mean con-
trol breathing rates although it should be noted that there were only two mice alive at this 
time. Mice receiving cis-platinum 0.5 h before irradiation showed an increase in breathing 
rates at about the same time as mice treated with radiation alone. There was a trend for 
this group to show a lower breathing rate than for the group treated with 12Gy radiation 
only. 
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A sharp dip was seen in the mean breathing rate at 148 days after treatment of the group 
given cis-platinum immediately after radiation, the group given cis-platinum 0.5 h before 
radiation and the radiation only treatment group. In each of these a significant portion of 
the mice in the group had died by that time. It is not clear whether this dip is a result of a 
selection of breathing rates that occurs with death or if it is perhaps an experimental arte-
fact occurring in measurement at that time. Of the two groups that did not show this dip 
the 1 h after group had 2 mice remaining alive and the 0.5 h after had 3 mice remaining 
alive at that time. 
In this series of experiments all 6 mice treated with cis-platinum immediately before ra-
diation died within 7 days of treatment. 
Figure 24. Changes in breathing rates of Balb/C mice after treatment with 6mg cis-
platinum /kg at different times relative to 12Gy 60Co y-rays. Error bars show SD and have 
been ommitted from all but one group for clarity. Control received placebo treatments. 
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Split radiation doses 
8mg cis-platinumlkg and 2 fractions of 6.5Gy 6°Co ~rays 
The breathing rate of mice treated with a split dose of radiation, with and without cis-
platinum was examined to investigate the effect of cis-platinum on repair of radiation 
damage. Radiation was given as 2 fractions of 6.5Gy separated by 0.5, 1, 2, 4, 8, or 24 h. 
The Eldorado 6 6°Co unit was used in this experiment. Cis-platinum (8mg/kg i.p.) was 
given immediately before the first dose of radiation. Significant toxicity was experienced 
in the cis-platinum treated mice with only the groups with 0.5, 2, 4 and 8 h between frac-
tions completing treatment with sufficient mice to enable analysis. 
Five-month-old mice weighing 20±2g were used to avoid the age related changes seen in 
earlier single dose experiments. Twelve mice were treated in each group. The radiation 
alone groups received an i.p. injection of saline of volume equivalent to that required for 
8mg/kg cis-platinum. Mice in the combined group were injected i.p. with 8mg/kg cis-
platinum. 
Radiation only 
There did not appear to be any significant difference in breathing rate in mice, irrespective 
of the inter-fraction intervals, until 84 days after treatment when, as with the single dose 
protocol, a radiation induced increase in breathing rates was seen (Figure 25A). During 
the period from 84 to 112 days the 24 h between fractions group showed a consistently 
lower breathing rate than the 0.5 H between fractions group. During this period the other 
groups did not show a consistent difference from the O. 5 h between fractions group but 
did show a trend to a lower breathing rate. Between 12 and 16 weeks after treatment the 
0.5 h between fraction group showed a higher breathing rate than the 24 h between frac-
tions group. The other time intervals were somewhat erratically arranged between these 
extremes with the 1 and 4 h between groups showing a trend toward a higher breathing 
rate than the 0.5 h group. 
The increase in breathing rate appeared to start at about the same time ( -80 days after 
treatment) as recorded for the group treated with a single dose of 13Gy. The 0.5 h be-
tween fractions group breathing rate increased to above that of the single dose group at 
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about 100 days after treatment. The longer time intervals between fractions groups 
showed lower breathing rates than the single dose group for all times after about 80 days. 
Although it was not possible to demonstrate clearly for all time intervals between two 
fractions of radiation, there was an indication of repair when fractions were separated by 
24h. The repair was manifested by a decrease in breathing rate relative to breathing rates 
after a single dose. 
Cis-platinum and radiation 
No trends were evident in the groups given 8mg/kg cis-platinum immediately before the 
first fraction (Figure 25B). The error bars for each point were larger in the combined 
treatment groups than for the radiation alone groups. Significant early toxicity was seen 
with all mice in the lh and 24h between fractions groups dead within 2 weeks of treat-
ment. This toxicity was presumed to be drug related. 
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Figure 25. Changes in breathing rates of Balb/C female mice after treatment with 2 frac-
tions of 6.5Gy 60Co y-rays separated by various times. Chart A shows the breathing rates 
when radiation only was administered and chart B shows the breathing rate when 8mg 
cis-platinum/kg was given immediately before the first fraction of radiation. The control 
and radiation only (12Gy) breathing rates from the subsequent split dose experiment are 
shown in grey. The legend shows time between fractions. Error bars show SD and have 
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Breathing rates in the groups treated with radiation only and with cis-platinum and radia-
tion but where radiation fractions were separated by the same time interval were directly -
compared, and the data is shown in Figure 26 ( data from Figure 25). There was a trend for 
the groups treated with cis-platinum immediately before radiation to show a reduced 
breathing rate over the time period 11 to 15 weeks when compared against the groups 
treated without cis-platinum at the same inter-fraction interval. The breathing rate also 
showed a trend to be reduced relative to the single dose group (Figure 25B). 
Figure 26A, shows the results for the 0.5 hr inter-fraction interval. For this inter-fraction 
interval the breathing rates are the same in both the cis-platinum treated and radiation 
alone groups until 90 days after treatment. After this the cis-platinum treated mice show a 
breathing rate approximately 10% below that of the radiation treated group. The same 
trend was seen in 2, 4 and 8 hr inter-fraction intervals but with only isolated points being 
Figure 26. Changes in breathing rate with time after 2 fractions of 6.5Gy 60Co r-rays sepa-
rated by various times. Each chart compares the breathing rate with time for a group 
treated with radiation alone to that of a group treated with 8mg cis-platinum/kg immedi-
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different (Figure 26B, C and D). 
6mg cis-platinum/kg and 2 fractions of 6Gy 6°Co y-rays 
The split dose experiment was repeated using lower doses of both cis-platinum and radia-
tion and using the Theratron 2 rather than the Eldorado 6 to irradiate the mice. Six Balb/C 
female mice, weighing 20±2 g and at least 5 months old were used per group. All groups 
were treated in the late afternoon to minimise early drug related deaths. In this experiment 
only 1 mouse of 30 receiving cis-platinum died within the first two weeks. The rest sur-
vived until at least 131 days after treatment when the first deaths that may be ascribed to 
radiation pneumonitis occurred. Mice receiving cis-platinum were treated and placed in 
the jig at the same time as their radiation only counterparts. 
Radiation only 
The breathing rates after split doses of radiation are shown in Figure 27 A. The mean 
breathing rate of all groups is not different from control mice until about 124 days when a 
gradual increase can be seen. The increase shows a trend to occur at a later time after 
treatment than seen for mice receiving a single dose of 12Gy. The increase appears to 
continue until the experiment was terminated at 159 days after treatment. At this time a 
significant number of mice (> 3 of 6) in all but one group ( 12h between fractions) had 
died. The 12h between fractions group also showed the highest mean breathing rate of all 
radiation only groups. While the increased breathing rate for mice treated with a split dose 
of radiation occurs later than for a single dose, no consistent signs of repair as evidenced 
by a decreased breathing rate could be discerned between the different split dose groups. 
It is thus only possible to say, on the basis of this data, that splitting the dose of radiation 
produced less damage than a single dose of radiation. No repair half times could be de-
termined from the data. 
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Figure 27. Changes in breathing rates of Balb/C female mice after treatment with 2 frac-
tions of 6Gy 60Co y-rays separated by various times. Chart B shows the breathing rate 
when 6mg cis-platinum/kg was given immediately before the first fraction of radiation. 
The breathing rate of mice treated with a single dose of 13Gy from a previous experiment 
is shown in grey. The legend shows time between fractions. Error bars show SD and have 
omitted from some groups for clarity. 
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Cis-platinum and radiation 
Figure 27B shows the results obtained when 6mg/kg of cis-platinum was given before the 
first fraction of radiation. There was a trend for the increase in breathing rate to occur at 
the same time as or before ( -100 days) the increase in breathing rate of the single dose 
(12Gy), radiation only group, but there was no consistent difference between the groups 
with the different time intervals between radiation fractions. 
Figure 28. Changes in breathing rates of Balb/C female mice after treatment with 2 
fractions of 6Gy 60Co y-rays with and without 6mg cis-platinum/kg given immediately 
before the first fraction. Error bars show SD. 
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A comparison between mice treated with cis-platinum and their corresponding radiation 
only group showed that for the shorter inter-fraction intervals there was a trend to higher 
breathing rates in the groups that received cis-platinum. In some isolated points at greater 
than 120 days this was significant (Figure 28A and B). Groups with longer inter-fraction 
intervals showed very similar breathing rates for the duration of measurement (Figure 
28C, D and E). 
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Histology 
Lung sections from control mice and mice treated with cis-platinum only, showed very 
few occluded alveoli. Mean scores of 3% and 2% were seen in the control group and the 
group treated with cis-platinum alone respectively (Figure 29). 
The radiation treated group showed a significantly higher score, with respect to the con-
trol group, of 35% (p<<0.0001). The score (55%) for the combined treatment group was 
significantly greater than that of the radiation only group (p=0.033) 
Sample sections from normal lung, stained with haemotoxylin and eosin are shown in 
Figure 30. 
Figure 29. Box and whisker plot showing mean score, standard error and standard devia-
tion for lung sections from mice killed at 120 days after treatment with 6mg cis-
platinum/kg (cddp), 12Gy 60Co y-rays (rads) or 6mg cis-platinum/kg immediately before 
12Gy 60Co y-rays (comb). Controls received placebo treatments. 
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The section shows an open latticework of alveoli interspersed with bronchioles and blood 
vessels. Little or no evidence of alveolar obstruction was seen. The occurrence of alveolar 
macrophages was extremely rare. In most normal sections none were observed. 
Figure 30. Sections from normal lung stained with haemotoxylin and eosin. 
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Figure 31 shows a sample section from an irradiated lung, stained with haemotoxylin and 
eosin. In contrast to normal lung many alveoli were obstructed and a large number of al-
veolar macrophages were observed. 
Figure 31. Sections from irradiated lung stained with haemotoxylin and eosin. 
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TGF-P analysis 
TGF-f3 has been implicated in the aetiology of radiation fibrosis, and therefore levels were 
determined with radiation and with cis-platinum and radiation. Two strains of mice - the 
weakly fibrosing Balb/C' s and the fibrosis prone C57/Bl strain - were treated with the 
standard treatments used thus far. 
12 mice per group were treated with 6mg cis-platinum/kg, 12Gy 6°Co y-rays from the 
Theratron 2 or 6mg cis-platinum/kg immediately before 12Gy 6°Co y-rays as described in 
Chapter 9. Control groups (12 mice per group for each strain) received placebo treat-
ments. Balb/C female mice and C57 /Bl female mice were treated. There were thus 4 
groups of each strain treated - in each case a control group and three treatment groups. 
Care was taken to treat each group at the same time of day, with all irradiation taking 
Figure 32. Weight lost or gained at one week and at one month by Balb/C female mice and 
C57/Bl female mice after treatment with 6mg cis-platinum/kg (CDDP), 12Gy 60Co (Rads) 
or 6mg cis-platinum/kg immediately before 12Gy (Comb.). Controls received placebo 
treatment. 
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place between 17h30 and 18h30. 
Half of the mice in each group were killed at 1 week after treatment and the lungs la-
vaged. Both the lung tissue and lavage were placed in cryotubes immediately after ex-
traction and immersed in liquid nitrogen. The remaining mice were killed at 1 month after 
treatment and the lungs lavaged as described in the methods section. Again, both lavage 
and lung tissue were place in cryotubes and immersed in liquid nitrogen immediately after 
extraction. The weight of each mouse was recorded at treatment and at time of death. 
Once all samples had been collected they were prepared for analysis of TGF-~ using the 
sandwich enzyme immuno-assay as described in Chapter 9. The lung homogenate sam-
ples were also processed for total protein content as described in Chapter 9. 
The amount of TGF-B was calculated per lavage sample, per lung, per g lung wet weight 
and per mg total protein. 
Changes in mouse weight 
The weight change induced by the various treatments is shown in Figure 32. Balb/C mice 
showed a significant weight loss within the first week of treatment. The radiation only 
group lost approximately 1.65g which was significantly different from the mean weight 
change of the control group (p=0.024). The cis-platinum plus radiation groups weight loss 
of 3g was significantly greater than that of the radiation only group (p=0.0062). The cis-
platinum only group showed a mean weight loss of 1.18g that was not significantly differ-
ent from the control group' s weight change. 
C57 /Bl groups receiving either cis-platinum, radiation or cis-platinum plus radiation 
showed a slight weight loss at one week after treatment. However, none of the treated 
group' s weight loss was significantly different from each other nor significantly different 
from the control group' s weight change. 
Three of six mice in the C57 /Bl group assayed at 1 week after treatment died before the 
week elapsed and were excluded from further analysis. 
At one month after treatment the Balb/C mice continued to show an overall weight loss. 
The combined treatment group showed an increase in weight from that recorded at 1 week 
that was not significant at the 5% level. Only the radiation only group was significantly 
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different to controls (p=0.026) at one month after treatment. All mice treated survived till 
time of assay. 
All C57 /Bl groups showed an increase in weight at one month after treatment as com-
pared to one week after treatment. While the radiation only group and the cis-platinum 
and radiation groups showed less weight gain than their control and cis-platinum counter-
parts this was not significant at the 5% level. 
Both Balb/C and C57 /Bl mice treated with either radiation or cis-platinum and radiation 
showed a trend to weight loss at 1 month after treatment, relative to the respective control 
groups. 
Changes in lung wet weight 
None of the Balb/C groups at either 1 week or 1 month showed any significant changes in 
Figure 33. Changes in lung wet weight (g) at one week and at one month after treatment 
with 6mg cis-platinum/kg (cddp), 12Gy 60Co y-rays (rads) or 6mg cis-platinum/kg immedi-
ately before 12Gy (comb). Controls received placebo treatment. 
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lung wet weight. 
The C57 /Bl radiation only group at 1 week after treatment showed a lung wet weight that 
was significantly different less than controls (p=0.042) as did the group which received 
6mg cis-platinum/kg immediately before 12Gy 6°Co y-rays (p=0.0013). The lung wet 
weight in this group was lower than the radiation only group but the difference was not 
significant. 
The C57 /Bl control groups lung wet weight was significantly less at one month after 
treatment than at 1 week after treatment (p=0.019). The C57/Bl cis-platinum treated group 
and the C57 /Bl radiation treated group showed a trend to lower lung wet weight than 
controls at 1 month after treatment that was not significant. The C57 /Bl combined treat-
ment group only contained one mouse at one month. 
Changes in lung protein 
Protein changes after treatment with cis-platinum alone, radiation alone or cis-platinum 
immediately before radiation are shown in Figure 34. The Balb/C groups did not show a 
significant increase in total protein at 1 week after treatment with cis-platinum, radiation 
or cis-platinum immediately before radiation. There was a very slight trend for the treated 
groups to show slightly more total protein per g wet weight lung homogenised than the 
control group. 
The C57 /Bl mice responded quite differently with the control group showing significantly 
less total protein per g wet weight lung than the corresponding Balb/C' s (p=0.028). The 
C57 /Bl mice receiving cis-platinum only showed a non-significant increase relative to the 
controls. The irradiated C57 /Bl groups mean total protein was significantly greater than 
that of controls (p=0.022). The combined treatment group showed a mean increase in total 
protein per g wet weight lung homogenised that was greater (statistically not significant) 
than the radiation only group and significantly greater than cis-platinum only (p=0.021). 
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At one month after treatment the total protein per gram wet weight lung for Balb/C con-
trol mice was increased slightly - a mean at one week of 148mg protein/g tissue com-
pared with a mean of 173mg protein lg tissue - but this was not statistically significant. 
The cis-platinum treated group and the radiation only treated group showed significantly 
less protein than the control group with p values of 0.029 and 0.031 respectively. The cis-
platinum and radiation treatment group also showed a decrease in total protein per g wet 
weight homogenised lung that was statistically not significant when compared to the con-
trol group. C57 /Bl mice showed an increase in total protein for both the cis-platinum 
treated group and the radiation only treated group. This was significant for the radiation 
treated group (p=0.013). 
The total protein per g wet weight extracted at one month in all C57 /Bl groups appeared 
to be increased relative to that at one week but this increase was not significant at the 5% 
level. 
Figure 34. mg protein per g homogenised lung at one week and at one month in Balb/C 
female mice and C57/Bl female mice after treatment with 6mg cis-platinum/kg (cddp), 
12Gy 60Co (rads) or 6mg cis-platinum/kg immediately before 12Gy (comb). Controls (ctrl) 
received placebo treatments. 
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The protein content per g wet weight lung was significantly lower in control (placebo 
treated) C57 /Bl mice both at one week and one month after treatment compared with 
Balb/C mice (p=0.027 and p=0.00012 respectively). 
TGF-P per sample lavaged surfactant 
A pronounced strain dependent difference in TGF-13 in pulmonary lavage was seen be-
tween the Balb/C groups and the C57/Bl groups (Figure 35). The mean TGF-13 value in 
the control C57 /Bl group at one week after treatment was significantly greater than that of 
the Balb/C control group by a factor of approximately 2.5 (p=0.00027). At one month af-
ter treatment the C57/Bl control group showed approximately three times more TGF-13 
than the Balb/C control group. This difference was also highly significantly (p=0.0016). 
Both the Balb/C and the C57/Bl control groups showed a slight decrease (non-significant) 
Figure 35. TGF-f3 per sample lavaged surfactant (pg) at one week and at one month in 
Balb/C female mice and C57/Bl female mice after treatment with 6mg cis-platinum/kg 
(CDDP), 12Gy 60Co (Rads) or 6mg cis-platinum/kg immediately before 12Gy (Comb.). 
Control groups received placebo treatments. 
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in the mean TGF-f3 levels at one month compared to the levels at one week. 
No significant changes were recorded in TGF-f3 in lavage fluid at one month after treat-
ment as compared to one week after treatment for any of the Balb/C groups. 
Within the C57/Bl strain at one week after treatment a significant decrease (as compared 
to the control group) in TGF-f3 was seen in the cis-platinum immediately before radiation 
group (p=0.021). At one month after treatment the cis-platinum only group showed a non-
significant decrease and the combined cis-platinum and radiation group showed a non-
significant increase relative to the control group. The TGF-f3 values for both these groups 
were significantly different to their 1 week counterparts (cis-platinum only p=0.031 , com-
bined p=0.018). The radiation only group did not appear to change. 
Figure 36. TGF-13 (pg) per g wet weight homogenised lung at one week and at one month 
in Balb/C female mice and C57/Bl female mice after treatment with 6mg cis-platinum/kg 
(cddp), 12Gy 60Co (rads) or 6mg cis-platinum/kg immediately before 12Gy (comb). 
Controls received placebo treatments. 
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TGF-P in homogenised lung 
For Balb/C mice the amount of TGF-13 in pg per g wet weight lung tissue did not show 
any significant difference for any of the treatment groups as compared to controls at one 
week after treatment (Figure 36). At one month after treatment both the control and the 
cis-platinum treated groups showed a trend to higher TGF-13 levels than at one week but 
this was not significant. The radiation and combined treatment groups at one month 
showed TGF-13 levels lower than controls but this was not significant. 
The amount of TGF-13 per g wet weight lung tissue in C57 /Bl mice did not appear to 
change for any of the treatment groups at either 1 week or 1 month after treatment (Figure 
36). Although the radiation treated group at one month after treatment showed a lower 
level of TGF-13 than the controls this was not significant. Only one sample could be ana-
lysed for pg TGF-13 per gram wet weight homogenised lung for cis-platinum plus radia-
Figure 37. Picograms TGF-J3 per µg protein lung at one week and at one month after 
treatment in Balb/C female mice and C57/BI female mice after treatment with 6mg cis-
platinum/kg (cddp), 12Gy 60Co (rads) or 6mg cis-platinum/kg immediately before 12Gy 
(comb). 
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tion group at one month after treatment (Figure 36). This single value was well within one 
std. deviation of the mean value for the control group at one month after treatment. 
None of, either the Balb/C nor the C57/Bl groups at one week after treatment showed any 
change in pg TGF-13 per µg protein (Figure 37). 
At one month after treatment the Balb/C control group and the Balb/C group treated with 
cis-platinum appeared to be increased relative to the control group at one week after 
treatment but this was not significant. Similarly the C57 /Bl control and cis-platinum 
group appeared to show elevated levels of TGF-13 compared to the C57/Bl control at 1 
week but this was not significant. The Balb/C radiation and combined groups at one 
month after treatment showed TGF-13 levels lower than controls but this was not signifi-
cant (Figure 37). 
The level of TGF-13 in the C57/Bl radiation treated group was less than that of the control 
group. This difference was significant (p=0.046). No samples could be analysed for pg 
TGF-13 per µg protein per g lung for the cis-platinum plus radiation group (Figure 37). 
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Chapter 11. Discussion 
Introduction 
It is vital to consider the response of the lung ( or any normal tissue system) as a complex 
and dynamic interaction of factors that act to produce an endpoint. Changes in any one of 
these factors may produce a change in outcome, which may be clinically beneficial or 
could lead to an enhanced normal tissue toxicity. Thus in the lung it would be naive to 
consider radiation induced pulmonary toxicity merely as the result of radiation mediated 
cell loss in any particular cellular compartment within the lung. 
Toxicity in the lung appears to be related to either the early pneumonitic toxicity charac-
terised by inflammation and oedema or to be due to the later fibrotic reaction. Both of 
these pathological states may be viewed as evolutionary processes. 
In pneumonitis or fibrosis, radiation events would certainly include cell loss in one or 
more critical populations but may also involve direct effects not related to mitotic death of 
cells. Thus the almost immediate observation of surfactant release and associated changes 
in lamellar bodies of the type II cell could be the initial events in a physiological and bio-
molecular cascade which lead to the toxic effect. Release of biologically active molecules 
(cytokines, icams (inter cellular adhesion molecules), growth factors or chemotaxins) may 
recruit other cell populations which in term will play an active role in the final clinical 
outcome. 
The final fibrotic state may be an inappropriately large response to damage caused by fi-
broblasts responding not only to actual cell loss but also to a selection of the many factors 
present in the lung during the course of its response to radiation. 
It has also been hypothesised that injury to other systems in the thoracic region may con-
tribute to lung damage. Watanabe et al. (1974) suggested that fibrosis may be a conse-
quence of radiation induced blockage in the mediastinal lymphatic channels leading to an 
accumulation of mast cells within the lung. While this hypothesis has not been proved it is 
an example of the systemic approach to lung damage under discussion. 
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Within this framework it is not meaningful to ascribe the response of the lung to a single 
cell population. There may be times at which a group of cells predominates - for example 
type II pneumocytes during the pneumonitic phase. It should be noted that the type II 
pneumocytes might in turn be responding at that time to stimulus from another group of 
cells. 
The usefulness of a model that assumes a single target cell would lie in devising strategies 
that result in reducing the radiation effect on that cell. This may then allow a therapeutic 
gain to be achieved. 
The usefulness of a systemic (holistic) approach lies in developing strategies that modify 
one or more pathways within the process thus producing a reduction in the toxic response. 
A reduction in pulmonary toxicity after radiation may reduce undesired side effects of 
therapy and may enable higher doses to be administered thus achieving better tumour 
control. Where radiation sensitising drugs are present in treatment protocols a reduction in 
the radiosensitivity of the lung may allow higher doses of either drug or radiation to be 
used again with better tumour control. 
Understanding and applying a systemic model of radiation effect on a normal tissue is 
potentially liberating as, while it may not be possible to protect a specific cell population 
from radiation induced mitotic death, it may be possible to change the biochemical envi-
ronment within which the reaction is occurring and hence modify the outcome. 
For example corticosteroids which have multiple regulatory effects have been observed to 
protect against radiation induced pulmonary lethality (Phillips et al. 1975). Gross et al. 
(1988) noted both stimulation of surfactant release and of type II proliferation after ad-
ministering corticosteroids. Thus this observation may be used to provide evidence either 
for a single target cell model or for a systemic model. TGF-13 has been implicated as im-
portant in causing fibrosis after radiation (Rodeman et al. 1995). If this is so, then control 
of TGF-13 synthesis and release after radiation may facilitate control of radiation induced 
fibrosis in spite of underlying cell death. 
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Pulmonary surfactant 
Effects of single doses of radiation 
Rubin et al. 1980 and 1983 proposed that surfactant release might be a predictor of later 
occurring radiation damage to the lung after demonstrating the correlation between sur-
factant released at 7 and at 28 days after radiation with death during radiation pneumoni-
tis. A part of this project was based on the hypothesis that this marker effect could be used 
to assess pulmonary damage due to combinations of chemotherapy drugs and radiation. 
The first experiments presented in this work show that the HPLC assay used was able to 
duplicate the results obtained by Rubin et al. (1979, 1983) after treatment with radiation 
only (Figure 12, page 81). The technique used to determine the level of surfactant in la-
vaged fluid was different to that used by Rubin et al. (1979, 1983) who made use of thin 
layer chromatography followed by two chemical assays to determine total phosphorus and 
disaturated phosphatidyl choline. The HPLC technique presented here only examined the 
relative levels of the phosphatidyl choline peak. 
The hypothesis that surfactant release could be used as a marker for radiation damage may 
be naive and has come under criticism (Down et al. 1988). For release of surfactant to 
predict later radiation damage the release would need to be part of the mechanistic path-
way leading to the later effect. The specific origin of surfactant release does not appear to 
have been clarified yet. It may result from increased synthesis and turnover as a result of 
some signal - perhaps part of the response to DNA damage. It may result from the release 
of stored surfactant from damaged and / or dying cells. In either case, until the precise 
mechanism of release is better understood as well as its relationship to later occurring 
damage, its value as a predictor must be established empirically for every new pulmonary 
challenge. The wide variety of treatment combinations and possible variations in response 
make this extremely difficult. As discussed in Chapter 5, Ahier et al. (1985) showed no 
difference between release of surfactant after neutrons or after x-rays. This did not corre-
late with the difference seen in later responses (LD50) . 
It may be that the release of surfactant after treatments including cis-platinum would not 
correlate with later effects. If surfactant were to be used as a measure of the pulmonary 
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toxicity of treatments including cis-platinum and radiation its reliability as a predictor of 
effect under these treatment conditions would need to be established. 
The release of surfactant is however of interest in its own right as surfactant levels are an 
important part of the homeostatic balance in the lung. In addition, surfactant may play a 
role in minimising the effect of radiation damage. It is thus important to identify agents 
which on their own or in combination with radiation cause changes in surfactant levels. 
Single doses of cis-platinum 
While no significant increase ( apart from a slight trend) could be seen when surfactant 
was measured by HPLC after cis-platinum alone, changes were observed using the enzy-
matic technique. The level of surfactant at 2 days after treatment with cis-platinum only 
was approximately 1.5 times that observed at 56 days after treatment (Figure 15, page 84) 
and was significantly different to controls. This increase after cis-platinum would appear 
to be a novel finding. 
It may be that the HPLC technique while measuring changes in one component is missing 
changes that are detected by the enzymatic analysis, which measures changes in all phos-
pholipids. In addition loss of surfactant can occur in the HPLC analysis during the extrac-
tion of the phospholipid component. The enzymatic analysis does not require an extrac-
tion procedure. 
The release may be a manifestation of the pulmonary response to damage. Cis-platinum 
as a DNA active agent may induce damage response mechanisms that result in the release 
of surfactant. It also may be a more direct response with DNA-protein links directly af-
. fecting the surfactant release mechanism. 
Cis-platinum at different times relative to radiation 
There is some conflicting evidence in the literature as to whether cis-platinum causes an 
enhanced reaction in the lung when administered with radiation. It is possible that this 
controversy arises as a result of schedule dependent differences in the way that lung tissue 
responds after treatment with the combined agents. Von der Maase et al. (1986) presented 
data showing no effect of the drug on radiation whereas Tanabe et al. (1987) showed 
schedule dependent increases in breathing rates after treatment with both agents. In the 
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experiments presented here cis-platinum was given either before or after radiation at times 
chosen to be within or close to the maximum (hypothesised) concentration of cis-platinum 
in the lung. This was based on measured concentrations in the lung after i.v. injection 
showed an initial rapid appearance and subsequent clearance with a tv.a of 0.61 h and tv.13 
of 1.28 h. The peak concentration occurred at 10mins after injection (Siddik et al. 1988). 
Maximum plasma concentration after an i.p. injection of 6mg/kg was seen at 5 minutes in 
C3Hf/Sed mice (Fu et al. 1988). 
As indicated in Chapter 10 (Figure 14, page 83) the amount of surfac_tant measured after 
cis-platinum was administered at different times relative to a single dose ( 11 Gy) of radia-
tion was not statistically different to that after radiation alone. Although the number of 
mice treated in this experiment was small, surfactant released after cis-platinum at be-
tween 1 h before and 1 h after radiation as measured by HPLC does not appear to change 
the release after radiation alone. 
Time course of surfactant release 
A statistically significant early release in surfactant after combined treatment with cis-
platinum and radiation was shown in the experiment examining the time course of sur-
factant release after treatment with cis-platinum alone or in combination with radiation 
(Figure 15, page 84 ). This result is of particular interest as it may be indicative of a drug -
radiation interaction. Drug-radiation interactions in general are complex and subject to 
debate. It is often difficult to discern when a true synergistic interaction is taking place. 
The cumulative effect, with time, on the surfactant system may be represented by calcu-
lating the area under the curve of surfactant level against time (Figure 15, page 84) up to a 
particular time for each treatment minus the corresponding control area. This would hy-
pothetically represent the total amount of surfactant released during that time interval by 
the treatment. Then, if the sum of the individual areas up to a particular time is less than 
the area under the combined treatment curve for that time it may be suggested that the two 
agents are acting synergistically to give a greater than additive effect. Table 6 shows the 
calculated areas. 
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Table 6. Area under the curve for surfactant level against time after treatment 
with cis-platinum, radiation alone or cis-platinum immediately before radiation. 
Treatment Time interval (days) 
1 to 2 2to 7 7 to 14 14 to 28 28 to 56 TOTAL 
Radiation alone 0.2 1.9 3.8 14.5 25 .1 45 .5 
Cis-platinum alone 0.4 1.7 1.8 3.1 3.0 10.0 
Cis-platinum immediately 0.5 4.6 8.4 17.3 24.4 55.2 
before radiation 
Areas added separately 0.7 3.7 5.5 17.6 28.1 55 .5 
Ratio of areas 0.8 1.2 1.5 1.0 0.9 1.0 
The areas for the intervals from 2 to 7 days and 7 to 14 days for the combined treatment 
appear to be greater than the sum of the individual treatment areas and may thus indicate a 
greater than additive effect during this period. The ratio of the area under the combined 
treatment curve to the sum of the individual areas in these cases is greater than 1. How-
ever, the ratio of areas for the overall measured period (56 days) is close to 1 indicating 
that the same amount of surfactant in total over this period was released after combined 
treatment as after the individual treatments summed. 
The early release in surfactant may be a result of release of stored surfactant, of increased 
synthesis of surfactant or a combination of release and synthesis. The same is true for the 
release of surfactant after treatment with radiation alone where precursor studies have 
shown an increase in synthesis and turnover (Coultas et al. 1987). Increased release, with-
out compensatory synthesis, may result in depletion of surfactant at later times after ra-
diation treatment. This may have a deleterious effect on the adaptive response of the lung 
to damage. Furthermore, re-treatment during any period of depletion may result in addi-
tional inability of the lung to maintain function during this time. 
An alternate hypothesis is also possible. The late radiation response of the lung may be a 
result of excessive early release of biologically active substances during the pneumonitic 
phase. Re-treatment during a time of depletion of these substances may increase lung tol-
erance to radiation. 
HPLC and enzymatic assay for surfactant 
The HPLC technique was developed because of the potential that it might offer in ana-
lysing any changes that might have been visible in the different components of surfactant. 
The dominant peak in the chromatogram was presumed to be phosphatidylcholine from 
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its correspondence with values in the literature for elution time (Jungawala et al. 1975) 
and because phosphatidylcholine is the predominant phospholipid in surfactant (King et 
al. 1972). At the time of these experiments a phosphatidylcholine standard was not avail-
able. 
It was found that the HPLC technique was not well adapted to processing multiple sam-
ples as each sample had to be run in series. Periodic column regeneration was needed. The 
gradient elution technique used added greatly to the time required per sample as the col-
umn had to be returned to the starting solvent composition between samples and a stable 
baseline ensured. At best speed, a single sample required nearly an hour to process. Col-
umns and HPLC grade solvents used added to the expense of the technique. Its use is thus 
more appropriate if specific use were made of the technique' s ability to separate a sample 
into constituent components. 
In contrast to the HPLC technique the enzymatic assay was well suited to multiple small 
samples once the kit had been adapted as described in the methods section (Chapter 9, 
page 67). Samples could be prepared in parallel and readings taken rapidly and easily us-
ing a spectrophotometer. The modifications to the kit make it highly cost effective assay. 
The enzymatic assay measures changes in total phospholipid thus giving an overall pic-
ture of total surfactant release following treatment. 
Because of the lack of clarity on surfactant as a mar~er in combined treatment protocols 
and the lack of any mechanistic hypothesis for its role in radiation damage, this line of 
investigation was not persued 
Comments on broncho-alveolar lavage 
The lavage procedure in these experiments, in which surfactant is extracted from the lung, 
is an extremely delicate procedure. Between 8 and 10% of all extraction attempts failed 
for reasons such as the trachea slipping off the catheter during extraction and spilling la-
vage fluid. When this happened the sample was not included in the experiment. Variabil-
ity in lavage efficiency may have a pronounced effect on the level of surfactant recorded. 
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Breathing rates 
Single dose studies 
The following single dose breathing rate experiments were performed: 
• Breathing rates after 8mg/kg and 13Gy 
• Breathing rates after 7mg and 12Gy 
• Breathing Rates after 6mg and 12Gy 
In comparison with placebo treated controls, in each case no change was seen after cis-
platinum alone, an increase in breathing rate was seen at some time after radiation and a 
similar increase was seen after combined cis-platinum and radiation. No consistent trend 
or obvious differences could be seen between the radiation only groups and the cis-
platinum plus radiation groups. The experiments all exhibited a high degree of variability. 
A mouse' s breathing rate will change depending on numerous factors. These include 
normal physiological factors such as response to stress, temperature or degree of activity. 
The magnitude of these responses may be at least as great or greater than changes induced 
by radiation. Changes of up to 40% were observed within the first two weeks after treat-
ment in control mice as the mice adapted to the unfamiliar and possibly stressful envi-
ronment of the plethysmograph. This took the form of a rapid decrease in the measured 
breathing rate. After this, a week to week variation of 5 to 15% for the control groups was 
observed. Age related changes were evident in control groups. Generally a small decrease 
was noted but for the first breathing rate experiment this was as large as 52% (Figure 16, 
page 86). 
Variability in breathing rate measurements 
Every effort was made to minimise variability in the measuring technique. Steps taken 
included: measurements taken at the same time each day in the same environment; meas-
urements made across groups rather than completing groups in series, waiting for mice to 
settle, discarding results which did not show a sharp Fast Fourier transform and using 
mice matched for age and weight. In spite of this it may be that the endpoint is not suffi-
ciently discerning to allow small changes to be detected. 
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Travis et al. (1979) showed that for an increase in dose from 13 to 16Gy CBA male mice 
showed an increase in breathing rate of approximately 10% at 16 weeks after treatment. 
For an increase in radiation dose from 8 to 13Gy they showed an increase of approxi-
mately 5%. No increase in breathing rate was seen when the dose was increased from Oto 
8Gy. The data presented here show an increase at 16 weeks of between 5 and 8% from 0 
to 12Gy and of 17% between O and 13Gy. The mean breathing rate of untreated mice in 
Travis et al ' s work was reported as approximately 340 breaths per minute or 5.6Hz with a 
standard error of the mean of approximately 5 to 15 b.p.m. or 0.08 to 0.25Hz. In compari-
son the mean breathing rate of control mice in the data presented here ranged from ap-
proximately 4.5 to 5.5Hz with standard deviations of ±0.25 to ±1.0Hz with occasional 
points having a standard deviation as high as 2.5Hz. The errors presented by Travis et al. 
appear smaller but it should be emphasised that these authors used standard errors of the 
mean with only 10 mice in each group. In this work, the errors are expressed as standard 
deviations, as this is more appropriate for the small groups (n= 6 to 12). 
Down and Steel (1983) reported on breathing rates of C57Bl and CBA male mice which 
showed a similar variability and error as described above for both control mice and mice 
treated with 13Gy. Likewise, results from Travis et al. (1980) showed a similar variability 
and error for controls, mice treated with 12Gy and mice treated with 13Gy (male CBA/Ht 
mice). Higher doses (15 and 20Gy) did not appear to show as great a variability, instead 
showing steep dose response curves at earlier times. Mice in these groups were all dead 
within 25 weeks. 
The work presented here would thus appear to be qualitatively similar to results reported 
in the literature and the measuring technique neither substantially better nor worse. 
The data from the first experiment in the breathing rate series (Figure 16, page 86) was 
complicated by the age dependent decrease in the breathing rate of the controls. Older 
mice were used in later experiments and this decrease was no longer evident. 
Control mice in different experiments showed substantial variation. While a possible ex-
planation exists for the higher breathing rate of all the mice in the first breathing rate ex-
periment - they were treated at a younger age - it is less clear what may have caused the 
variation in later experiments. Possible explanations could include variations in measuring 
conditions For example ambient temperature differences between summer and winter. 
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Different times of day for measurement of one group as compared to the next may also 
contribute. An additional factor may be small age differences between groups at the time 
of treatment. 
Cis-platinum toxicity 
Despite the hydration protocol used when administering cis-platinum considerable and 
often unpredictable early toxicity was seen in groups of mice receiving cis-platinum. Ini-
tial attempts to reduce the toxicity included reducing the cis-platinum dose from 8mg/kg 
to 6mg/kg and reducing the radiation dose from 13Gy to 12Gy. 
The initial group of mice treated with 8mg/kg cis-platinum (page 86) did not show early 
drug-related toxicity. Subsequent attempts to repeat experiments at this dose of cis-
platinum were abandoned because of high levels of toxicity and the dose of cis-platinum 
was reduced to 7mg/kg and then to 6mg/kg. The reason for the lack of toxicity in the ini-
tial group is not clear. 
The variation in cis-platinum toxicity between experiments may be due to circadian vari-
ability in the tolerance of mice to cis-platinum as recorded by Shakil et al. 1993. (see 
Chapter 7, page 50). In these experiments time of injection for any particular group of 
mice was determined by logistical factors such as beam availability and number of groups 
treated per day. In retrospect, time at which cis-platinum was administered should have 
been a controlled aspect of the experimental design and indeed was factored into the later 
breathing rate experiments (See Figure 21, Figure 22, Figure 23, page 92). 
Effect of death on mean breathing rate 
Death of mice in the breathing rate analysis may cause significant changes in the mean 
breathing rate for a particular group as each death will remove a value from the group. 
Such data censoring may lead to anomalies in interpreting the results that could be sig-
nificant with small numbers of mice in each group - or with small numbers remaining at 
the end of a measurement period. The longer a treatment is followed the 'better' the 
breathing rate data might appear as only the stronger mice remain in the experiment. If a 
mouse with a high breathing rate dies then the mean breathing rate of the remaining mice 
will be reduced. Conversely if a mouse with a low breathing rate dies then the mean will 
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shift to a higher value. A possible means of accounting for this is discussed below in the 
split dose experiments by using a 'Kaplan-Meier" survival type analysis. 
Comparison between Balb/C mice and C57/BI mice 
It has previously been shown in the literature that C57 /Bl mice do not show pneumonitis 
for doses of radiation causing late radiation fibrosis (Down and Steel 1983 ). C57 /Bl mice 
have also been observed to show signs of fibrosis during the acute phase of the radiation 
response. This progresses to extensive contracted fibrosis during the late phase. The 
Balb/C strain shows small foci of fibrosis during the acute phase of the radiation response 
that progresses to foci of contracted fibrosis during the late phase (Sharplin and Franko, 
1989a and 1989b). 
The steep increase to approximately 7Hz ( 420 BPM) in breathing rates seen (page 86, 
Figure 16) in the Balb/C strain from 90 to 115 days (13 to 16 weeks) after irradiation with 
13Gy are consistent with pulmonary insufficiency caused by radiation pneumonitis. A 
slightly lower dose of 12Gy (Figure 17, page 87 and Figure 18, page 89) caused a similar 
increase but occurring slightly later at about 125 to 140 days ( 17 to 20 weeks) after treat-
ment. 
Similar results were recorded for CBA by Down and Steel (1983) who observed a peak of 
approximately 420 BPM at 14 weeks after treatment with 13Gy. Travis et al. (1980) did 
not see the same peak at 14 weeks after treatment of CBA mice with 13Gy. Instead the 
breathing rate was observed to gradually increase to and then fluctuate between 360 and 
380 BPM from 16 to 52 weeks after treatment. They did however see a steep increase 
with a maximum breathing rate of 450 occurring at about 22 weeks after treatment with 
14Gy. 
The less severe and more gradual increase in breathing rate seen in the C57 /Bl strain 
(page 94, Figure 23) may be consistent with the onset of radiation fibrosis without a sig-
nificant pneumonitic reaction. Down and Steel (1983) observed a similar gradual increase 
in the breathing rate of C57Bl mice after treatment with 13Gy that reached a maximum of 
450 BPM at 36 weeks after treatment. They were however not able to correlate this with 
histological observations of fibrosis and instead noted the presence of pleural effusions. 
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While cis-platinum did not have a measurable effect on the breathing rate of either strain 
in these experiments there was a trend for the combined treatment groups to exhibit a 
higher breathing rate. This may be due to the rise in breathing rate starting slightly earlier 
after treatment with both cis-platinum and radiation than after treatment with radiation 
only. The trend was most persistently observed in the C57/Bl group that showed a higher 
breathing rate for most times between 180 and 350 days after treatment (Figure 23, page 
94). 
If the breathing rate in fact increased earlier after treatment with both cis-platinum and 
radiation then this would correlate with the early release of surfactant seen after combined 
treatment (Figure 15, page 84). 
Breathing rates after cis-platinum administered at different times 
relative to radiation 
The variability seen towards the end of the experiment, with few mice remaining in the 
groups prevents conclusion being made about dose-time effects of cis-platinum on radia-
tion. Once again, a trend toward an early increase in breathing rate is visible with the 
groups given cis-platinum one hour and half an hour after radiation showing increased 
breathing rates occurring before those treated with radiation only. This trend however is 
not evident in the groups where cis-platinum is given before radiation. 
While all mice in the group in which cis-platinum was given immediately before radiation 
died at one week after treatment in this experiment, other experiments where cis-platinum 
was given immediately before radiation showed a trend toward an early increase (Figure 
22, page 93 and Figure 21, page 92). It is thus unlikely that the trend for breathing rates to 
occur earlier after combined treatment is a schedule dependent effect. 
The lh before treatment group did not show any substantial increases in breathing rates 
typifying the breathing rate of other groups that received radiation. The O. 5h before group 
showed a trend to a lesser increase in breathing rates than that observed in other experi-
ments where cis-platinum was given immediately before radiation. The increase in 
breathing rate was also less where cis-platinum was given after radiation in this same ex-
periment. This lack of increase in breathing rate may be an effect of combined treatment 
on the lung but may also be due to the effect of these combined treatment schedules on 
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other tissues within the field. It should be noted that in the lh before group 3 of 6 mice 
had died by 134 days and in the 0.5h before group 3 of 6 mice had died by 148 days. 
Split doses of radiation 
Two split dose experiments - the first with 8mg/k:g cis-platinum and 2 fractions of 6.5Gy 
and the second with 6mg cis-platinum/kg and two fractions of 6Gy - were performed. The 
second set with lower doses was performed to try and reduce the toxicity seen after higher 
doses and thus to produce more consistent results. (This was also done with the single 
dose studies in which the dose of cis-platinum was reduced from 8mg/k:g to 6/mg/k:g and 
the dose ofradiation from 13Gy to 12Gy). 
Substantial change in control breathing rates was noted between the two sets of experi-
ments. In the first set the breathing rate of the control group settled at about 6Hz (360 
BPM) after age related changes had stabilised. In the second set of experiments performed 
24 months later and starting with slightly older mice, the breathing rate of control mice 
was about 5Hz (300 BPM). It is not clear what the cause of this difference was. 
There is some contrast between the two experiments. The first set, where groups were 
treated with cis-platinum immediately before 2 fractions of 6.5Gy, a trend for the breath-
ing rate to be lower than the radiation only groups was seen. The second set, where 
groups were treated with cis-platinum immediately before 2 fractions of 6Gy, a trend for 
the breathing rate to be higher at shorter inter-fraction intervals than the corresponding 
radiation only groups was seen. The second set was performed with the revised treatment 
set up on the Theratron 2. Treatment also occurred at a consistent time for each group 
(approximately 6pm) resulting in no early toxicity. 
While the control groups in the two sets of experiments showed differing breathing rates 
the higher radiation doses (13Gy or 2 fractions of 6.5Gy) appeared to cause an earlier in-
crease in breathing rate for both single and split doses than the lower radiation doses 
(12gy and 2 fractions of 6Gy). 
Kaplan-Meier type analysis of breathing rates 
An alternative analysis for breathing rate data makes use of Kaplan-Meier type survival 
analysis that accounts for censoring. In this analysis 'survival' is replaced by a defined 're-
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sponse' breathing rate. Mice which exceed the response breathing rate are scored as hav-
ing responded while those that do not achieve the response breathing rate within the pe-
riod of the experiment or were removed from the experiment before completion ·are 
scored as censored. This type of analysis has not been reported in the literature. A similar 
analysis that allows ordinal data to be transformed into a quantal response and analysed 
using probit or logit techniques has been reported (Travis et al. 1986, Van Rongen et al. 
1995). 
A difficulty in designing this kind of experiment lies in choosing the 'response' breathing 
rate. The response breathing rate should be low enough to be sensitive and yet must be 
high enough to measure a real response i.e. it must be high enough such that the control 
group does not show a response. The level chosen should not be so high such that all 
points are censored. It should also be consistent between experiments. 
Von Rongen et al. (1995) chose levels of 20, 25 and 30% above that of controls to inves-
tigate repair half-times in lung after clinically relevant doses per fraction. They did not 
justify this choice but found that values for repair half-time (0.2 to 0.6 h) were not incon-
sistent with those obtained using mortality (-0.3 h). 
There are at least three potential difficulties in designing an analysis using the Kaplan-
Meier technique: 
1. Variability in control breathing rate may mean that at some time after treatment indi-
vidual control mice will exceed the response. 
2. The choice of breathing rate is not related to an underlying mechanism i.e. arbitrarily 
sliding the response level up and down could vary the result significantly. 
3. Number of mice required is high. Kaplan-Meier type survival analyses require at least 
30 subjects in each treatment group for reliable estimates of median 'survival'. 
(StatSoft, Inc. 1997.) 
A suitable study in which groups of at least 30 mice were treated with increasing doses of 
radiation and their breathing rates recorded may allow a suitable response breathing rate 
to be chosen such that the median response rate showed a dose response comparable to 
that obtained using other techniques. Although none of the groups in this project con-
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tained more than 30 mice the analysis was performed with the results from the experiment 
in which mice were treated with 2 fractions of 6Gy 6°Co y-rays with and without cis-
platinum preceding the first fraction (Figure 38). Response levels of 6 and 7Hz were used 
which represent breathing rates approximately 20% and 40% above that of controls. 
Figure 38 compares the results at these two levels of response, and a comparison of p val-
ues is given in Table 7 
Table 7. Comparison of p-values from Cox's F-test. A 'Kaplan-Meier' survival 
type analysis was performed on groups treated with 2 x 6Gy 6°Co rays separated 
by various times. Cis-platinum was administered immediately before the first 
fraction in half of the groups. 
6Hz (- 20% above controls) 7Hz (-40% above controls) 
Time between Comment p value Comment p value 
fractions 
0.5 cis-plat group shows trend 0.065 cis-plat group responds O.oIS 
to respond slightly early 
2 cis-plat group shows trend 0.096 cis-plat group shows trend 0.12 
to respond slightly to respond slightly 
6 Radiation only group 0.26 Radiation only group 0.27 
shows trend to respond shows trend to respond 
early early 
12 about same response 0.065 Radiation only group 0.019 
responds early 
24 about same response 0.30 Radiation only group 0.29 
shows trend to respond 
earl 
It is important to note that the statistical methods used are only powerful for groups of 30 
or more. Bearing this in mind, the analysis shows a trend for cis-platinum with radiation 
to cause an early response at both levels chosen. This is similar to the trend observed in 
Figure 28, page 104 but, with sufficient mice, would have the additional power of a sta-
tistical test comparing groups and accounting for censoring. 
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Figure 38. Cumulative percent non-responders for response breathing rates of 6Hz (left) 
and 7Hz (right) after treatment with 286Gy with and without cis-platinum. 
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Overall comments on breathing rate experiments 
In summary, considerable variability was seen in the breathing rate experiments that may 
be masking fine changes. Some evidence of repair as shown by a decrease in breathing 
rate after a split dose of radiation was observed but repair half times could not be deter-
mined. Although a trend for cis-platinum treated groups to show an early increase in 
breathing rate was observed in both single radiation dose and split dose experiments it 
could not be statistically verified and was not observed in all experiments. 
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Histology 
The pneumonitic phase of radiation injury to the lung is characterised by interstitial oe-
dema, fluid leakage into the alveoli, an infiltration of inflammatory cells and possible 
desquamation of epithelial cells from the alveoli walls. Travis (1995) used these lesions as 
the basis for a scoring system to quantitatively evaluate lung sections after radiation 
treatment. Mild lesions involving less than a third of the section were scored as 1, one 
third to two thirds a value of 2 and more than two thirds a value of 3. Normal sections 
were assigned a value of 0. 
Initially Travis (1995) used an ocular grid to count the percentage of lesions occupying a 
section and this number converted to the appropriate score. After a large number of sec-
tions had been counted it was found that the severity of injury could be estimated using 
the scoring system. T-tests were used to compare treatment groups. As only relatively few 
sections were to be evaluated in the work presented here the results were not converted to 
a reaction score but were evaluated using the actual percentages of lesion for each section. 
While the result is statistically significant the experiment may be criticised in that only 
one section from each mouse was evaluated. This was taken parallel to the thoracic mid-
line and approximately through the midline of the left half lung. In contrast Travis ( 1995) 
evaluated two sections from each lobe. (There are 5 lobes in a mouse lung - one in the left 
lung and four in the right lung). 
In evaluating the sections the four different lesions are not equally easy to observe. 
Macrophages are generally obvious. Oedema in alveolar walls or air spaces is somewhat 
subjective and on H&E stained sections is difficult to distinguish from fibrin in the air 
spaces. In practice this was evaluated simply as matter occluding the air space. 
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TGF-P 
If TGF-13 is involved in the development of radiation fibrosis in the lung it may be ex-
pected that changes could be determined in the amount of TGF-13 present in either lung 
tissue or broncho-alveolar lavage fluid after radiation treatment. Further it may also be 
expected that there would be strain dependent differences in the levels of TGF-13 that 
would correlate with the different fibrotic response shown by suitably chosen strains. Fi-
nally if cis-platinum were to sensitise the lung to late radiation damage with the underly-
ing reaction being an increase in lung fibrosis then treatment with cis-platinum might pro-
duce changes in TGF-13 after treatment with both cis-platinum and radiation. It is conceiv-
able that cis-platinum might cause changes in the fibrotic response by some pathway 
which does not include TGF-13. 
Changes in mouse weight 
Weight changes after treatment were used in these experiments as an indicator of possible 
systemic effects of treatment. The results indicate that Balb/C mice are more sensitive to 
the acute effects of treatment at the dose of both cis-platinum and radiation used as they 
showed a greater initial weight loss than the C57 /Bl mice. This trend was continued at one 
month with the Balb/C mice not showing similar weight gains as the C57 /Bl mice. 
Changes in lung wet weight 
The decrease in lung wet weight noted in the C57 /Bl strain after treatment with radiation 
and after treatment with cis-platinum immediately before radiation at one week and at one 
month after treatment may be an experimental artefact due to the low numbers of mice 
contributing to each point. As this was an invasive assay lungs from a different group of 
mice contributed to the mean weight of control mice at one month as opposed to that at 
one week after treatment. It should also be noted that lung weight changes after treatment 
have been noted as being variable (Coggle et al. 1986). 
Changes in lung protein 
The results indicate that radiation caused an early increase in total protein in lung in 
C57/Bl mice but not in Balb/C mice (Figure 34, page 114). Since the protein content is 
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measured with respect to lung wet weight it may be that Balb/C mice are showing a 
greater relative increase in lung wet weight from non-protein components than C57 /Bl 
mice. The documented strain differences indicate that the Balb/C mice show a typical 
early pneumonitis characterised by pulmonary oedema that may be masking increases in 
total protein. The increase in total protein shown in the C57/Bl's may include components 
responsible for the later fibrotic response shown by the strain. 
At one week after treatment, lung protein levels in the C57/Bl group treated with both cis-
platinum and radiation showed a trend to increase more than for the group treated with 
radiation only. The protein samples for the group treated with cis-platinum and radiation 
were lost during the extraction and analysis process. It was thus not possible to determine 
if this trend persisted at one month after treatment. 
The differences in protein response between strains may be a contributing factor in the 
differences in fibrotic response. It has previously been suggested that the increase in lung 
permeability and associated protein leakage may be part of the progressive development 
of fibrosis (Gurley et al. 1993). The increased protein levels may be due to greater loss of 
endothelial function in the C57/Bl strain. As discussed in Chapter 3, page 25, Franko et al. 
(1991) showed lower activities for factors important in angio-genesis in those strains that 
showed fibrosis, including C57 /Bl. 
TGF-P per sample lavaged surfactant 
If TGF-J3 is part of the pathway to pulmonary fibrosis then it might be expected that the 
Balb/C strain would have less TGF-J3 in lavage as the Balb/C only shows foci of fibrosis 
while the C57 /Bl shows extensive contracted fibrosis. The results did show no significant 
changes for the Balb/C mice and various significant differences between points for the 
C57/Bl groups. However, these followed a somewhat random pattern of change and al-
though some significant differences between points were evident they were not part of a 
properly constructed hypothesis. It would not be valid to draw conclusions from them 
without supporting evidence from repeat experiments. Indeed, it may be that the changes 
in TGF-J3 observed for the C57/Bl mice are artefacts resulting from experimental error or 
small numbers of mice. 
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The experimental design must be criticised on two counts. In the first place, the TGF-J3 is 
recorded per lavage sample. While every effort was made to perform the lavage consis-
tently different amounts of lavage fluid were retrieved from each mouse both because of 
physical differences between mice and because of variation in extraction efficiency. An 
improvement in the experiment may be to record the amount of TGF-J3 per mg lavage 
fluid extracted. 
In the second place, the sample is processed after lavage by the addition of two aliquots of 
buffer and centrifuged twice with the supernatant being the component of interest. Differ-
ent samples may be processed with differing efficiencies. Clearly an internal control, con-
sisting of a known amount of TGF-J3 added before processing may help to assess and cor-
rect for this. 
TGF-/3 in homogenised lung 
While no obvious trends could be observed in TGF-J3 in homogenised lung- one isolated 
point where TGF-J3 was measured in C57 /Bl mice at one month after radiation was sig-
nificantly lower than controls - it is of interest to note the strain difference in TGF-J3 lev-
els in lavaged surfactant at both one week and one month after treatment. This difference 
is not apparent in TGF-J3 in homogenised lung. The C57/Bl and Balb/C strains have been 
observed to have different fibrotic responses to radiation (Sharplin and Franko 1989b ). 
The C57 /Bl strain shows diffuse fibrosis after radiation whereas the Balb/C only shows 
foci of fibrosis. 
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Future direction 
In many of the experiments the inconclusive results may be clarified by using larger num-
bers of mice. Of the endpoints investigated the histology scoring system showed a signifi-
cant increase in damage after combined treatment. The ability of the assay to discern this 
change should be verified by establishing a radiation dose response curve and then re-
peating the combined treatment with at a fixed dose of cis-platinum preceding at least 
three different radiation doses. 
Analysis of breathing rates using the Kaplan-Meier 'survival' type analysis should be in-
vestigated to ascertain if it would improve the ability of the breathing rate assay to inves-
tigate small changes. One possible way to do this would be to treat three groups of at least 
30 mice with small increments in radiation dose e.g. 12Gy, 12.25Gy and 12.75Gy. An es-
timate of the resolving power of the assay could then be obtained in terms of radiation 
dose. If the technique proved sensitive then it could be used to test for schedule dependent 
effects of cis-platinum administered at different times relative to radiation. It is important 
that this be established for two reasons. Firstly, in the terms of the clinical use of com-
bined cis-platinum and radiation adverse schedules must be identified and avoided. Sec-
ondly, in order to investigate adverse effects of cis-platinum in combination with radiation 
on such factors as repair of radiation damage a schedule that produces a measurable ad-
verse effect must be established. In a negative sense, it is important that the 'optimum' 
time of administration of cis-platinum should be used in further investigations of its effect 
on radiation pulmonary toxicity. 
The experiment investigating schedule dependent effects of cis-platinum on surfactant 
should be repeated using the enzymatic assay and extending it to additional time points 
both within the 56 day period repeated here and to times beyond 56 days. 
If the early release of surfactant after combined treatment with cis-platinum and radiation 
is a real result then it would be of interest to investigate the mechanism of action. It would 
also be of interest to see if other, known pulmonary toxic drugs such as Bleomycin pro-
duced a similar result. If so, this would be relevant information for consideration in the 
debate regarding the role of surfactant as a marker for later pulmonary damage. Surfactant 
release data from treatment protocols including radiation that were know to cause in-
creased pulmonary damage could be compared to protocols, such as those including cis-
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platinum, that were not know to cause increased pulmonary damage. A positive correla-
tion between surfactant release and the inclusion of pulmonary toxic drugs may indicate 
that the surfactant system is predictive for later damage. A negative correlation may indi-
cate that it was not involved. However, without a proper mechanistic understanding nei-
ther would be conclusive. 
It would also be of interest to see if these drugs, used on their own, produced a release of 
surfactant as was shown for cis-platinum. 
An in-vitro system may be useful as a model to further investigate the release after treat-
ment with cis-platinum alone and after combined treatment. (In-vitro models have been 
developed using cultured type II pneumocytes e.g. Shapiro et al. 1984, Burger et al. 1994a 
and Burger et al. 1994b). 
Differences in TGF-13 in lavaged surfactant between Balb/C mice and C57/Bl mice should 
be confirmed using larger groups of mice in each point. It would also be of interest to ex-
tend this work to a mouse strain in the third group identified by Sharplin and Franko 
( 1989b) that showed no signs of fibrosis. A suitable candidate might be the CBA mouse. 
The TGF-13 results obtained for homogenised lung should also be reinvestigated with 
larger groups of mice. It is extremely difficult in this kind of experiment where the levels 
of the substance being investigated are likely to change with time to decide on time points 
for investigation. The times chosen in this work were based on the time points used in in-
vestigating surfactant. In the first instance reliable values for untreated controls should be 
obtained. 
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Conclusions 
In conclusion the work presented here was unable to identify a consistent, substantive ef-
fect of cis-platinum on the radiation response of the lung as assessed using the methods 
described. The breathing rate assay, the focus of much of the work presented, does not 
appear to be sensitive enough to detect small changes between groups of mice treated 
with different protocols. 
A trend may exist for cis-platinum to cause an early release in surfactant and an early in-
crease in breathing rates as compared to that induced by radiation alone. Cis-platinum 
alone may cause a release of surfactant. 
Cis-platinum was observed to increase radiation damage assessed using a histology based 
scoring system. 
The level ofTGF-f3 in lavaged surfactant was greater for the C57/Bl strain as compared to 
the Balb/C strain. Cis-platinum may cause a decrease in TGF-f3 in lavaged surfactant 
from C57 /Bl mice at 1 week after treatment but further work is necessary to confirm this. 
The level of TGF-f3 in homogenised lung was not different for C57 /Bl mice as compared 
with Balb/C mice. No changes in TGF-f3 in homogenised lung could be observed in either 
strain at one week and at one month after treatment with cis-platinum, radiation or cis-
platinum immediately before radiation. 
Cis-platinum, radiation and mouse lung Chapter 11 - Discussion page 142 
References 
Adamson I.Y.R., Young L, Drummond D.H., Relationship of alveolar epithelial in-
jury and repair to the induction of pulmonary fibrosis., Am. J. Path., 130(2), 377-383, 
1988. 
Adamson, I.Y.R., Bowden, D.H., Wyatt, J.P., A pathway to pulmonary fibrosis: An 
ultrastructural study of mouse and rat following radiation to the whole body and 
hemithorax., Am. J. Pathology., 58(3), 481-487, 1970. 
Ahier R.G., Anderson R.L., Coultas P.G., Responses of mouse lung to irradiation: 1. 
Alterations in alveolar surfactant after neutrons and X-rays., Rad. One., 3, 61-68, 
1985. 
Alvarez V., Cobreros G., Heras A, Lopez Zumel C., Studies on cis-
dichlorodiammineplatinum(II) as a radiosensitiser., Br. J. Cancer., 37, Suppl III, 68-
72, 1978. 
Anderson R.L., Ahier R.G., Coultas P.G., Responses of mouse lung to irradiation: 2. 
Levels of alveolar protein in lung lavage fluid following neutrons or X-rays., Rad. 
One., 4, 167-174, 1985. 
Andrews PA, Murphy MB, Howell SM., Metallothionein-mediated cisplatin resis-
tance in human ovarian carcinoma cells., Cane. Chemo. Pharm., 19, 149-154, 1987. 
Barry M.A., Behnke C.A., Eastman A, Activation of programmed cell death (apopto-
sis) by cisplatin, other anticancer drugs, toxins and hyperthermia., Biochem. Pharma-
col., 40, 2353-2362, 1990. 
Bhoughattas N.A., Levi F., Fournier C., Hecquet B., Lemaigre G., Roulon A, Mathe 
G., Reinberg A, Stable circadian mechanisms of toxicity of two platinum analogs 
(cisplatin and carboplatin) despite repeated dosages in mice. , J. Pharmacol Exp 
Ther., 255(2), 672-679, 1990. 
Bligh E.G., Dyer W.J., A rapid method of total lipid extraction and purification., Can. 
J. Biochem. Physiol., Vol 37, 911-917, 1959. 
Bradford M., Anal. Biochem., 72., 248., 1976. 
Burger A, Bamberg M., Rodemann H.P., Radiation induced synthesis of the fibro-
genic cytokine TGF-13 by type II pneumocytes.,personal communication 1994a 
Burger A, Guven N., Hammerle H., Bamberg M., Rodemann H.P.: Co-culture sys-
tems of alveolar type-II-pneumocytes and lung fibroblasts as a model for radiation 
induced lung fibrosis., Eur. J. Cell Biol., 63, 113- 1994b. 
Calvert H., Judson I., Van der Vijgh W., Platinum Complexes in cancer Medicine: 
Pharmacokinetics and Pharmodynamics in relation to toxicity and therapeutic activity. 
Cancer Surveys., 17. 189-217, 1993. 
Cis-platinum, radiation and mouse lung References page 143 
Calvert H., Judson I., Van der Vijgh W.J.F.: Platinum complexes in cancer medicine: 
Pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic ac-
tivity., Cancer Surveys., 17, 189-217, 1993. 
Chu G.: Cellular responses to Cisplatin. The roles of DNA-binding proteins and DNA 
repair., J. Biol. Chem., 269(2), 787-790, 1994. 
Chung-Hsin Ts'ao, Ward, W.F., Port, C.D., Radiation injury in the lung I. Prostacy-
clin (PGI2) production, arterial perfusion, and ultrastructure., Rad. Res., 96, 284-293, 
1983. 
Chung-Hsin Ts'ao, Ward, W.F., Port, C.D.: Radiation injury in rat lung III. Plasmino-
gen activator and fibrinolytic activities., Rad. Res., 96, 301-308, 1983. 
Chung-hsin Ts'ao., Ward, W.F., Plasminogen activator activity in lung and alveolar 
macrophages of rats exposed to graded single doses of y rays to the right hemithorax., 
Radiation Research., 103, 393-402, 1985. 
Coff RJ. Jr, Derynk R , Wilcox J.J., Bringman T.S., Goustin AS., Moses H.L., Pit-
telkow M.R, Production and auto-induction of transforming growth factor alpha in 
human keratinocytes., Nature., 328, 817-820, 1987. 
Coggle, J.E., Tarling, J.D., Cell Kinetics of pulmonary alveolar macrophage in the 
mouse. , Cell & Tiss. Kinet., 15(2), 139-143, 1982. 
Comis RL. , Cisplatin: The Future., Seminars in Oncology., 21(5 Suppl 12), 109-113, 
1994. 
Coughlin C.T., Richmond RC. , Biologic and clinical developments of cisplatin com-
bined with radiation: Concepts, Utility, Projections for New Trials, and the emergence 
ofCarboplatin., Seminars in Oncology., 16(4) Sup 6, 31-43, 1989. 
Coultas P.G., Ahier RG., Anderson RL. , Altered turnover and synthesis rates oflung 
surfactant following thoracic irradiation. , Int. J. Radiat. Oneal. Biol. Phys., 13, 233-
237, 1987. 
Coultas, P.G., Ahier, RG., Field, S.B. , Effects of neutron and x-irradiation on cell 
proliferation in mouse lung., Radiation Research., 85, 516-528, 1981. 
Dewit L., Begg AC., Kohler Y., Stewart F.A , Bartelink H., Influence of cis-
diamminedichloroplatinum(II) on mouse duodenal crypt stem cell survival after mul-
tifraction x ray treatment. , Int. J. Radiat. Oneal. Biol. Phys., 11, 1809-1816, 1985. 
Dorie M.J., Bedarida G., Kallman RF., Protection by interleukin 1 against lung tox-
icity caused by cyclophosphamide and irradiation., Rad. Res., 128(3), 316-319, 1991. 
Douple E.B., Eaton W.L., Tulloh M.E., Skin radiosensitisation studies using com-
bined cis-dichlorodiammineplatinum(Il) and radiation., Int. J. Radiat. Oneal. Biol. 
Phys., 5, 1383-1385, 1979. 
Douple E.B., Keynote address: Platinum-Radiation Interactions., NCI Monographs., 
6, 315-319, 1988. 
Cis-platinum, radiation and mouse lung References page 144 
Douple E.B., Richmond RC., Logan M.E. , Therapeutic potentiation in a mouse 
mammary tumor and an intracerebral rat brain tumor by combined treatment with cis-
dichlorodiammineplatinum(II)., J. Clin. Hematol. Oneal., 7, 585-603, 1977. 
Down J.D., Coultas P.G., Field S.B. , Letter to the editors: Is surfactant release a reli-
able predictor ofradiation pneumonytis., Int. J. Radial. Oneal. Biol. Phys., 14(1), 211-
212, 1988. 
Down J.D., Easton D.F., Steel G.G., Repair in the mouse lung during low dose-rate 
irradiation., Radiother. Oneal. , 6(1), 29-42, 1986. 
Down J.D., Laurent G.J. , McAnulty R.J. , Steel G.G. , Oxygen-dependent protection of 
radiation lung damage in mice by WR-2721. , Int. J. Radial. Biol. Re/at. Stud. Phys. 
Chem. Med, 46(5), 597-607, 1984. 
Down J.D., Nicholas D., Steel G.G., Lung damage after hemithoracic irradiation: de-
pendence on mouse strain., Radiother. Oneal., 6(1 ), 43-50, 1986. 
Down J.D., Steel G.G., The expression of early and late damage after thoracic irra-
diation: a comparison between CBA and C57Bl mice., Rad Res., 96(3), 603-610, 
1983. 
Down, J.D., Steel, G.G., The expression of early and late damage after thoracic irra-
diation: A comparision between CBA and C57Bl mice., Radiation Research. , 96, 603-
610, 1983. 
Dritschilo A , Piro AJ. , Kelman AD., The effect of cis-platinum on hte repair of ra-
diation damage in plateau phase chinese hamster (V-79) cells., Int. J. Radial. Oneal. 
Biol. Phys., 5., 1345-1349, 1979. 
Field S.B. , Homsey S., Slow repair after X rays and fast neutrons., Br. J. Radio!., 50., 
600-601 ., 1977. 
Finkelstein, J.N. , Johnston, M.S. , Baggs, R , Rubin, P. , Early alterations in extracel-
lular matrix and transforming growth factor B gene expression in mouse lung indica-
tive oflate radiation fibrosis .,Int. J. Radial. Oneal. Biol. Phys., 28(3), 621-631 , 1994. 
Franko, AJ. , Sharplin, J. , Ward, W.F., Hinz, J.M., The genetic basis of strain-
dependent differences in the early phase of radiation injury in mouse lung., Radiation 
Research., 126, 349-356, 1991. 
French AP., Vibrations and Waves. M.I.T. Introductory Physics Series., Van 
Nostrand Reinhold (UK) Co. Ltd , pl 89, 1982. 
Fu K.K. , DeGregorio M. W., Phillips J.W., Plasma and tumour concentrations of Cis-
platin following intraperitoneal infusion or bolus injection with or without continuous 
low dose rate irradiation. , NCI Monographs. , 6, 123-127, 1988. 
Goerke J., Lung Surfactant. , Biochem et Biophys. Acta. , Vol 344., 241-261. , 1974. 
Golding RP., Van Zanten T.E.G., Lung destruction after cis-platinum radiosensitisa-
tion. Correspondence., Br. J. Radiology. , 56, 281-281 , 1983. 
Cis-platinum. radiation and mouse lung References page 145 
Gross N.J., Early physiologic and biochemical effects of thoracic X-irradiation on the 
pulmonary surfactant system., J. Lab. Clin. Med., 91(3), 537-544. 1978. 
Gross N.J. , Experimental Radiation pneumonitis. III. Phospholipid studies on the 
lungs., J. Lab. Clin. Med., 93, 627-637, 1979. 
Gross N.J., Experimental radiation pneumonitis: changes in physiology of the alveolar 
surface., J. Lab. Clin. Med., 92, 991-1001, 1978. 
Gross N.J., Inhibition of surfactant subtype convertase in radiation model of adult 
respiratory distress syndrome., Am. J. Physiol. , 260, 1311-1317, 1991. 
Gross N.J., Mechanical properties of mouse lungs: effects of degassing on normal, 
hyperoxic, and irradiated lungs., J. Appl. Physiol., 51(2), 391-398, 1981. 
Gross N.J., Pulmonary effects of radiation therapy., Ann. Inter. Med., 86., 81-92., 
1977. 
Gross N.J. , Surfactant subtypes in experimental lung damage: radiation pneumonitis., 
Am. J. Physiol., 260, 1302-1310, 1991. 
Gross, N.J. , Alveolar macrophage number: An index of the effect of radiation on the 
lung., Radiation Research., 72, 325-332, 1977. 
Gross, N.J. , Narine, K.R., Couletti-Squinto, L., Replicative activity of lung type 2 
cells following X irradiation., Radiation Research., 111, 143-150, 1987. 
Gross, N.J., Narine, K.R., Experimental Radiation Pneumonitis, Corticosteroids in-
crease the replicative activity of alveolar type 2 cells., Radiation Research. , 115, 543-
549, 1988. 
Gross, N.J., Radiation pneumonitis in mice: Some effects of corticosteroids on mor-
tality and pulmonary physiology., J. Clin. Invest., 66, 504-510, 1980. 
Gurley L.R. , London J.E., Tietjen G.L., van der Kogel A.J., Dethloff L.A. , Lehnert 
B.E.: Lung Hyperpermeability and changes in biochemical constituents in broncho-
alveolar lavage fluids following X irradiation of the thorax., Rad. Res., 134, 151-159, 
1993. 
Haston C.K., Hill RP., Newcomb C.H. , Van Dyk J., Radiation-induced lung damage 
in rats: the influence of fraction spacing on effect per fraction., Int. J. Radiat. Oneal. 
Biol. Phys. , 28(3), 633-640, 1994. 
Herrmann T., Baumann m., Voigtmann L., Knorr A, Effect of irradiated volume on 
lung damage in pigs., Radiother Oneal., 44(1), 35-40, 1997. 
Hill S.A. , Travis E.L., Denekamp J., Actinomycin D and radiation: effects on mouse 
lung., Eur J Cancer Clin Oncol. , 22(5), 577-582, 1986. 
Hoyt D.G., Lazo J.S., Alterations in pulmonary mRNA encoding procollagens, fibro-
nectin and transforming growth factor-13 precede bleomycin-induced pulmonary fibro-
sis in mice., J. Pharmacol. Exp. Ther., 246, 765-771, 1988. 
Cis-platinum, radiation and mouse lung References page 146 
Hoyt D.G., Lazo J.S., Bleomycin and cyclophosphamide increase pulmonary type IV 
procollagen mRNA in mice., Am. J. Physiol., 259, L47-L52, 1990. 
Hrushesky W.J., Levi F.A., Halberg F., Kennedy B.J., Circadian stage dependence of 
cis-diamminedichloroplatinum lethal toxicity in rats., Cancer Research., 42(3), 945-
949, 1982. 
Ishikawa T., Ali-Osman F., Glutathione-associated cis-diamminedichloroplatinum(ll) 
metabolism and ATP-dependent efflux from leukemia cells. Molecular characteriza-
tion of glutathione-platinum complex and its biological significance., J. Biol. Chem., 
268, 20116-20125, 1993. 
Johnston C.J. , Piedboeuf B., Baggs RB., Rubin P., Finkelstein J.N. , Differences in 
correlation of mRNA gene expression in mice sensitive and resistant to radiation-
induced pulmonary fibrosis., Rad. Res. , 142, 197-203, 1995. 
Jungawala F.B., Evans E.E., McCluer R.H., High Performance Liquid Chromatogra-
phy of Phasphatidycholine and Sphingomyelin with detection in the region of 200nm., 
Biochem J., Vol 155. , 55-60, 1975. 
Kallman RF., Rapacchietta D., Zaghloul M.S., Schedule dependent therapeutic gain 
from the combination of fractionated irradiation plus c-DDP and 5-FU or plus c-DDP 
and cyclophosphamide in c3H/Km mouse model systems., Int. J. Radiat. Oneal. Biol. 
Phys., 20, 227-232, 1991. 
Kallman RF., The importance of schedule and drug dose intensity in combinations of 
modalities.,Jnt. J. Radial. Oneal. Biol. Phys., 28(3), 761-771, 1994. 
Kaplan E.L. , Meier P., Non-parametric estimation from incomplete Observations., 
Journal of the American Statistical Association., 53, 457-481 , 1958. 
King R.J., Clements J.A., Surface Active materials from dog lung. IL Composition 
and physiological correlations., Am. J. Physiol., Vol 223, 715-726, 1972. 
Korbelik M. , Skov K.A., Inactivation of Hypoxic cells by Cisplatin and radiation at 
clinically relevant doses., Radiation Research. , 119, 145-156, 1989. 
Kwock L. , Davenport W.C. , Clark R.L., Zarembra J., Lingle B., Chaney E.L., Fried-
man M., The effects of ionizing radiation on the pulmonary vasculature of intact rats 
and isolated pulmonary endothelium., Radiation Research., 111, 276-291 , 1987. 
Lange RC. , Spencer RP., Harder HC., Synthesis and distribution of Pt cis-
dichlorodiammineplatinum(ll)., Journal of Nuclear Medicine., 13, 328-330, 1972. 
Law, M.P. , Vascular permeability and Late Radiation fibrosis in mouse lung., Radia-
tion Research., 103, 60-76, 1985. 
Law, M.P., Ahier R.G., Vascular and Epithelial damage in the lung of the mouse after 
X-rays or neutrons., Radiation Research., 117., 128-144., 1989. 
Cis-pkrtinum, radiation and mouse lung References page 147 
Lehnert B.E., Dethloff L.A. , Finkelstein J.N. , Van der Kogel. , Temporal sequence of 
early alterations in rat lung following thoracic X-irradiation. , Int. J. Radiat. Biol. , 
60(4), 657-675, 1991. 
Liao Z.X. , Travis E.L. , Tucker S.L., Damage and morbidity from pneumonitis after 
irradiation of partial volumes of mouse lung., Int. J. Radiat. Oncol. Biol. Phys., 32(5) 
1359-1370, 1995. 
Litterst CL. , LeRoy AF., Guarino AM., Disposition and distribution of platinum fol-
lowing parenteral administration cis-Dichloro diammineplatinum(II) to animals., 
Cancer Treatment Reports., 63(9-10) 1485-1492, 1979. 
Lockart S.P., Down J.D. , Steel G.G., Mouse hemithoracic irradiation and its interac-
tion with cytotoxic drugs., Radiother Oncol. , 24(3), 177-185, 1992. 
Lundbeck F., Overgaard J. , Early and late changes in the normal mouse bladder reser-
voir function due to irradiation and cis-DDP., Br. J. Cancer., 66, 99-105, 1992. 
Lundgren, D.L. , Hahn, F.F., Suppression of pulmonary clearance of staphylococcus 
aureus in mice that had inhaled either Ce02 or Pu02., Radiation Research., 77, 361-
376, 1979. 
McDonald, S., Rubin, P., Chang, A.Y.C., Penney, D.P., Finkelstein, J.N., Grossberg, 
S., Feins, R. , Gregory, P.K. , Pulmonary changes induced by combined mouse B-
interferon (rMuIFN-B) and irradiation in normal mice - toxic versus protecive effects., 
Rad. One., 26, 212-218, 1993. 
Melvik J.E. , Dornish J.M. , Pettersen E.O., The binding of cis-
dichlorodiammineplatinum(Il) to extracellular and intracellular compounds in relation 
to drug uptake and cytotoxicity in vitro., Br. J. Cancer., 66, 260-265, 1992. 
Meyer, K.R. , Ullrich, R.L. , Effects of x-rays and fission neutrons on an induced pro-
liferative response in lung type II epithelial cells., Radiation Research. , 85, 380-389, 
1981. 
Molls, M. , Van Beuningen, D., Radiation Injury of the Lung: Experimental Studies, 
Observations after Radiotherapy and Total Body Irradiation prior to bone marrow 
transplantation., In: Radiopathology of Organs and Tissues., Edited by Scherer, E., 
Streffer, C., Rudiger Trott, K., Springer-Verlag, Berlin Heidelberg, 1991. 
Morgan G.W., Breit S.N. , Radiation and the lung: A re-evaluation of the mechanisms 
of mediating pulmonary injury., Int. J. Radiat. Oncol. Biol. Phys. , 31(2), 361-369, 
1995. 
Muggia F.M., Glatstein E., Summary of investigations on platinum compounds and 
radiation interactions., Int. J. Radiat. Oncol. Biol. Phys. , Vol 5, 1407-1409, 1979. 
Muggia F.M.: Cisplatin Update., Seminars in Oncology., 18(1 Suppl 3), 1-4, 1994. 
Munchausen L.L. , Rahn RO., Biologic and chemical effects of cis-
dichlorodiammineplatinum (II) (NSC-119875) on DNA, Cane. Chem. Rep., 59, 643-
646, 1979. 
Cis-platinum, radiation and mouse lung References page 148 
O'Conner-McCourt M.D., Wakefield L.M., latent transforming growth factor-b in 
serum., J. Biol. Chem., 262, 14090-14099, 1987. 
Parkins C.S., Fowler J.F., Denekamp J., Lung radioprotection by WR-2721 at low X-
ray doses per fraction., Eur. J. Cancer Clin. Oncol., 20(11), 1445-1450, 1984. 
Parkins C.S., Fowler J.F., Repair in mouse lung of multifraction X rays and neutrons: 
extension to 40 fractions., Br. J. Radio/., 58(695), 1097-1103, 1985. 
Peckham M.J., Collis C.H., Clinical objectives and normal tissue responses in com-
bined chemotherapy and radiotherapy., Bull cancer., 68(2), 132-141, 1981. 
Peel, D.M., Coggle, J.E., The effect of x-irradiation on alveolar macrophages in mice., 
Radiation Research., 81, 10-19, 1980. 
Penny, D.P., Rubin, P.R., Specific early fine structural changes in the lung following 
irradiation., Int. J. Radiat. Oncol. Biol. Phys., 2, 1123-1132, 1977. 
Pera M.F., Rawlings C.J., Roberts J.J., The role of DNA repair in the recovery of hu-
man cells from cisplatin toxicity. , Chem.-Biol. Interactions., 37, 245-261, 1981. 
Peterson L.M., Evans L.M., Thomas K.L., Graham M.M., Vascular response to frac-
tionated irradiation in the rat lung., Rad. Res., 131, 224-226, 1992b. 
Peterson L.M., Evans M.L., Graham M.M., Eary J.F., Dahlen D.D., Vascular response 
to radiation injury in the rat lung., Rad. Res., 129, 139-148, 1992a. 
Peto J., The calculation and interpretation of survival curves., Cancer clinical trials -
Methods and Practice., Buyse et al. Oxford Medical Publishers., p362-380. 
Phillips T.L., Wharam M.D., Margolis L.W., Modification of radiation injury to nor-
mal tissues by chemptherapeutic agents., Cancer., 35, 1678-1684, 1975. 
Phillips, T.L., An ultrastructural study of the development of radiation injury in the 
lung., Radiology., 87, 49-54, 1966. 
Phillips, T.L., Margolis, L., Radiation pathology and the clinical response of lung and 
oesophagus., Front Radiat Ther Oncol., 6, 254-273, 1974. 
Pretorius R.G., Petrilli E.S., Kean C., Ford L.C., Hoeschele J.D., Lagasse L.D., Com-
parision of the Iv and Ip routes of administration of Cisplatin in Dogs., Cancer Treat-
ment Reports., 65, 1055-1062, 1981. 
Richmond R.C., Powers E.L., Radiation sensitization of a bacterial spore by cis-
dichlorodiammineplatinum(Il) and other metals., J. Clin. Hematol. Oncol., 7, 580-
584, 1977. 
Richmond R.C., Toxic variability and radiation sensitization by dichlorodiammine-
platinum(Il) complexes in Salmonella typhimurium cells., Radiation Research., 99, 
596-608, 1984. 
Cis-platinum, radiation and mouse lung References page 149 
Richmond RC., Zimbrick J.D., Hykes D.L., Radiation-induced DNA damage and le-
thality in E coli as modified by the antitumor agent c1s-
dichlorodiammineplatinum(II)., Radiation Research., 71, 447-460, 1977b. 
Rodemann H.P., Bamberg M., Cellular Basis of radiation-induced fibrosis., Rad. 
One., 35, 83-90, 1995. 
Rooney S.A., Page-Roberts B.A., Motoyama E.K., Role of lamellar inclusions in sur-
factant production: studies on phospholipid composition and biosynthesis in rat and 
rabbit lung subcellular fractions., J. Lipid Res., Vol. 16, 418-425., 1975. 
Rosenberg B., Van Camp L., Krigas T., Inhibition of cell division in Escerichia Coli 
by electrolysis products from a platinum electrode., Nature., 205, 698-699, 1965. 
Rosenberg B. , Van Camp L. , Trosco J.E., Platinum compounds: A new class of potent 
antitumour agents., Nature., 222, 385-386. 1969. 
Rubin P., Casarett G.W., Respiratory System. In: Clinical Radiation Pathology., 
Voll., Saunders, Philadelphia, pp 423-470, 1968. 
Rubin P. , Finkelstein J. , Shapiro D., Molecular biology mechanisms in the radiation 
induction of pulmonary injury syndromes: Interrelationship between the alveolar 
macrophage and the septal fibroblast., Int. J. Radiat. Oneal. Biol. Phys., 24, 93-101, 
1992. 
Rubin P., Finkelstein J.N, Siemann D.W., Shapiro D.L., Van Routte P., Penney D.P., 
Predictive biochemical assays for late radiation effects., Int. J. Radiat. Oneal. Biol. 
Phys., 12, 469-476, 1986. 
Rubin P.R., McDonald S, Maasilta P, Finkelstein J.N., Shapiro D.L., Penney D., 
Gregory P.K., Serum markers for prediction of pulmonary radiation syndromes. Part 
I: Surfactant Apoprotein.,Int. J. Radiat. Oneal. Biol. Phys., 17, 553-558, 1989. 
Rubin P.R., Shapiro D.L., Finkelstein J.N., Penney D.P., The early release of surfac-
tant following lung irradiation of alveolar type II cells., Int. J. Radiat. Oneal. Biol. 
Phys., 6, 75-77, 1980. 
Rubin P.R. , Siemann D.W., Shapiro D.L., Finkelstein J.N., Penney D.P., Surfactant 
release as an early measure of radiation pneumonitis., Int. J. Radiat. Oneal. Biol. 
Phys., 9, 1669-1673, 1983. 
Rubin R., Finkelstein J.N., Prophets that don't predict., Int. J. Radiat. Oneal. Biol. 
Phys., 14(1), 212, 1988. 
Rubin, P., Shapiro, D.L., Finkelstein, J.N., Penney, D.P., The early release of surfac-
tant following lung irradiation of alveolar type II cells., Int. J. Radial. Oneal. Biol. 
Phys., 6, 75-77, 1980. 
Schaake-Koning C, van den Bogaert W, Dalesio 0, Festen J, Hoogenhout J, van 
Routte P, Kirkpatrick A, Koolen M, Maat B, Nijs A, et al., Radiosensitization by cy-
Cls-platinum, radiation and mouse lung References page 150 
totoxic drugs. The EOR TC experience by the Radiotherapy and Lung Cancer Coop-
erative Groups., Lung Cancer, 10, Suppl 1 :S263-70, 1994. 
Scherer, E., Streffer, C., Rudiger Trott, K., Radiopathology of Organs and Tissues., 
Springer-Verlag, Berlin Heidelberg, 1991 
Shakil A , Hirabayashi N., Toge T., Circadian variation of 5-flourouracil and cis-
platinum toxicity in mice., Hiroshima Journal of Medical Sciences. , 42(4), 147-154, 
1993. 
Shapiro D.L., Finkelstein J.N., Penney D.P., Siemann D.W., Rubin P., Sequential ef-
fects of irradiation on the pulmonary surfactant system., Int. J. Radiat. Oneal. Biol. 
Phys. , 8, 879-882, 1982. 
Shapiro D.L. , Finkelstein J.N., Rubin P.R., Renney D.P. , Siemann D.W., Radiation 
induced secretion of surfactant from cell cultures of type II pneumocytes: An in vitro 
model of radiation toxicity. , Int. J. Radial. Oneal. Biol. Phys., 10, 375-378, 1984. 
Sharplin, J. , Franko, A.J., A qauntitative histological study of strain dependent differ-
ences in the effects of irradiation on mouse lung during the intermediate and late 
phases., Radiation Research., 119, 15-31, 1989b. 
Sharplin, J. , Franko, A.J., A quantitative histological study of strain-dependent differ-
ences in the effects of irradiation on mouse lung during the early phase., Radiation 
Research. , 119, 1-14, 1989a. 
Siddik Z.H. , Jones M., Boxall F.E., Harrap K.R., Comparative distribution and excre-
tion of carboplatin and cisplatin in mice., Cancer Chemotherapy and Pharmacology., 
21 , 19-24, 1988. 
Sorenson C.M., Barry M.A. , Eastman A , Analysis of events associated with cell cy-
cle arrest at G2 phase and cell death induced by cisplatin., J. Natl. Cane. Inst., 82, 
749-755, 1990. 
Sorenson C.M., Eastman A , Influence of cis-diamminedichloroplatinum(II) on DNA 
synthesis and cell cycle progression in excision repair proficient and deficient Chinese 
hamster ovary cells. , Cancer Res., 48, 6703-6707, 1988. 
StatSoft, Inc. Electronic Statistics Textbook. Tulsa, OK: StatSoft. WEB: 
http://www. statsoft. com/textbook/stathome.html. 1997. 
Steinberg F., Rehn B., Kraus R. , Quabeck K. , Bruch J. , Beelen DW., Schaefer 
UW., Streffer C., Activity testing of alveolar macrophages and changes in surfactant 
phospholipids after irradiation in broncho-alveolar lavage: experimental and clinical 
data., Environmental Health Perspectives., 97, 171-5, 1992. 
Stewart F.A. , Oussoren Y. , Bartelink H., The influence of cisplatin on the response of 
mouse kidneys to multifraction irradiation., Radiotherapy and Oncology., 15, 93-102, 
1989. 
Takayama M., Clinica Chimica Acta. , Vol 79, pp93, 1977. 
Cis-platinum, radiation and mouse lung References page 151 
Tanabe M., Godat D., Kallman RF., Effects of fractionated schedules of irradiation 
combined with cis-diamminedichloroplatinum(II) on the SCCVII/ST tumor and nor-
mal tissues of the C3H/KM mouse., Int. J. Radiat. Oneal. Biol. Phys., 13, 1523, 1987. 
Terry N.H., Tucker S.L., Travis E.L., Residual radiation damage in murin lung as-
sessed by pneumonitis., Int. J. Radiat. Oneal. Biol. Phys., 14(5), 929-938, 1988. 
Tillman B.F. , Loyd J.E., Malcolm AW., Holm B.A, Brigham K.L., Unilateral radia-
tion pneumonytis in sheep: physiological changes and broncho-alveolar lavage., J. 
Appl. Physiol., 66(3), 1273-1279, 1989. 
Travis E.L., Bucci L., Fang M.Z., Residual damage in mouse lungs at long intervals 
after cyclophosphamide treatment., Cancer Res., 50(7), 2139-2145, 1990. 
Travis E.L., Down J.D., Hall L., Vojnovic B. , Holmes S.J., Factors affecting the 
breathing rate of mice as used for studies of radiation damage to lungs., Br. J. Radial., 
54(637), 50-53, 1981. 
Travis E.L., Liao Z.X. , Tucker S.L., Spatial heterogeneity of the volume effect for 
radiation pneumonitis in mouse lung., Int. J. Radiat. Oneal. Biol. Phys., 38(5), 1045-
1054, 1997. 
Travis E.L. , Newman RA, Helbing S.J. WR 2721 modification of type II cell and 
endothelial cell function in mouse lung after single doses of radiation., Int. J. Radiat. 
Oneal. Biol. Phys., 13, 1355-1359, 1987. 
Travis E.L. , Parkins C.S., Down J.D., Fowler J.F., Maughan RL., Is there a loss of 
repair capacity in mouse lungs with increasing numbers of dose fractions?, Int. J. Ra-
diat. Oneal. Biol. Phys. , 9(5), 691-699, 1983. 
Travis E.L., Parkins C.S., Down J.D., Fowler J.F., Thames HD. Jr., Repair in mouse 
lung between multiple small doses ofX rays., Radiat. Res., 94(2), 326-339, 1983. 
Travis E.L. , Parkins C.S. , Holmes S.J. , Down J.D. , Fowler J.F., WR-2721 protection 
of pneumonitis and fibrosis in mouse lung after single doses of x rays., Int. J. Radiat. 
Oneal. Biol. Phys., 10(2), 243-251, 1984. 
Travis E.L. , The sequence of histological changes in mouse lungs after single doses of 
X-rays., Int. J. Radiat. Oneal. Biol. Phys., Vol 6, 345-347, 1980. 
Travis E.L. , Vojnovic B, Davies E.E. , Hirst D.G., A plethysmographic method for 
measuring function in locally irradiated mouse lung., Br. J. Radial. , 52, 67-74, 1979. 
Travis E.L. , Vojnovic B., Davies E.E., Hirst D.G., A plethysmographic method for 
measuring function in locally irradiated mouse lung. , Br. J. Radiology., 52, 67-74, 
1979. 
Travis E.L., Vovnovic B., Hirst D.G., Hill S.A, Quantitative changes in rodent lungs 
after irradiation (Abstract)., Br. J. Radial., 51, 239, 1978. 
Cis-platinum, radiation and mouse lung References page 152 
Travis, E.L., Harley, RA., Fenn, C.O., Klobukowski C.J., Hargrove H.B., Pathologic 
changes in the lung following single and multifraction irradiation., Int. J. Radial. On-
eal. Biol. Phys., 2, 475-490, 1977. 
Travis E.L., Tucker S.L., The relationship between functional assays of radiation re-
sponse in the lung and target cell depletion., Br. J. Cancer., 53., Suppl VII. , 304-319., 
1986. 
Tucker S.L., Travis E.L., Time course for the hazard of radiation-induced pneumoni-
tis death in mice., Int. J. Radial. Biol., 62(5), 627-639, 1992. 
Twentyman P.R., Kallman RF. , Brown J.M., The effect of time between x-irradiation 
and chemotherapy on the growth of three solid mouse tumors. III. cis-
diamminedichloroplatinum., Int. J. Radial. Oncol. Biol. Phys., 5, 1365-1367, 1979. 
Ullrich R.L., Meyer K.R., The influence of Butylated Hydroxytoluene-Induced Cell 
Proliferation on Mouse Lung Damage after X Rays or Fission Netrons., Rad. Res., 
89., 428-432., 1982. 
Van den Berg H.W., Roberts J.J. , Post-replication repair of DNA in chinese hamster 
cells treated with cis-platinum (II) diammine dichloride. Enhancement of toxicity and 
chromosome damage by caffeine., Mutation Research. , 33, 279-284, 1975. 
Vergara, J.A., Thet, RU., Thet, L.A., Changes in Lung morphology and cell number 
in radiation pneumonitis and fibrosis: A quantitative ultrastructural study., Int. J. Ra-
dial. Oncol. Biol. Phys., 13, 723-732, 1987. 
Von der Maase H., Interactions of radiation and adriamycin, bleomycin, mitomycin C 
or cis-diamminedichloroplatinum(II) in intestinal crypt cells., Br. J. Cancer., 42, 779-
786, 1984. 
Von der Maase H., Overgaard J., Vaeth M., Effect of cancer chemotherapeutic drugs 
on radiation-induced lung damage in mice., Rad. One., 5, 245-257, 1986. 
Von Rongen E., Travis E.L., Thames H.D. Jr., Repair rate in mouse lung after clini-
cally relevant radiation doses per fraction., Rad. Res., 141 ( 1 ), 7 4-78, 1995. 
Ward, W.F., Sharplin, J., Franko, A.J., Hinz, J.M., Radiation induced pulmonary en-
dothelial dysfunction and hydroxyproline accumulation in four strains of mice., Ra-
diation Research., 120, 113-120, 1989. 
Ward, W.F., Solliday, N.H., Molteni, A. , Port C.D., Radiation Injury in rat lung II. 
Angiotensin converting enzyme activity., Radiation Research., 96, 294-300, 1983. 
Watanabe S., Watanabe K., Ohishi T., Aiba M., Kageyama K., Mast cells in the rat 
alveolar septa undergoing fibrosis after ionizing radiation., Lab. Invest., 31, 555-567, 
1974. 
Wodinsky I., Swiniarski J., Kensler C.J., Venditti J.M., Combination radiotherapy and 
chemotherapy for P388 lymphocytic leukemia in vivo. , Cane. Treat. Rep., 4, 73, 
1974. 
Cis-platinum, radiation and mouse lung References page 153 
Wyllie A.H., Kerr J.F.R., Currie AR.: Cell death: the significance of apoptosis., Int. 
Rev. Cytol., 68, 251-306, 1980. 
Zak M., Drobnik J., Effect of cis-dichlorodiammineplatinum (II) on the post-
irradiation lethality in mice after irradiations with X-rays., Strahlentherapie., 142, 
112-115, 1971. 
Cis-platinum, radiation and mouse lung References page 154 
Appendix A. Index of figures 
Figure 1. Radiation jig and shielding. The jig comprises two rows of six perspex chambers sized hold 
one mouse each. The shielding was milled to account for beam divergence at an SSD of 80cm. __ 57 
Figure 2. Close up of jig with one mouse in position. Shielding has been removed for the photo. __ 58 
Figure 3. Trace of an X-ray of mice showing position in jig.. 59 
Figure 4. Sample densitometer scans from check films of the treatment jig i"adiated using the 
Eldorado 6 unit. _____________________________ 60 
Figure 5. Whole Body Plethysmograph. 62 
Figure 6. Circuit diagram of amplifier and.filter for plethysmograph. 63 
Figure 7. Sample trace of the phospholipid component from broncho-alveolar lavage fluid extracted 
from Balb!C female mice and analysed using HPLC. The area of the peak labelled with an arrow was 
used as arelative measure of surfactant. _____________________ 67 
Figure 8. FFT frequency vs. input frequency for calibration of plethysmograph. 77 
Figure 9. Log amplitude of the FFT peak vs. log frequency for calibration of plethysmograph. __ 78 
Figure 10. Plethysmograph calibration. The left hand, top figure shows the recorded trace from a 6Hz 
sine wave produced by a signal generator. The left hand bottom figure shows the recorded trace from 
an 8Hz sine wave. The right hand.figures show the associated Fast Fourier Transform. 79 
Figure 11. Breathing rate waves and associated FFT in a Balb!C mouse. Chart A shows a portion of 
the data collected for a Balb!C mouse. The screen was zoomed in to allow some detail to be discerned 
showing only 5 sofa total of 80 s collected Chart B shows the Fast Fourier Transformation of the 
data. The breathing rate is read off the screen using a movable cross hair (not visible in the picture). 
The reading/or this mouse was 5.47Hz. 80 
Figure 12. Relative level of surfactant at 28 days after treatment with single doses ojmCo r-rays. 
Surfactant was determined using HPLC. Error bars show SD. 81 
Figure 13. Relative level of surfactant vs. dose of cis-platinum. Surfactant was measured using HPLC. 
Cis-platinum was administered by i.p. injection. Error bars show SD. 82 
Figure 14. Relative level of surfactant lavaged from Balb!C female mice at 28 days qfter treatment with 
8mglkg cis-platinum administered at different times relative to a single dose of l lGy 60Co r-rays. E"or 
bars show SD. 83 
Figure 15. Changes in /avaged phospholipid with time after treatment. Balb!C female mice were 
treated with either 8mglkg cis-platinum, l 3Gy 60Co or 8mglkg cis-platinum immediately before l 3Gy. 
Error bars show SD. 84 ----------------------------
Figure 16. Changes in breathing rates with time after treatment. Balb/C female mice were treated with 
either 8mglkg cis-platinum, a single dose of l 3Gy 60Co or with 8mglkg cis-platinum immediately before 
l 3Gy. Control mice received placebo treatments. Error bars show SD. ___________ 86 
Figure 17. Changes in breathing rates with time qfter treatment. Balb!C female mice were treated with 
either 7mglkg cis-platinum, a single dose of l 2Gy 60Co or with 7mglkg cis-platinum immediately before 
l 2Gy. Error bars show SD. 87 
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Figure 18. Changes in breathing rates in Balb/C female mice with time after treatment with 6mg cis-
platinumlkg or a single dose of l 2Gy 6°Co. (All mice receiving combined treatment in this experiment 
died within 1 week of treatment). Error bars show SD. Control mice received placebo treatments. _ 89 
Figure 19. Cumulative proportion of Balb/c female mice surviving after treatment with J 2Gy 60Co y-
rays or 6mg cis-platinumlkg immediately before l 2Gy. 90 
Figure 20. Cumulative proportion of C57 /Bl female mice surviving after treatment with J 2Gy 60Co y-
rays or 6mg cis-platinum !kg immediately before l 2Gy. 91 
Figure 21. Changes in breathing rate in Balb/Cfemale mice with time after treatment. Mice were 
treated with 6mg cis-platinumlkg, a single dose of l 2Gy 60Co y-rays or with 6mglkg immediately before 
J 2Gy. Error bars show SD and have been omitted from some groups for clarity. Controls received 
placebo treatment. ____________________________ 92 
Figure 22. Changes in breathing rate in Balb/C female mice with time after treatment. Mice were 
treated with 6mg cis-platinumlkg, a single dose of J 2Gy 60Co y-rays or with 6mg/kg immediately before 
l 2Gy. Error bars show SD and have been omitted from some groups for clarity. Controls received 
placebo treatments. (Repeat experiment). 93 
Figure 23. Changes in breathing rate in C57/Blfemale mice with time after treatment. Mice were 
treated with 6mg cis-platinumlkg, a single dose of l 2Gy 60Co y-rays or with 6mglkg immediately before 
12Gy. Error bars show SD and have been omitted from some groups for clarity. Controls received 
placebo treatments. 94 
Figure 2 4. Changes in breathing rates of Balb/C mice after treatment with 6mg cis-platinum /kg at 
different times relative to l 2Gy 60Co y-rays. Error bars show SD and have been ommitted from all but 
one group for clarity. Control received placebo treatments. 97 
Figure 25. Changes in breathing rates of Balb/C female mice after treatment with 2 fractions of 6. 5Gy 
6°Co y-rays separated by various times. Chart A shows the breathing rates when radiation only was 
administered and chart B shows the breathing rate when 8mg cis-platinum/kg was given immediately 
before the first fraction of radiation. The control and radiation only (J 2Gy) breathing rates from the 
subsequent split dose experiment are shown in grey. The legend shows time between fractions. Error 
bars show SD and have been omittedfrom some groups for clarity. JOO 
Figure 26. Changes in breathing rate with time after 2 fractions of 6.5Gy 60Co y-rays separated by 
various times. Each chart compares the breathing rate with time for a group treated with radiation 
alone to that of a group treated with 8mg cis-platinumlkg immediately before the first fraction of 
radiation. Error bars show SD. 101 
Figure 2 7. Changes in breathing rates of Balb/C female mice qfter treatment with 2 fractions of 6Gy 
60Co y-rays separated by various times. Chart B shows the breathing rate when 6mg cis-platinumlkg 
was given immediately before the first fraction of radiation. The breathing rate of mice treated with a 
single dose of l 3Gy from a previous experiment is shown in grey. The legend shows time between 
fractions. Error bars show SD and have omitted from some groups for clarity. 103 
Figure 28. Changes in breathing rates of Balb/C female mice qfter treatment with 2 fractions of 6Gy 
6°Co y-rays with and without 6mg cis-platinumlkg given immediately before the first fraction. Error 
bars show SD. 104 
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Figure 29. Box and whisker plot showing mean score, standard error and standard deviation for lung 
sections from mice killed at 120 days after treatment with 6mg cis-platinumlkg (cddp), 12Gy {,()Co r-
rays (rads) or 6mg cis-platinumlkg immediately before 12Gy {,()Co y-rays (comb) . Controls received 
placebo treatments. 107 
Figure 30. Sections from normal lung stained with haemotoxylin and eosin. 108 
Figure 3 J. Sections from irradiated lung stained with haemotoxylin and eosin. 109 
Figure 32. Weight lost or gained at one week and at one month by Balb!Cfemale mice and C57/Bl 
female mice after treatment with 6mg cis-platinumlkg (CDDP), 12Gy {,()Co (Rads) or 6mg cis-
platinumlkg immediately before 12Gy (Comb.). Controls received placebo treatment. 110 
Figure 33. Changes in lung wet weight (g) at one week and at one month after treatment with 6mg cis-
platinum/kg (cddp), J 2Gy {,()Co y-rays (rads) or 6mg cis-platinumlkg immediately before 12Gy (comb). 
Controls received placebo treatment. 112 
Figure 34. mg protein per g homogenised lung at one week and at one month in Balb!C female mice 
and C57 /Bl female mice qfter treatment with 6mg cis-platinumlkg (cddp), 12Gy {,()Co (rads) or 6mg cis-
platinumlkg immediately before 12Gy (comb) . Controls (ctr/) received placebo treatments. 114 
Figure 35. TGF-/3 per sample lavaged surfactant (pg) at one week and at one month in Balb!C female 
mice and C57 /Bl female mice qfter treatment with 6mg cis-platinumlkg (CDDP), 12Gy {,()Co (Rads) or 
6mg cis-platinumlkg immediately before 12Gy (Comb.) . Control groups received placebo treatments. 
115 ---------------------------------
Figure 36. TGF-/3 (pg) per g wet weight homogenised lung at one week and at one month in Balb!C 
female mice and C57/Blfemale mice after treatment with 6mg cis-platinumlkg (cddp) , 12Gy {,()Co 
(rads) or 6mg cis-platinum/kg immediately before 12Gy (comb). Controls received placebo treatments. 
---------------------------------
Figure 37. Picograms TGF-/Jper µg protein lung at one week and at one month after treatment in 
Balb!C female mice and C57 /Bl female mice after treatment with 6mg cis-platinumlkg (cddp), 12Gy 
116 
6°Co (rads) or 6mg cis-platinum/kg immediately before 12Gy (comb). 117 
Figure 38. Cumulative percent non-responders for response breathing rates of 6Hz (left) and 7Hz 
(right) after treatment with 286Gy with and without cis-platinum. J 34 
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